<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Montelukast</title><meta name="description" content="Montelukast is a selective, orally active antagonist of the cysteinyl leukotriene receptor 1 (CysLT1), which inhibits the physiologic actions of leukotriene D4, thereby reducing airway inflammation, bronchoconstriction, and related symptoms in respiratory conditions. Developed by Merck &amp; Co. and approved by the U.S. Food and Drug Administration (FDA) in 1998 as Singulair, it is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients as young as six months,..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="Singulair"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Montelukast"/><meta property="og:title" content="Montelukast"/><meta property="og:description" content="Montelukast is a selective, orally active antagonist of the cysteinyl leukotriene receptor 1 (CysLT1), which inhibits the physiologic actions of leukotriene D4, thereby reducing airway inflammation, bronchoconstriction, and related symptoms in respiratory conditions. Developed by Merck &amp; Co. and approved by the U.S. Food and Drug Administration (FDA) in 1998 as Singulair, it is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients as young as six months,..."/><meta property="og:url" content="https://grokipedia.com/page/Montelukast"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Montelukast"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:44.320Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Montelukast"/><meta name="twitter:description" content="Montelukast is a selective, orally active antagonist of the cysteinyl leukotriene receptor 1 (CysLT1), which inhibits the physiologic actions of leukotriene D4, thereby reducing airway inflammation, bronchoconstriction, and related symptoms in respiratory conditions. Developed by Merck &amp; Co. and approved by the U.S. Food and Drug Administration (FDA) in 1998 as Singulair, it is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients as young as six months,..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="d157474c3a041edd573d6578d6f3f977-192e77d3f5c91d9e-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=d157474c3a041edd573d6578d6f3f977,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.25755175954001674,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#montelukast" class="transition-opacity hover:opacity-100 opacity-50">Montelukast</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#history-and-development" class="transition-opacity hover:opacity-100 opacity-50">History and Development</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#discovery-and-synthesis" class="transition-opacity hover:opacity-100 opacity-50">Discovery and Synthesis</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#clinical-trials-leading-to-approval" class="transition-opacity hover:opacity-100 opacity-50">Clinical Trials Leading to Approval</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#patent-timeline-and-expiry" class="transition-opacity hover:opacity-100 opacity-50">Patent Timeline and Expiry</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pharmacology" class="transition-opacity hover:opacity-100 opacity-50">Pharmacology</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#chemical-structure-and-properties" class="transition-opacity hover:opacity-100 opacity-50">Chemical Structure and Properties</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#mechanism-of-action" class="transition-opacity hover:opacity-100 opacity-50">Mechanism of Action</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pharmacokinetics-and-metabolism" class="transition-opacity hover:opacity-100 opacity-50">Pharmacokinetics and Metabolism</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#clinical-uses" class="transition-opacity hover:opacity-100 opacity-50">Clinical Uses</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#approved-indications" class="transition-opacity hover:opacity-100 opacity-50">Approved Indications</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#dosage-and-administration" class="transition-opacity hover:opacity-100 opacity-50">Dosage and Administration</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#off-label-applications" class="transition-opacity hover:opacity-100 opacity-50">Off-Label Applications</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#efficacy-evidence" class="transition-opacity hover:opacity-100 opacity-50">Efficacy Evidence</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#clinical-trial-outcomes" class="transition-opacity hover:opacity-100 opacity-50">Clinical Trial Outcomes</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#comparative-effectiveness" class="transition-opacity hover:opacity-100 opacity-50">Comparative Effectiveness</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#limitations-and-patient-subgroups" class="transition-opacity hover:opacity-100 opacity-50">Limitations and Patient Subgroups</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#adverse-effects" class="transition-opacity hover:opacity-100 opacity-50">Adverse Effects</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#common-and-mild-effects" class="transition-opacity hover:opacity-100 opacity-50">Common and Mild Effects</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#serious-non-neuropsychiatric-effects" class="transition-opacity hover:opacity-100 opacity-50">Serious Non-Neuropsychiatric Effects</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#neuropsychiatric-effects" class="transition-opacity hover:opacity-100 opacity-50">Neuropsychiatric Effects</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#safety-profile-and-controversies" class="transition-opacity hover:opacity-100 opacity-50">Safety Profile and Controversies</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#reported-risks-vs-causal-evidence" class="transition-opacity hover:opacity-100 opacity-50">Reported Risks vs. Causal Evidence</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#patient-and-physician-reports" class="transition-opacity hover:opacity-100 opacity-50">Patient and Physician Reports</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#long-term-use-concerns" class="transition-opacity hover:opacity-100 opacity-50">Long-Term Use Concerns</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#regulatory-history" class="transition-opacity hover:opacity-100 opacity-50">Regulatory History</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#fda-approval-and-warnings" class="transition-opacity hover:opacity-100 opacity-50">FDA Approval and Warnings</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#international-regulatory-actions" class="transition-opacity hover:opacity-100 opacity-50">International Regulatory Actions</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#post-marketing-surveillance" class="transition-opacity hover:opacity-100 opacity-50">Post-Marketing Surveillance</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#drug-interactions" class="transition-opacity hover:opacity-100 opacity-50">Drug Interactions</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pharmacodynamic-interactions" class="transition-opacity hover:opacity-100 opacity-50">Pharmacodynamic Interactions</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pharmacokinetic-interactions" class="transition-opacity hover:opacity-100 opacity-50">Pharmacokinetic Interactions</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#clinical-implications" class="transition-opacity hover:opacity-100 opacity-50">Clinical Implications</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#society-and-culture" class="transition-opacity hover:opacity-100 opacity-50">Society and Culture</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#brand-names-and-formulations" class="transition-opacity hover:opacity-100 opacity-50">Brand Names and Formulations</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#generic-availability-and-market-dynamics" class="transition-opacity hover:opacity-100 opacity-50">Generic Availability and Market Dynamics</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#prescribing-patterns-and-economic-impact" class="transition-opacity hover:opacity-100 opacity-50">Prescribing Patterns and Economic Impact</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="montelukast" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Montelukast<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7"><br/>
Montelukast is a selective, orally active antagonist of the cysteinyl leukotriene receptor 1 (CysLT1), which inhibits the physiologic actions of leukotriene D4, thereby reducing airway inflammation, bronchoconstriction, and related symptoms in respiratory conditions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_80qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><br/>
Developed by Merck &amp; Co. and approved by the U.S. Food and Drug Administration (FDA) in 1998 as Singulair, it is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients as young as six months, prevention of exercise-induced bronchoconstriction in patients six years and older, and relief of symptoms associated with seasonal and perennial allergic rhinitis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup><br/>
Available in tablet, chewable tablet, and granule formulations, montelukast offers once-daily dosing and has been widely prescribed as an add-on therapy to inhaled corticosteroids or as monotherapy for mild persistent asthma, contributing to improved asthma control in millions of patients globally without the need for inhaled delivery in some cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_s0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><br/>
Despite its efficacy in leukotriene-mediated pathways, montelukast has faced scrutiny over potential neuropsychiatric adverse effects, prompting the FDA in 2020 to mandate a boxed warning highlighting risks of serious mood changes, depression, and suicidality based on post-marketing surveillance data involving thousands of reports, though causality remains debated in peer-reviewed analyses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_120qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_140qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_160qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup></span>
<h2 id="history-and-development" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">History and Development<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="discovery-and-synthesis" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Discovery and Synthesis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<span class="mb-4 block break-words text-[1em] leading-7">Montelukast was discovered through a dedicated medicinal chemistry program at Merck Frosst Canada Ltd. in Montreal, Quebec, initiated in the early 1980s to develop selective antagonists for the leukotriene D4 (LTD4) receptor, recognized as a critical mediator in asthma pathophysiology following the 1979 identification of leukotrienes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_42qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_62qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> The effort, spanning nearly two decades, began with lead generation via screening of natural products and rational design based on LTD4 structure, progressing through iterative structure-activity relationship studies to optimize potency, selectivity for CysLT1 over other receptors, oral bioavailability, and duration of action.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> Robert N. Young and team at Merck Frosst synthesized and evaluated hundreds of analogs, selecting montelukast (initially designated MK-0476) for its superior profile, including nanomolar affinity for human LTD4 receptors and once-daily dosing potential.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The initial synthesis of montelukast was detailed in European Patent EP 480717 B1, with priority filing on December 21, 1990, by Merck Frosst inventors including Young. This multi-step process commences with the preparation of a mercaptomethylcyclopropylacetic acid derivative, which undergoes alkylation with a dihalide to form a thioether linkage, followed by coupling to a 2-(2-chloroquinolin-3-yl)acetic acid moiety via amide bond formation using activating agents. Subsequent steps include reduction of a nitro group to an amine, acylation with a methoxyacetamide, and hydrolysis of an ester to the carboxylic acid, culminating in sodium salt formation. This route established the stereoselective assembly of montelukast&#x27;s key structural elements, including the carboxymethylcyclopropyl and quinoline-piperazine motifs essential for receptor binding. Later improvements focused on yield, purity, and scalability, but the original method laid the foundation for clinical material production.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_43abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup></span>
<h3 id="clinical-trials-leading-to-approval" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Clinical Trials Leading to Approval<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The U.S. Food and Drug Administration approved montelukast sodium (branded as Singulair by Merck Research Laboratories) on February 20, 1998, for prophylaxis and chronic treatment of asthma in adults and adolescents aged 15 years and older.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_44abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> This approval relied on efficacy and safety data from phase II dose-ranging studies and multiple phase III trials, which established montelukast as a once-daily oral leukotriene receptor antagonist superior to placebo in improving asthma control without the need for inhaled corticosteroids.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_84abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Pivotal evidence came from three 12-week, multicenter, randomized, double-blind, placebo-controlled phase III studies enrolling a total of 2,471 patients aged 15 years or older with mild persistent asthma inadequately controlled by as-needed Î²-agonists alone.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_44qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> In these trials, montelukast at 10 mg once daily in the evening significantly increased morning peak expiratory flow by 20â€“25 L/min, improved forced expiratory volume in one second (FEV<sub>1</sub>) by approximately 0.3â€“0.4 L or 8â€“13% from baseline, reduced daytime and nighttime asthma symptoms, and decreased Î²-agonist rescue use by 1â€“2 puffs per day compared to placebo, with all differences statistically significant (p &lt; 0.001).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> One such study, involving 373 adults, reported montelukast-treated patients achieving a mean FEV<sub>1</sub> increase of 0.49 L versus 0.31 L for placebo, alongside fewer asthma exacerbations requiring corticosteroids.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_m4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Safety profiles across these trials showed montelukast was well tolerated, with adverse event rates comparable to placebo (around 80â€“90% incidence overall), primarily mild gastrointestinal or headache-related, and no significant differences in serious adverse events or discontinuations due to side effects.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_45abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_65abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> Additional supportive data included a 12-week trial specifically for exercise-induced bronchoconstriction in 47 patients aged 15â€“55 years, where montelukast reduced the maximal percent fall in FEV<sub>1</sub> post-exercise from 40% to 20% versus placebo.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> These outcomes, derived from standardized endpoints like spirometry and symptom diaries, confirmed montelukast&#x27;s role as an add-on or alternative controller without systemic steroid risks, informing the initial labeling excluding acute asthma relief.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></span>
<h3 id="patent-timeline-and-expiry" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Patent Timeline and Expiry<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The primary patent covering montelukast sodium, the active ingredient in Singulair, is U.S. Patent No. 5,565,473, which claims leukotriene antagonists including the compound.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_46abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> This patent traces its priority to an application filed on October 12, 1990, with the U.S. filing occurring on February 23, 1995, and issuance on October 15, 1996.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_86abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> Merck &amp; Co., the developer, defended the patent against challenges, including a 2009 federal court ruling upholding its validity and enjoining generic entry by Teva Pharmaceuticals until the expiration date.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The patent&#x27;s original term was extended through regulatory adjustments and pediatric exclusivity, resulting in an effective expiry on August 3, 2012.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_46qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup> On that date, the U.S. Food and Drug Administration approved multiple abbreviated new drug applications for generic montelukast sodium, enabling market entry and substantial erosion of Singulair&#x27;s U.S. sales, which exceeded $5 billion annually prior to expiry.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_86qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup> Subsequent patents, such as U.S. Patent No. 8,007,830 for certain formulations, extended protection for specific products until October 24, 2022, but did not block generic versions of the core compound post-2012.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup></span>
<h2 id="pharmacology" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Pharmacology<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="chemical-structure-and-properties" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Chemical Structure and Properties<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">
Montelukast is chemically designated as 2-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_68abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup> The compound features a 7-chloroquinoline moiety linked via a trans-ethenyl bridge to a phenyl ring, which is connected to a chiral propyl chain bearing a 2-(1-hydroxy-1-methylethyl)phenyl substituent; this chain terminates in a sulfanylmethyl group attached to a cyclopropylacetic acid.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup> Its molecular formula is Câ‚ƒâ‚…Hâ‚ƒâ‚†ClNOâ‚ƒS, with a molecular weight of 586.19 g/mol.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup>
The pharmaceutical form is the monosodium salt, with the formula Câ‚ƒâ‚…Hâ‚ƒâ‚…ClNNaOâ‚ƒS and molecular weight of 608.18 g/mol.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> Montelukast sodium appears as a hygroscopic, optically active, white to off-white, free-flowing powder.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_m8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> It exhibits solubility in ethanol but limited aqueous solubility, consistent with its lipophilic profile indicated by a calculated logP of approximately 6.4.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup> The melting point of the free acid is reported as 145â€“148 Â°C in solvents such as toluene and methanol.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_u8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup></span>
<h3 id="mechanism-of-action" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Mechanism of Action<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Montelukast is a selective and orally active antagonist of the cysteinyl leukotriene type 1 receptor (CysLT<sub>1</sub>), a G-protein-coupled receptor expressed on airway smooth muscle cells, macrophages, eosinophils, and other inflammatory cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_89abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> Cysteinyl leukotrienes (LTC<sub>4</sub>, LTD<sub>4</sub>, and LTE<sub>4</sub>), derived from arachidonic acid metabolism via the 5-lipoxygenase pathway, are released from mast cells, eosinophils, and basophils in response to allergic or inflammatory stimuli.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_s9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup> These mediators bind to CysLT<sub>1</sub>, triggering downstream signaling that promotes bronchoconstriction, enhanced mucus production, increased vascular permeability, eosinophil chemotaxis, and edema formation in the airways.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_149abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_189abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">By competitively binding to CysLT<sub>1</sub> with high affinity (K<sub>i</sub> â‰ˆ 0.9 nM for LTD<sub>4</sub> inhibition) and without intrinsic agonist activity, montelukast prevents cysteinyl leukotrienes from eliciting these effects, thereby attenuating airway inflammation and hyperresponsiveness.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup> Unlike 5-lipoxygenase inhibitors such as zileuton, montelukast does not block leukotriene biosynthesis but specifically antagonizes receptor-mediated actions, demonstrating selectivity for CysLT<sub>1</sub> over other leukotriene receptors (e.g., CysLT<sub>2</sub>) and unrelated receptors like histamine or prostaglandin types.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_109qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_149qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In pharmacodynamic studies, montelukast inhibits LTD<sub>4</sub>-induced bronchoconstriction in asthmatics, with near-complete blockade achieved at therapeutic doses (e.g., 5-10 mg), correlating with plasma concentrations above 5 nM.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> This receptor antagonism reduces early- and late-phase asthmatic responses without altering histamine-mediated effects, underscoring its targeted role in leukotriene-driven pathology.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_caabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup></span>
<h3 id="pharmacokinetics-and-metabolism" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Pharmacokinetics and Metabolism<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Montelukast is rapidly absorbed after oral administration, achieving peak plasma concentrations typically within 3 to 4 hours in adults, with a mean absorption time of approximately 2.6 hours in females and 3.4 hours in males.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup> The oral bioavailability is estimated at around 64%, though systemic absorption of the administered dose is about 58%, with the remainder likely undergoing first-pass metabolism.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup> Food does not significantly alter its absorption profile.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The drug exhibits high plasma protein binding, exceeding 99%, primarily to albumin, with a steady-state volume of distribution averaging 8 to 11 liters, indicating moderate tissue distribution.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Montelukast undergoes extensive hepatic metabolism, with cytochrome P450 2C8 (CYP2C8) mediating approximately 80% of its biotransformation, contrary to earlier product information emphasizing CYP3A4 and CYP2C9; these isoforms play lesser roles.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup> Multiple metabolites are formed, but the parent compound retains pharmacological activity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Elimination occurs primarily via biliary excretion into feces, with montelukast and its metabolites accounting for nearly exclusive fecal recovery and negligible urinary excretion, even in renal impairment.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> The mean plasma elimination half-life ranges from 2.7 to 5.5 hours in healthy individuals, supporting once-daily dosing, and pharmacokinetics remain linear for oral doses up to 50 mg.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ccqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<h2 id="clinical-uses" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Clinical Uses<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="approved-indications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Approved Indications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Montelukast, marketed under the brand name Singulair, is approved by the U.S. Food and Drug Administration (FDA) for the prophylaxis and chronic treatment of asthma in adults and pediatric patients aged 12 months and older.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup> This indication encompasses maintenance therapy to reduce the frequency of asthma exacerbations and improve daytime and nighttime symptoms, but it is not intended for the relief of acute bronchospasm or status asthmaticus.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup> Approval for asthma was granted based on clinical trials demonstrating reductions in inhaled corticosteroid requirements and improvements in lung function metrics such as forced expiratory volume in one second (FEV1).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ceabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The drug is also indicated for the prevention of exercise-induced bronchoconstriction (EIB) in patients aged 6 years and older, with a single dose administered at least 2 hours prior to exercise shown to inhibit bronchoconstriction triggered by physical activity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> Efficacy in this context was established in trials where montelukast reduced the maximal percent fall in FEV1 following exercise challenge by approximately 50% compared to placebo.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For allergic rhinitis, montelukast is approved to provide relief of symptoms associated with seasonal allergic rhinitis in adults and pediatric patients aged 2 years and older, and perennial allergic rhinitis in adults and pediatric patients aged 6 months and older.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup> These approvals stem from randomized controlled trials showing statistically significant improvements in total symptom scores, including nasal congestion, rhinorrhea, itching, and sneezing, versus placebo.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup> The FDA specifies that montelukast should not be used as monotherapy for allergic rhinitis but may be added to other treatments as appropriate.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup></span>
<h3 id="dosage-and-administration" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Dosage and Administration<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Montelukast is administered orally once daily, with or without food, for the prophylaxis and chronic treatment of asthma and for the management of allergic rhinitis. For asthma, dosing occurs in the evening regardless of time of day symptoms occur, while for allergic rhinitis alone, timing may be individualized; patients with both conditions receive only one dose daily in the evening. It is not indicated for acute asthma attacks or status asthmaticus, and patients must have appropriate rescue medication available. Doses should not exceed the recommended amount, and no more than one dose is permitted within 24 hours.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The following table summarizes recommended dosages by age group, indication, and formulation:</span>









































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Age Group</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Asthma</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Allergic Rhinitis (Seasonal or Perennial)</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Exercise-Induced Bronchoconstriction (EIB)</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â‰¥15 years</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">10 mg tablet, once daily evening</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">10 mg tablet, once daily (timing flexible)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">10 mg tablet, single dose â‰¥2 hours before exercise (not if on daily therapy)</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">6â€“14 years</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">5 mg chewable tablet, once daily evening</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">5 mg chewable tablet, once daily (timing flexible)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">5 mg chewable tablet, single dose â‰¥2 hours before exercise (not if on daily therapy)</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">2â€“5 years</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">4 mg chewable tablet or 4 mg oral granules, once daily evening</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">4 mg chewable tablet or 4 mg oral granules, once daily (timing flexible)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Not established</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">12â€“23 months</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">4 mg oral granules, once daily evening</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">4 mg oral granules, once daily (perennial only; timing flexible)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Not established</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">6â€“11 months</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Safety and efficacy not established</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">4 mg oral granules, once daily (perennial only; timing flexible)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Not established</span></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">Chewable tablets must be chewed before swallowing; film-coated tablets are swallowed whole. Oral granules may be administered directly into the mouth, dissolved in â‰¥1 teaspoon (5 mL) of cold or room-temperature baby formula or breast milk (for infants â‰¥12 months who are not breastfed), or mixed with a small amount of soft foods such as applesauce, mashed carrots, or ice cream, but only if the mixture is consumed within 15 minutes of preparation to avoid degradationâ€”do not mix with hot, acidic, or carbonated foods/drinks. Granules should not be chewed. No dose adjustments are required for mild-to-moderate hepatic insufficiency or renal impairment, but data are limited in severe cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For EIB, montelukast provides protection for up to 24 hours but should not be used as a substitute for inhaled short-acting beta-agonists during acute episodes; routine administration before exercise is not recommended if the patient is already receiving daily montelukast for asthma or rhinitis. Missed doses should be skipped, with the next taken at the regular timeâ€”doubling is prohibited.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup></span>
<h3 id="off-label-applications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Off-Label Applications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Montelukast has been investigated for off-label use in chronic spontaneous urticaria (CSU), where it is often combined with antihistamines to achieve modest reductions in urticaria activity scores compared to antihistamines alone, based on a 2024 meta-analysis of randomized clinical trials.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup> This adjunctive role is supported by evidence of leukotriene involvement in mast cell-mediated inflammation, though montelukast monotherapy shows limited standalone efficacy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In atopic dermatitis (AD), particularly moderate-to-severe cases, montelukast has demonstrated inconsistent benefits as an adjunct therapy, with a 2018 systematic review concluding limited evidence for symptom improvement, primarily in adults.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup> A 2025 review similarly noted potential efficacy in adult AD patients but highlighted variability across studies, attributing this to heterogeneous leukotriene pathways in skin inflammation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[41]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For COVID-19, montelukast has been explored in mild-to-moderate outpatients, where a 2024 randomized trial found it shortened time to sustained recovery by approximately one day versus placebo, potentially via anti-inflammatory effects on cytokine release and lung edema.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[42]</sup> In hospitalized patients, observational data suggest reduced inflammation akin to preclinical models of viral respiratory distress, though large-scale confirmation remains pending.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Emerging off-label applications include multiple sclerosis (MS), with 2024 real-world evidence indicating reduced relapse rates when added to standard therapies, possibly due to modulation of neuroinflammation via cysteinyl leukotriene receptors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup> Ongoing trials are assessing montelukast in Alzheimer&#x27;s disease for mild cognitive impairment, hypothesizing benefits from its anti-inflammatory properties in amyloid-beta pathways, but results are preliminary.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup> Off-label prescribing for chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea occurs, driven by interest in leukotriene-mediated airway remodeling, yet controlled evidence is sparse.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ckqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Overall, these uses underscore montelukast&#x27;s repurposing potential in leukotriene-driven pathologies, tempered by the need for further randomized trials to establish causality and optimal dosing.</span>
<h2 id="efficacy-evidence" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Efficacy Evidence<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="clinical-trial-outcomes" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Clinical Trial Outcomes<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In randomized, double-blind, placebo-controlled trials establishing montelukast&#x27;s efficacy for asthma prophylaxis in adults, treatment with 10 mg daily for 12 weeks resulted in significant improvements in lung function and symptom control. Morning peak expiratory flow increased by an average of 20-25 L/min compared to placebo, while forced expiratory volume in 1 second (FEV1) improved by approximately 0.1-0.2 L.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> Beta-agonist rescue use decreased by 27.7% in montelukast groups versus 1.6% with placebo, and asthma-specific quality-of-life scores rose by 0.3-0.5 points on standardized scales.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_amabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Pediatric trials, such as a 12-month study in children aged 2-5 years, demonstrated a 31.9% reduction in exacerbation rates with montelukast 4 mg daily versus placebo, alongside fewer days with asthma symptoms and reduced healthcare utilization.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup> In adolescents and adults with exercise-induced bronchoconstriction, montelukast attenuated maximal fall in FEV1 by 50-60% post-exercise compared to 20-30% with placebo.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[48]</sup> However, a Cochrane meta-analysis of 19 pediatric RCTs found montelukast inferior to inhaled corticosteroids for overall symptom control and lung function gains, though it provided additive benefits in patients with comorbid allergic rhinitis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cmqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For seasonal allergic rhinitis, a randomized trial showed montelukast 10 mg superior to placebo in reducing daytime nasal symptom scores by 0.09 points (95% CI: -0.17 to -0.01; P=0.003), with comparable improvements in quality-of-life measures.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[50]</sup> In patients with both asthma and rhinitis, add-on montelukast to intranasal corticosteroids or antihistamines enhanced rhinitis symptom relief and asthma control, with 86.5% of adults reporting marked daytime asthma symptom improvement after 10 mg dosing.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_anabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup> Acute asthma trials yielded mixed results; intravenous montelukast improved FEV1 by 0.22 L more than placebo at 60 minutes in emergency settings, but oral add-on in moderate exacerbations showed no significant benefit over standard care alone.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_enabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[53]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gnabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup></span>
<h3 id="comparative-effectiveness" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Comparative Effectiveness<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In asthma management, montelukast demonstrates efficacy comparable to low-dose inhaled corticosteroids (ICS) in mild persistent cases, particularly for metrics such as rescue-free days and forced expiratory volume in one second (FEV1) improvements, but ICS generally outperform montelukast in reducing exacerbations and achieving overall symptom control.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[56]</sup> A systematic review of pediatric asthma trials confirmed montelukast&#x27;s superiority over placebo in symptom control, yet ICS were consistently more effective across lung function, exacerbation rates, and quality-of-life measures.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aoabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[57]</sup> In adult smokers with asthma, montelukast yields responses similar to ICS, potentially due to reduced corticosteroid efficacy in this subgroup from inflammation patterns less responsive to steroids.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_eoabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[48]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">As add-on therapy to ICS, montelukast enhances outcomes in patients with comorbid allergic rhinitis, improving asthma control and reducing rescue medication use beyond ICS monotherapy, though benefits are modest in isolated asthma without rhinitis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[58]</sup> Combinations of montelukast with ICS, such as fluticasone, show higher total effective rates and lower recurrence compared to ICS alone in some randomized trials, particularly for cough variant asthma.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For allergic rhinitis, montelukast improves nasal symptoms and quality of life versus placebo but is inferior to second-generation antihistamines (e.g., loratadine) in total nasal symptom scores and to intranasal corticosteroids (e.g., fluticasone) in overall efficacy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[60]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[61]</sup> Guidelines prioritize intranasal steroids or antihistamines over montelukast monotherapy, with the latter reserved for patients intolerant to first-line options or as adjunctive therapy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_apabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[62]</sup> Combinations of montelukast with antihistamines provide additive benefits in symptom relief and quality of life compared to either agent alone, supporting their use in moderate-to-severe cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_epabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[63]</sup></span>
<h3 id="limitations-and-patient-subgroups" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Limitations and Patient Subgroups<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Montelukast exhibits variable efficacy across asthma patients, with clinical trials indicating that approximately 20-30% of individuals may be non-responders to leukotriene modifiers, limiting its utility as a universal controller therapy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4qabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[48]</sup> Meta-analyses confirm its effectiveness over placebo in reducing symptoms and exacerbations in mild to moderate asthma, but it consistently underperforms compared to inhaled corticosteroids (ICS), which achieve superior lung function improvements and symptom control in persistent cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8qabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[57]</sup> In preschool children with recurrent wheezing, daily ICS regimens outperform montelukast in preventing exacerbations, highlighting its suboptimal role as monotherapy in early-onset or intermittent disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cqabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[64]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Efficacy is notably enhanced in specific phenotypes, such as exercise-induced bronchoconstriction, where montelukast reduces post-exercise forced expiratory volume decline by 50% or more in responsive subgroups.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[65]</sup> Patients with aspirin-exacerbated respiratory disease (AERD) or NSAID-exacerbated respiratory phenotypes show greater symptom relief and reduced polyp recurrence when treated with montelukast adjunctively, owing to elevated cysteinyl leukotriene levels in these groups.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup> Similarly, asthma comorbid with allergic rhinitis benefits disproportionately, with combination therapy yielding additive improvements in nasal symptoms and asthma control scores versus ICS alone.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Subgroup analyses reveal heightened responsiveness in allergic or eosinophilic asthma, obese patients, and those with small airway involvement, where montelukast targets leukotriene-mediated inflammation more effectively than in neutrophilic or non-atopic variants.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[48]</sup> In women with moderate asthma on ICS, add-on montelukast improves forced expiratory volume and reduces inflammation markers beyond what is seen in men.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup> Elderly patients with mild to moderate disease experience comparable lung function gains to younger adults, though data remain limited by smaller trial cohorts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_crabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[68]</sup> Cough variant asthma responds moderately as adjunctive therapy, but evidence for standalone use is weaker, with inconsistent reductions in cough frequency.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_grabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[69]</sup> Overall, phenotyping via biomarkers like fractional exhaled nitric oxide or leukotriene levels may predict responders, underscoring montelukast&#x27;s niche rather than broad-spectrum application.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_krabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[70]</sup></span>
<h2 id="adverse-effects" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Adverse Effects<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="common-and-mild-effects" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Common and Mild Effects<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Montelukast is associated with mild adverse effects that are typically transient and similar in frequency to those observed with placebo in controlled clinical trials. In adults and adolescents aged 15 years and older with asthma, headache was the most common, occurring in 18.4% of montelukast-treated patients compared to 17.8% on placebo; other frequent mild effects included asthenia or fatigue (1.8% vs. 1.2%), dyspepsia (2.1% vs. 1.1%), and abdominal pain (2.9% vs. 2.5%).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4sqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[71]</sup> Cough (2.7% vs. 2.4%) and upper respiratory infection were also reported but reflected underlying respiratory conditions in many cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8sqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In pediatric patients, common mild effects varied by age group but included fever, upper respiratory infection, cough, and abdominal pain. For children aged 2 to 5 years in asthma trials, upper respiratory infection affected 8.3% on montelukast versus 6.6% on placebo, fever 6.5% versus 4.4%, and cough 3.9% versus 2.8%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4tabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup> For ages 6 to 14 years, similar patterns emerged with headache (10.2% vs. 8.3%), abdominal pain (2.6% vs. 1.6%), and cough (2.6% vs. 2.0%).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8tabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup> These effects were generally self-limiting and did not lead to discontinuation in most instances.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ctabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Gastrointestinal disturbances such as diarrhea, nausea, and vomiting occurred infrequently, with incidences around 1-2% and often indistinguishable from placebo. Dermatological reactions like rash were reported in approximately 1.6% of treated patients across trials, also mild in nature.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Overall, post-marketing surveillance confirms these mild effects predominate in routine use, with no significant dose-response escalation for non-serious events.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup></span>
<h3 id="serious-non-neuropsychiatric-effects" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Serious Non-Neuropsychiatric Effects<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Montelukast has been associated with rare serious hypersensitivity reactions, including anaphylaxis, angioedema, and urticaria, which can occur even after prolonged use.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[73]</sup> These events typically manifest as swelling of the face, lips, tongue, or throat, difficulty breathing, or rash, requiring immediate discontinuation and supportive care such as epinephrine.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[74]</sup> Case reports document such reactions in both adults and children, with some classified as serious due to hospitalization needs, though population-level incidence remains low at approximately 1 in 1000 users based on post-marketing surveillance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cuqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[73]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Hepatotoxicity represents another infrequent but documented risk, with case reports describing acute hepatitis, elevated liver enzymes (e.g., ALT levels exceeding 10 times the upper limit of normal), and cholestatic injury patterns.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4vabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[75]</sup> In one pediatric case, a 4-year-old developed probable montelukast-induced hepatotoxicity after 3 months of therapy, presenting with jaundice and transaminase elevations resolving upon discontinuation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8vabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[76]</sup> Adult cases have similarly shown hepatocellular damage, with biopsy-confirmed findings in select instances, though causality is inferred from temporal association and exclusion of other etiologies rather than definitive mechanistic proof.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cvabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[77]</sup> LiverTox classifies montelukast as a rare cause of clinically apparent liver injury, with likelihood scores ranging from B (probable) to D (possible) across reports, emphasizing monitoring of liver function in at-risk patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gvabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[75]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A notable association exists with eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome), a systemic vasculitis characterized by asthma, eosinophilia, and multi-organ involvement. Multiple case reports link montelukast initiation to EGPA onset, including pulmonary infiltrates, neuropathy, and cardiac manifestations, often in patients tapering corticosteroids.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4vqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[78]</sup> For instance, a 1999 study identified cases emerging after montelukast use, hypothesizing unmasking of preclinical disease rather than direct causation via leukotriene blockade.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8vqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[79]</sup> Subsequent reports, such as a 2008 case of a 47-year-old woman developing vasculitis post-montelukast despite stable steroid doses, fuel debate, but large cohort analyses suggest confounding by asthma severity and steroid withdrawal rather than inherent drug toxicity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cvqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[80]</sup> EGPA incidence with montelukast appears exceedingly rare, estimated below 1 per 100,000 users, with no randomized trial confirmation of causality.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gvqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[81]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Other rare non-neuropsychiatric effects include systemic eosinophilia and potential vasculitic flares, though evidence is limited to isolated reports without robust epidemiological support.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_50abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[82]</sup> Overall, these serious effects underscore the need for vigilance in patients with predisposing factors like prior eosinophilic disorders, with prompt dechallenge typically leading to resolution.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_90abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[75]</sup></span>
<h3 id="neuropsychiatric-effects" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Neuropsychiatric Effects<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Montelukast has been associated with reports of neuropsychiatric adverse events, including agitation, irritability, anxiety, depression, sleep disturbances, hallucinations, aggression, and suicidality, prompting regulatory scrutiny. The U.S. Food and Drug Administration (FDA) mandated a Boxed Warning in March 2020 highlighting serious neuropsychiatric risks, based on postmarketing surveillance data accumulating since 2007, with most events occurring during treatment and some persisting after discontinuation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_51abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_71abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[83]</sup> These reports, often derived from voluntary adverse event databases like the FDA Adverse Event Reporting System (FAERS), indicate a signal for neuropsychiatric outcomes, though such data cannot establish causality due to potential confounders like underlying asthma severity or comorbid conditions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[84]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Observational studies yield mixed findings on the association. A 2022 cohort analysis of over 500,000 patients with asthma or allergic rhinitis found increased odds of new neuropsychiatric diagnoses (e.g., depression, anxiety, ADHD) within 30 days of montelukast initiation, with adjusted odds ratios ranging from 1.25 to 1.58 compared to non-users.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_51qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Similarly, a 2021 FAERS-based retrospective study reported disproportionate reporting of neuropsychiatric events like completed suicide and psychotic disorders with montelukast, yielding reporting odds ratios exceeding 2 for several outcomes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_91qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[84]</sup> In pediatric populations, case reports and a 2024 case-crossover study documented elevated short-term risks of neuropsychiatric adverse events (NPAEs) such as aggression and hallucinations shortly after initiation in children and adolescents, with incidence rate ratios up to 1.8.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[85]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[86]</sup> Extended use beyond six months in older children (ages 6-11) has been linked to heightened neuropsychiatric risks in some analyses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_j1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[87]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Conversely, multiple systematic reviews and large-scale observational data challenge a strong causal link. A 2023 review of 33 studies, including FDA Sentinel Initiative analyses, found no consistent association with suicide-related or depression events in asthma patients, attributing signals to reporting biases or unadjusted confounders; one Sentinel study even reported reduced outpatient depression risk.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_52abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[88]</sup> A 2025 meta-analysis of leukotriene receptor antagonists, including montelukast, identified only small effect sizes for neuropsychiatric side effects, insufficient to alter clinical recommendations broadly.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_92abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> Pediatric-specific data from clinical trials and registries similarly show rarity, with suicidality reports comparable to placebo in pre-approval studies (e.g., 1-2 events per 1,000 patient-years).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[89]</sup> Disproportionality in adverse event reports may reflect heightened awareness post-2008 signals rather than true incidence elevation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[90]</sup></span>



































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Study Type/Source</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Key Finding</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Population</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Citation</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">FDA Boxed Warning (2020)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Reports of agitation, depression, suicidality; events mostly during use</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">All ages</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8d2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Cohort (JAMA Netw Open, 2022)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">OR 1.25-1.58 for new diagnoses post-initiation</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Asthma/allergic rhinitis patients</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8l2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Systematic Review (2023)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">No association with suicide/depression</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Asthma patients</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8t2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[88]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Case-Crossover (BMJ Paediatr Open, 2024)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">IRR up to 1.8 for NPAEs short-term</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Children/adolescents</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_952qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[85]</sup></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">Clinicians are advised to monitor for neuropsychiatric symptoms, particularly in children and those with psychiatric history, weighing benefits against risks; discontinuation often resolves symptoms, though reversibility varies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_53abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> While empirical evidence supports vigilance, the absence of randomized controlled trial confirmation underscores reliance on lower-tier evidence, with potential overestimation from biased reporting in pharmacovigilance systems.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_93abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[88]</sup></span>
<h2 id="safety-profile-and-controversies" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Safety Profile and Controversies<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="reported-risks-vs-causal-evidence" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Reported Risks vs. Causal Evidence<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Post-marketing surveillance has documented thousands of adverse event reports associated with montelukast, predominantly neuropsychiatric in nature, via systems such as the FDA&#x27;s Adverse Event Reporting System (FAERS). Between 1998 and 2020, FAERS recorded over 10,000 neuropsychiatric events linked to montelukast, including agitation, depression, hallucinations, sleep disturbances, and suicidality, with many cases occurring shortly after initiation or persisting post-discontinuation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_54qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_94qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[84]</sup> A 2021 FAERS analysis calculated a reporting odds ratio exceeding 2 for neuropsychiatric events, indicating disproportionate reporting relative to other leukotriene antagonists.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[91]</sup> These voluntary reports, while signaling potential signals, suffer from inherent limitations including stimulated reporting following FDA warnings (issued March 2020 with a boxed warning for neuropsychiatric risks), lack of denominator data on exposure, and confounding by indication, as asthma and allergies correlate with baseline anxiety and mood disorders.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[92]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Controlled studies assessing causality reveal a more nuanced profile, with randomized controlled trials (RCTs) generally showing no excess risk beyond placebo for serious neuropsychiatric outcomes. A 2023 meta-analysis of 22 RCTs involving over 15,000 patients with asthma or allergic rhinitis found no statistically significant increase in composite neuropsychiatric events (odds ratio 1.06, 95% CI 0.89-1.26), though subgroup analyses hinted at minor elevations in agitation or insomnia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_55abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[93]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_95abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[94]</sup> Similarly, a 2025 meta-analysis of RCTs confirmed efficacy against asthma symptoms without elevating depression or suicidality risks, but noted a modest anxiety hazard ratio of 1.32 (95% CI 1.05-1.66), potentially attributable to nocebo effects in aware trial participants.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[95]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[96]</sup> These findings align with pre-approval RCT data from montelukast&#x27;s development, where neuropsychiatric discontinuation rates mirrored placebo (approximately 1-2%).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[97]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Observational evidence introduces variability, often magnifying associations due to unmeasured confounders like disease severity or polypharmacy. A 2022 population-based cohort study in Finland reported adjusted odds ratios of 1.22-1.57 for incident neuropsychiatric diagnoses (e.g., depression, anxiety) in the 60 days post-montelukast initiation versus non-users, yet acknowledged residual bias from channeling severe asthmatics to the drug.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_55qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup>  Contrasting this, multiple case-crossover and self-controlled analyses, including a 2024 pediatric study, found no temporal clustering of events beyond background rates, except possibly for sleep-related complaints.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_95qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[85]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[98]</sup> For non-neuropsychiatric risks, such as eosinophilic conditions historically tied to montelukast (e.g., Churg-Strauss syndrome), pharmacovigilance reviews attribute reports to unmasking of vasculitis in steroid-weaning patients rather than direct causation, with incidence rates in RCTs indistinguishable from comparators.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Discrepancies between reported risks and causal evidence underscore the challenges of inferring causation from pharmacovigilance data alone, where signal amplification via media and regulatory alerts can inflate perceptions without proportional RCT confirmation. High-quality trials prioritize internal validity through randomization and blinding, revealing montelukast&#x27;s risks as rare and often non-specific, whereas real-world reports capture broader correlations amenable to bias. This divergence informs clinical judgment, favoring evidence hierarchies that distinguish temporal associations from mechanistic causality.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_56abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_96abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[99]</sup></span>
<h3 id="patient-and-physician-reports" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Patient and Physician Reports<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Patient reports of neuropsychiatric adverse effects associated with montelukast use, submitted to the FDA&#x27;s FAERS database, include symptoms such as agitation, aggression, anxiety, depression, hallucinations, insomnia, irritability, and suicidal ideation or attempts, with 82 cases of completed suicide identified, often accompanied by prior neuropsychiatric symptoms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_57abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_77abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[100]</sup> Many patients describe onset within weeks of initiation, with resolution upon discontinuation, though some report persistent effects like ongoing mood disturbances despite cessation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[101]</sup> Support groups for montelukast side effects, comprising thousands of members, document experiences of vivid nightmares, behavioral changes, and cognitive issues, frequently noting initial dismissal by healthcare providers attributing symptoms to underlying asthma or allergies rather than the drug.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[101]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Physician-submitted case reports highlight similar patterns, including acute behavioral disturbances in pediatric patients, such as a 6-year-old boy developing aggression and hyperactivity shortly after starting montelukast for asthma, which abated post-discontinuation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_57qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[102]</sup> Two documented cases of montelukast-associated psychosis in children involved dose-dependent symptoms like anxiety, irritability, sleep disturbances, and hallucinations, prompting urgent withdrawal and symptom reversal.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_97qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[103]</sup> Clinicians have reported observing neuropsychiatric events in montelukast users, including sleep disorders, mood alterations, and aggression, with some studies analyzing physician-diagnosed outcomes showing elevated odds of new-onset diagnoses like depression or anxiety post-initiation compared to non-users.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[104]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">These reports, while voluntary and subject to reporting biases, have contributed to regulatory scrutiny, with analyses of FAERS data indicating disproportionately high signals for neuropsychiatric events relative to other asthma therapies, though causation remains debated due to confounding factors like comorbid conditions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_58abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[105]</sup> Physicians in surveys and commentaries emphasize monitoring for early signs, particularly in children and those with psychiatric history, and some advocate prescreening or alternative therapies given the persistence of symptoms in select cases even after drug cessation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_98abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[101]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[106]</sup></span>
<h3 id="long-term-use-concerns" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Long-Term Use Concerns<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Concerns regarding long-term montelukast use primarily center on the persistence and potential accumulation of neuropsychiatric adverse events, despite initial clinical trials demonstrating safety over periods up to 2 years. Post-marketing surveillance has identified ongoing reports of events such as depression, anxiety, sleep disturbances, and suicidality, which may not resolve upon discontinuation and have prompted regulatory warnings independent of treatment duration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_59abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_79abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[104]</sup> A 2023 systematic review found no overall significant association between montelukast and suicide-related events, but age-specific vulnerabilities remain under investigation, with events reported across all durations of use.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[88]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In pediatric populations, extended use beyond 63 days has been linked to elevated risks of tics or Tourette&#x27;s syndrome, particularly in children aged 6â€“15 years, based on claims data analysis adjusting for confounders like asthma severity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_59qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[87]</sup> Conversely, a cohort study reported no increased neuropsychiatric risk with use exceeding 24 months (hazard ratio 0.71, 95% CI 0.26â€“1.98), suggesting risks may cluster at initiation rather than accumulate linearly.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_99qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[97]</sup> These discrepancies highlight limitations in long-term observational data, including confounding by indication and underreporting in registries.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Beyond neuropsychiatric effects, chronic use has shown mild, reversible hepatotoxicity in 1â€“2% of patients, with alanine aminotransferase elevations typically resolving without intervention.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Rare associations with eosinophilic conditions like Churg-Strauss syndrome persist as a vigilance point, though causality remains debated and not clearly duration-dependent. Overall, while montelukast contributes to asthma control in long-term management, evidence gaps necessitate individualized risk-benefit assessments, prioritizing alternatives like inhaled corticosteroids for patients with emerging neuropsychiatric signals.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup></span>
<h2 id="regulatory-history" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Regulatory History<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="fda-approval-and-warnings" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">FDA Approval and Warnings<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Montelukast, marketed under the brand name Singulair by Merck &amp; Co., received initial U.S. Food and Drug Administration (FDA) approval on February 20, 1998, for the maintenance treatment of asthma as an add-on therapy in adults and pediatric patients aged 12 years and older not adequately controlled on inhaled corticosteroids.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> Subsequent approvals expanded its indications to include prevention of exercise-induced bronchoconstriction (approved July 27, 2005, for patients 15 years and older) and relief of symptoms of seasonal and perennial allergic rhinitis (approved February 2001 for seasonal in adults and children 2 years and older, and August 2002 for perennial).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[107]</sup> Formulations approved include 10 mg film-coated tablets (1998), 4 mg and 5 mg chewable tablets (January 28, 2000), and 4 mg oral granules (January 25, 2008).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[108]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The FDA label at initial approval included standard warnings for hypersensitivity reactions and potential effects on hepatic function, but neuropsychiatric risks were not prominently featured until post-marketing surveillance identified patterns of adverse events.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup> In July 2007, the FDA began receiving reports of neuropsychiatric events associated with montelukast use, prompting a review that led to label updates in 2009 adding precautions for agitation, depression, and other behavioral changes, though without establishing definitive causality.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[83]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">On March 4, 2020, the FDA required a Boxed Warningâ€”the agency&#x27;s strongest safety communicationâ€”for montelukast, highlighting serious neuropsychiatric events including suicidal ideation, attempted suicide, aggression, hallucinations, and sleep disturbances reported in post-marketing data involving over 82 cases of completed suicide by that date.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> The warning advises that these events may persist after discontinuation and recommends reserving montelukast for patients unresponsive to alternative therapies, with close monitoring for behavioral changes, particularly in children, adolescents, and patients with preexisting psychiatric disorders.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> Earlier label revisions in 2009 had included neuropsychiatric warnings in the Precautions section, but the 2020 escalation to a Boxed Warning reflected accumulating evidence from the FDA&#x27;s Adverse Event Reporting System (FAERS), where montelukast-associated reports outnumbered those for similar leukotriene modifiers.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dcqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Additional label warnings address rare but serious risks such as eosinophilic conditions resembling Churg-Strauss syndrome (now eosinophilic granulomatosis with polyangiitis), with over 100 cases reported by 2009 potentially linked to leukotriene inhibition rather than direct causality from montelukast, and hepatic enzyme elevations requiring monitoring in patients with impaired function.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> The FDA has emphasized that while montelukast&#x27;s benefits for asthma and allergy control remain established, prescribers must weigh these against neuropsychiatric risks, informed by disproportionate reporting rates in surveillance data.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[109]</sup></span>
<h3 id="international-regulatory-actions" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">International Regulatory Actions<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In July 2019, the European Medicines Agency (EMA), through its Coordination Group for Mutual Recognition and Decentralised Procedures â€“ Human (CMDh), concluded a pharmacovigilance review of montelukast following reports of neuropsychiatric events such as agitation, depression, sleep disturbances, and hallucinations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[110]</sup> The review determined that the benefits of montelukast continued to outweigh the risks but required harmonized updates to product information across EU member states, including a new warning stating that neuropsychiatric events have been reported in adults, adolescents, and children taking the drug, with advice to discontinue treatment if such symptoms occur.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[110]</sup> No changes to the approved indications or contraindications were made, and the EMA emphasized ongoing monitoring via periodic safety update reports.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_deabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[111]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) issued a drug safety update in September 2019 reminding healthcare professionals of the risk of neuropsychiatric reactions associated with montelukast, including sleep disturbances, depression, and agitation, based on an EU-wide review that confirmed the known risks without alteration in magnitude.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[111]</sup> Following an increase in Yellow Card reports, particularly in children, the MHRA initiated a safety review in March 2024 and, by April 2024, mandated prominent warnings in patient leaflets and product information, advising immediate withdrawal of montelukast if neuropsychiatric symptoms like hallucinations, anxiety, mood changes, or suicidal ideation emerge, with emphasis on monitoring in pediatric patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[112]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_deqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[104]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Australia&#x27;s Therapeutic Goods Administration (TGA) conducted a safety review in July 2018 evaluating medical literature and adverse event reports linking montelukast to neuropsychiatric effects, leading to enhanced risk mitigation measures.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[113]</sup> In January 2025, the TGA required more prominent warnings on all montelukast product labels and consumer medicine information, highlighting risks of behavioral changes, depression, and suicidality across all age groups, with instructions for patients and carers to report symptoms promptly and for prescribers to consider discontinuation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[114]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Health Canada issued a public warning in 2019 regarding the potential for montelukast to cause neuropsychiatric adverse events, including mood changes and sleep disturbances, advising healthcare providers to discuss risks with patients and monitor for symptoms, particularly in children and those with psychiatric history.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup> No restrictions on use were imposed, but the warning underscored the need for individualized risk-benefit assessment.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup></span>
<h3 id="post-marketing-surveillance" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Post-Marketing Surveillance<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Post-marketing surveillance of montelukast has relied on spontaneous reporting systems such as the U.S. Food and Drug Administration&#x27;s Adverse Event Reporting System (FAERS) and the World Health Organization&#x27;s VigiBase, capturing voluntary reports from healthcare providers, patients, and manufacturers. These systems have identified disproportionate signals for neuropsychiatric adverse events, including agitation, aggression, depression, hallucinations, insomnia, irritability, suicidal ideation, and completed suicides, with many cases occurring within weeks of initiation and some persisting after discontinuation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[84]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[115]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">By 2020, FDA analysis of FAERS data included review of 82 completed suicide cases associated with montelukast, often in patients with preexisting psychiatric conditions, alongside thousands of other neuropsychiatric reports deemed consistent with a drug-induced effect in select instances. Disproportionality analyses from FAERS (2004â€“2023) have confirmed reporting odds ratios exceeding thresholds for psychiatric disorders (e.g., ROR &gt;2 for anxiety and depression), with pediatric cases prominent for sleep disturbances and behavioral changes. Internationally, the European Medicines Agency&#x27;s pharmacovigilance efforts, including PRAC reviews, echoed these signals, prompting updates to product information for risks like nightmares and mood alterations based on EudraVigilance data.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[116]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[110]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Real-world pharmacoepidemiologic studies using post-marketing data have shown mixed causality evidence; for instance, a 2022 cohort analysis found adjusted odds ratios of 1.25â€“1.37 for new neuropsychiatric diagnoses within 90 days of montelukast initiation compared to inhaled corticosteroids, particularly for sleep disorders and anxiety. However, limitations of surveillance data include underreporting, confounding by asthma severity or comorbid conditions, and stimulated reporting post-FDA warnings, which may inflate signals without establishing definitive causation. Ongoing monitoring emphasizes patient education on early symptom recognition, with regulatory bodies like the UK&#x27;s MHRA issuing repeated alerts (e.g., 2019, 2024) on neuropsychiatric risks across age groups.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[104]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[117]</sup></span>
<h2 id="drug-interactions" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Drug Interactions<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="pharmacodynamic-interactions" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Pharmacodynamic Interactions<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Montelukast, as a selective cysteinyl leukotriene receptor 1 (CysLT1) antagonist, demonstrates limited pharmacodynamic interactions owing to its targeted mechanism, which primarily inhibits leukotriene-mediated bronchoconstriction, inflammation, and mucus production without broad effects on other pathways. Clinical evaluations indicate no clinically significant pharmacodynamic alterations when montelukast is co-administered with standard asthma maintenance therapies, including oral corticosteroids such as prednisone and prednisolone, theophylline, or inhaled corticosteroids, where additive bronchodilatory and anti-inflammatory effects support combined use without dose adjustments.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In patients with aspirin-exacerbated respiratory disease (a subset of asthma sensitive to cyclooxygenase inhibition), montelukast improves baseline airway function but does not prevent the acute bronchoconstrictor response triggered by aspirin or non-steroidal anti-inflammatory drugs (NSAIDs), requiring ongoing avoidance of these agents to prevent exacerbations. This reflects a lack of pharmacodynamic antagonism against NSAID-induced leukotriene shunting via the 5-lipoxygenase pathway, rather than a direct interaction with montelukast&#x27;s receptor blockade. No evidence of antagonistic effects or reduced efficacy has been reported with beta-2 adrenergic agonists or other bronchodilators, allowing safe concomitant administration in chronic asthma management.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Rare case reports suggest possible potentiation of corticosteroid-induced peripheral edema when montelukast is combined with systemic glucocorticoids, potentially via enhanced renal sodium retention, though this has not been confirmed in controlled studies and remains anecdotal.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[118]</sup> Overall, montelukast&#x27;s pharmacodynamic profile supports its integration into polytherapy for allergic rhinitis and asthma without routine concerns for synergistic toxicities or efficacy loss beyond disease-specific sensitivities.</span>
<h3 id="pharmacokinetic-interactions" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Pharmacokinetic Interactions<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Montelukast undergoes extensive hepatic metabolism primarily via cytochrome P450 2C8 (CYP2C8), which accounts for approximately 72-80% of its oxidative clearance, with minor contributions from CYP3A4 and CYP2C9.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5labav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[119]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7labav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[120]</sup> Its pharmacokinetics are characterized by rapid absorption, high bioavailability (about 64%), and a plasma half-life of 2.7-5.5 hours, with negligible renal excretion of unchanged drug (less than 0.2%).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_blabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Hepatic uptake transporters, such as organic anion-transporting polypeptide 1B1 (OATP1B1), also contribute to its disposition, potentially influencing interactions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_flabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[121]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">As a substrate, montelukast exposure is significantly increased by strong CYP2C8 inhibitors. For instance, co-administration with gemfibrozil, a potent CYP2C8 inhibitor, elevates montelukast&#x27;s area under the plasma concentration-time curve (AUC) by approximately 4.4-fold and maximum concentration (C_max) by 2.4-fold, without altering its half-life, confirming CYP2C8&#x27;s dominant role in elimination.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[122]</sup> Similarly, trimethoprim, a moderate CYP2C8 inhibitor, increases montelukast AUC by about 38%, suggesting dose adjustments or monitoring may be warranted with such agents, though clinical guidelines do not routinely recommend them due to montelukast&#x27;s wide therapeutic index.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[119]</sup> CYP3A4 inhibitors like ketoconazole show no significant effect on montelukast pharmacokinetics, underscoring CYP2C8&#x27;s primacy over CYP3A4.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dlqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[119]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">As a perpetrator, montelukast exhibits potent in vitro inhibition of CYP2C8 (K_i â‰ˆ 0.07 Î¼M), potentially affecting substrates like rosiglitazone, repaglinide, and pioglitazone.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[123]</sup> However, at clinical doses (10 mg daily), its low unbound plasma concentrations (â‰ˆ1-5 nM) result in negligible in vivo inhibition, with no clinically meaningful pharmacokinetic changes observed for co-administered drugs such as theophylline, warfarin, digoxin, prednisone, oral contraceptives, or fexofenadine.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_bmabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[124]</sup> Multiple-dose studies confirm montelukast does not significantly alter the pharmacokinetics of rosiglitazone or other CYP2C8 substrates at therapeutic levels, though caution is advised for narrow-index CYP2C8 substrates in polypharmacy scenarios.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_fmabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[125]</sup> Overall, pharmacokinetic interactions with montelukast are limited and rarely require dose modifications.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_jmabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[126]</sup></span>
<h3 id="clinical-implications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Clinical Implications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Montelukast demonstrates minimal clinically significant drug interactions, with most being moderate in severity and rarely necessitating dose adjustments due to its wide therapeutic index.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup> Pharmacokinetic interactions predominate, involving cytochrome P450 enzymes such as CYP2C8, CYP3A4, and CYP2C9, through which montelukast is primarily metabolized.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Strong inducers of these enzymes, including rifampin and phenobarbital, can reduce montelukast plasma concentrations by approximately 40%, potentially diminishing its efficacy in controlling asthma or allergic rhinitis symptoms, though clinical studies indicate this effect is unlikely to require routine intervention.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dnabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[127]</sup> Conversely, CYP2C8 inhibitors like gemfibrozil may elevate montelukast exposure up to 4.4-fold, but no dose reduction is typically recommended given the drug&#x27;s safety profile at higher levels.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hnabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[128]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Pharmacodynamic interactions are generally favorable or neutral in clinical practice. Concomitant use with inhaled corticosteroids or other asthma controller medications produces additive bronchodilatory effects without evidence of antagonism or heightened adverse events.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Montelukast does not significantly alter the pharmacokinetics or pharmacodynamics of common co-administered drugs such as theophylline, prednisone, or warfarin at therapeutic doses, minimizing risks in polypharmacy scenarios.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup> No major interactions with alcohol or food have been identified that impact efficacy or safety.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dnqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[129]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In patients with hepatic impairment or those on multiple CYP-modulating agents, clinicians should monitor for subtle changes in symptom control rather than relying on routine plasma level assessments, as montelukast&#x27;s linear pharmacokinetics up to 50 mg doses support predictable responses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Post-marketing data reinforce that interaction-related adverse events are rare, with over 118 documented moderate interactions but no absolute contraindications tied to co-therapy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[129]</sup> For high-risk populations, such as those with neuropsychiatric vulnerabilities, interactions do not exacerbate montelukast&#x27;s known mood-related risks but warrant baseline assessment regardless.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_doabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[130]</sup></span>
<h2 id="society-and-culture" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Society and Culture<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="brand-names-and-formulations" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Brand Names and Formulations<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Montelukast sodium is marketed primarily under the brand name <strong>Singulair</strong> by Merck Sharp &amp; Dohme (MSD).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_bpqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The branded product is available in multiple oral formulations tailored to different age groups: film-coated tablets containing 10 mg of montelukast for adults and adolescents aged 15 years and older; chewable tablets containing 4 mg or 5 mg for pediatric patients aged 2 to 14 years; and oral granules containing 4 mg for infants and children aged 6 to 23 months.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5qabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7qabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> The granules are designed for administration directly into the mouth, mixed with a spoonful of cold or room-temperature applesauce, or dissolved in 1 teaspoonful (5 mL) of cold or room-temperature baby formula or breast milk, without affecting bioavailability.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_bqabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dqabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup> No intravenous, inhaled, or other non-oral formulations have been approved.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hqabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<h3 id="generic-availability-and-market-dynamics" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Generic Availability and Market Dynamics<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Generic versions of montelukast became available in the United States following the expiration of Merck&#x27;s market exclusivity patents for Singulair, with the U.S. Food and Drug Administration approving the first generic equivalents on August 3, 2012, for tablets and chewable tablets.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[131]</sup> The compound patent for montelukast sodium expired on November 30, 2010, but subsequent pediatric exclusivity and formulation patents delayed full generic entry until mid-2012, after which at least 10 manufacturers received approvals initially, expanding to over 15 companies producing generics by 2025.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_drabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[132]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hrabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[133]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Post-generic entry, market dynamics shifted markedly toward price erosion and increased volume. Singulair&#x27;s U.S. sales, which peaked at over $5 billion annually for Merck in the late 2000s as a blockbuster for asthma and allergy treatment, declined sharply due to generic substitution rates exceeding 90% within years of launch, reducing average wholesale prices by approximately 80-90% compared to the brand.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[134]</sup> Generic competition fostered broader accessibility, with U.S. montelukast prescriptions stabilizing at around 20-25 million annually by the early 2020s, supported by lower costs averaging $10-20 per month versus $200+ for branded Singulair.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[135]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Globally, the montelukast sodium market, dominated by generics, grew from an estimated USD 450 million in 2023 to projected levels exceeding USD 1 billion by 2030, driven by rising asthma prevalence in emerging markets and API production expansions in Asia, though pricing pressures from commoditization limited per-unit margins.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5sabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[136]</sup> Key dynamics include ongoing formulation innovations by generics firms to differentiate via extended-release or combination products, amid stable demand but regulatory scrutiny on neuropsychiatric risks potentially capping growth.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9sabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[137]</sup> In regions like Europe and Canada, where patents expired earlier (e.g., October 2011 in Canada), generic penetration reached near-total by 2015, exemplifying rapid market commoditization typical of leukotriene antagonists.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dsabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[138]</sup></span>
<h3 id="prescribing-patterns-and-economic-impact" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Prescribing Patterns and Economic Impact<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In the United States, montelukast is among the most frequently prescribed medications for asthma prophylaxis and chronic treatment, as well as prevention of exercise-induced bronchoconstriction and allergic rhinitis symptoms. In 2023, it accounted for an estimated 25.9 million prescriptions, reaching approximately 6.5 million patients, with primary use in maintenance therapy for those aged 15 and older at 10 mg daily doses, and lower doses for children.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5tabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[139]</sup> Prescription patterns favor evening administration for chronic asthma to align with peak leukotriene activity, often as an add-on to inhaled corticosteroids, particularly in patients with allergic or eosinophilic phenotypes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9tabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Usage is highest among pediatric and primary care populations, with specialties like family medicine and pediatrics dispensing the majority of outpatient retail prescriptions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dtabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[140]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Recent trends indicate a modest decline in prescribing volume, with patient prescriptions dropping from 7.4 million in 2019 to 6.8 million in 2022â€”an 8.1% reductionâ€”attributed in part to the U.S. FDA&#x27;s 2020 boxed warning highlighting risks of neuropsychiatric events such as agitation, depression, and suicidal ideation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[141]</sup> This follows a period of rapid growth post-1998 FDA approval, when montelukast filled a niche for oral, non-steroidal therapy, leading to widespread adoption before peaking in the early 2010s. Post-marketing surveillance and guideline updates emphasizing inhaled therapies as first-line have tempered enthusiasm, though it remains common in step-up care for uncontrolled asthma.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Economically, branded Singulair (montelukast) generated peak worldwide sales of $5.5 billion for Merck in 2011, representing a substantial revenue driver prior to U.S. patent expiration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5uabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[142]</sup> Generic entry in August 2012 triggered an immediate 90% sales collapse within weeks due to price competition, shifting market dynamics toward low-cost alternatives.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9uabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[143]</sup> Generic montelukast now costs $9â€“$15 for a 30-day supply of 10 mg tablets without insurance via discount programs, versus over $150 for brand equivalents, yielding significant patient and payer savingsâ€”estimated in broader generic analyses to enhance access and reduce out-of-pocket burdens.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_duabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[144]</sup> The U.S. market persists at around $1.2 billion annually as of 2023, driven by persistent demand for affordable respiratory management amid rising allergy and asthma prevalence.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_huabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[135]</sup></span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="https://www.ncbi.nlm.nih.gov/books/NBK459301/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK459301/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK459301/</a></span></div></li><li id="https://go.drugbank.com/drugs/DB00471" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://go.drugbank.com/drugs/DB00471" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://go.drugbank.com/drugs/DB00471</a></span></div></li><li id="https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug</a></span></div></li><li id="https://www.fda.gov/safety/medical-product-safety-information/singulair-montelukast-and-all-montelukast-generics-strengthened-boxed-warning-due-restricting-use" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fda.gov/safety/medical-product-safety-information/singulair-montelukast-and-all-montelukast-generics-strengthened-boxed-warning-due-restricting-use" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fda.gov/safety/medical-product-safety-information/singulair-montelukast-and-all-montelukast-generics-strengthened-boxed-warning-due-restricting-use</a></span></div></li><li id="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2792596" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2792596" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2792596</a></span></div></li><li id="https://www.jwatch.org/na58696/2025/04/29/does-montelukast-cause-neuropsychiatric-side-effects" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.jwatch.org/na58696/2025/04/29/does-montelukast-cause-neuropsychiatric-side-effects" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.jwatch.org/na58696/2025/04/29/does-montelukast-cause-neuropsychiatric-side-effects</a></span></div></li><li id="https://www.merck.com/company-overview/history/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.merck.com/company-overview/history/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.merck.com/company-overview/history/</a></span></div></li><li id="https://onlinelibrary.wiley.com/doi/10.1002/9781118219683.ch8" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://onlinelibrary.wiley.com/doi/10.1002/9781118219683.ch8" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://onlinelibrary.wiley.com/doi/10.1002/9781118219683.ch8</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/11774796/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/11774796/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/11774796/</a></span></div></li><li id="https://pubs.acs.org/doi/10.1021/op900311z" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubs.acs.org/doi/10.1021/op900311z" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubs.acs.org/doi/10.1021/op900311z</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020829s000_SingulairTOC.cfm" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020829s000_SingulairTOC.cfm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020829s000_SingulairTOC.cfm</a></span></div></li><li id="https://www.tandfonline.com/doi/full/10.1586/eci.09.62" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.tandfonline.com/doi/full/10.1586/eci.09.62" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.tandfonline.com/doi/full/10.1586/eci.09.62</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/9625400/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/9625400/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/9625400/</a></span></div></li><li id="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/206943" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/206943" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/206943</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJM199807163390302" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJM199807163390302" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJM199807163390302</a></span></div></li><li id="https://patents.google.com/patent/US5565473A/en" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://patents.google.com/patent/US5565473A/en" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://patents.google.com/patent/US5565473A/en</a></span></div></li><li id="https://www.fiercebiotech.com/biotech/merck-wins-singulair-patent-infringement-lawsuit" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fiercebiotech.com/biotech/merck-wins-singulair-patent-infringement-lawsuit" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fiercebiotech.com/biotech/merck-wins-singulair-patent-infringement-lawsuit</a></span></div></li><li id="https://www.fda.gov/media/166048/download" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fda.gov/media/166048/download" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fda.gov/media/166048/download</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/090955Orig1s000ltr.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/090955Orig1s000ltr.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/090955Orig1s000ltr.pdf</a></span></div></li><li id="https://www.chemspider.com/Chemical-Structure.4444507.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.chemspider.com/Chemical-Structure.4444507.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.chemspider.com/Chemical-Structure.4444507.html</a></span></div></li><li id="https://pubchem.ncbi.nlm.nih.gov/compound/Montelukast" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubchem.ncbi.nlm.nih.gov/compound/Montelukast" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubchem.ncbi.nlm.nih.gov/compound/Montelukast</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020829s051_020830s052_021409s028lbl.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020829s051_020830s052_021409s028lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020829s051_020830s052_021409s028lbl.pdf</a></span></div></li><li id="https://pdf.hres.ca/dpd_pm/00060653.PDF" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pdf.hres.ca/dpd_pm/00060653.PDF" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pdf.hres.ca/dpd_pm/00060653.PDF</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020829s049%2C020830s051%2C021409s027lbl.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020829s049%2C020830s051%2C021409s027lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020829s049%2C020830s051%2C021409s027lbl.pdf</a></span></div></li><li id="https://www.chemicalbook.com/ChemicalProductProperty_US_CB7112818.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.chemicalbook.com/ChemicalProductProperty_US_CB7112818.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.chemicalbook.com/ChemicalProductProperty_US_CB7112818.aspx</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020829s073%2C020830s075%2C021409s051lbl.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020829s073%2C020830s075%2C021409s051lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020829s073%2C020830s075%2C021409s051lbl.pdf</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4967539/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4967539/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4967539/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10953006/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10953006/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10953006/</a></span></div></li><li id="https://www.atsjournals.org/doi/10.1164/ajrccm.157.6.mar-2" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.atsjournals.org/doi/10.1164/ajrccm.157.6.mar-2" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.atsjournals.org/doi/10.1164/ajrccm.157.6.mar-2</a></span></div></li><li id="https://onlinelibrary.wiley.com/doi/10.1046/j.1472-9725.2001.t01-1-00011.x" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://onlinelibrary.wiley.com/doi/10.1046/j.1472-9725.2001.t01-1-00011.x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://onlinelibrary.wiley.com/doi/10.1046/j.1472-9725.2001.t01-1-00011.x</a></span></div></li><li id="https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/montelukast" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/montelukast" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/montelukast</a></span></div></li><li id="https://labeling.pfizer.com/showlabeling.aspx?id=997" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://labeling.pfizer.com/showlabeling.aspx?id=997" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://labeling.pfizer.com/showlabeling.aspx?id=997</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC6033076/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6033076/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC6033076/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/9351905/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/9351905/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/9351905/</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021409s036lbl.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021409s036lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021409s036lbl.pdf</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020829s046lbl.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020829s046lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020829s046lbl.pdf</a></span></div></li><li id="https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=23964723-2df8-4d0a-a53d-8538469672f1&amp;type=display" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=23964723-2df8-4d0a-a53d-8538469672f1&amp;type=display" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=23964723-2df8-4d0a-a53d-8538469672f1&amp;type=display</a></span></div></li><li id="https://www.jacionline.org/article/S0091-6749%2824%2900571-2/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.jacionline.org/article/S0091-6749%2824%2900571-2/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.jacionline.org/article/S0091-6749%2824%2900571-2/fulltext</a></span></div></li><li id="https://onlinelibrary.wiley.com/doi/full/10.1111%252Fall.15850" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://onlinelibrary.wiley.com/doi/full/10.1111%252Fall.15850" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://onlinelibrary.wiley.com/doi/full/10.1111%252Fall.15850</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/29777328/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/29777328/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/29777328/</a></span></div></li><li id="https://medicaljournalssweden.se/actadv/article/view/43140/50291" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://medicaljournalssweden.se/actadv/article/view/43140/50291" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://medicaljournalssweden.se/actadv/article/view/43140/50291</a></span></div></li><li id="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2825081" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2825081" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2825081</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7938648/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7938648/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7938648/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11073911/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11073911/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11073911/</a></span></div></li><li id="https://www.clinicaltrials.gov/study/NCT03991988" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.clinicaltrials.gov/study/NCT03991988" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.clinicaltrials.gov/study/NCT03991988</a></span></div></li><li id="https://www.acpjournals.org/doi/10.7326/ACPJC-2002-137-1-020" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.acpjournals.org/doi/10.7326/ACPJC-2002-137-1-020" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.acpjournals.org/doi/10.7326/ACPJC-2002-137-1-020</a></span></div></li><li id="https://www.atsjournals.org/doi/10.1164/rccm.200407-894OC" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.atsjournals.org/doi/10.1164/rccm.200407-894OC" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.atsjournals.org/doi/10.1164/rccm.200407-894OC</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3513871/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3513871/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3513871/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7568952/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7568952/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7568952/</a></span></div></li><li id="https://www.annallergy.org/article/S1081-1206%2810%2962144-8/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.annallergy.org/article/S1081-1206%2810%2962144-8/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.annallergy.org/article/S1081-1206%2810%2962144-8/fulltext</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/16626955/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/16626955/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/16626955/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S0954611106001132" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S0954611106001132" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S0954611106001132</a></span></div></li><li id="https://www.atsjournals.org/doi/10.1164/rccm.200208-802OC" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.atsjournals.org/doi/10.1164/rccm.200208-802OC" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.atsjournals.org/doi/10.1164/rccm.200208-802OC</a></span></div></li><li id="https://bmcpulmmed.biomedcentral.com/articles/10.1186/1471-2466-13-20" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcpulmmed.biomedcentral.com/articles/10.1186/1471-2466-13-20" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcpulmmed.biomedcentral.com/articles/10.1186/1471-2466-13-20</a></span></div></li><li id="https://www.aafp.org/pubs/afp/issues/2006/0301/p903.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.aafp.org/pubs/afp/issues/2006/0301/p903.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.aafp.org/pubs/afp/issues/2006/0301/p903.html</a></span></div></li><li id="https://journals.lww.com/ebp/fulltext/2012/12000/how_does_montelukast_compare_with_inhaled.27.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.lww.com/ebp/fulltext/2012/12000/how_does_montelukast_compare_with_inhaled.27.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.lww.com/ebp/fulltext/2012/12000/how_does_montelukast_compare_with_inhaled.27.aspx</a></span></div></li><li id="https://publications.ersnet.org/content/errev/32/170/230124" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://publications.ersnet.org/content/errev/32/170/230124" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://publications.ersnet.org/content/errev/32/170/230124</a></span></div></li><li id="https://www.jacionline.org/article/S0091-6749%2808%2900140-1/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.jacionline.org/article/S0091-6749%2808%2900140-1/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.jacionline.org/article/S0091-6749%2808%2900140-1/fulltext</a></span></div></li><li id="https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-023-02721-z" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-023-02721-z" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-023-02721-z</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/27522261/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/27522261/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/27522261/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/32915441/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/32915441/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/32915441/</a></span></div></li><li id="https://www.jwatch.org/na58292/2025/01/23/oral-agents-or-nasal-sprays-allergic-rhinitis" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.jwatch.org/na58292/2025/01/23/oral-agents-or-nasal-sprays-allergic-rhinitis" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.jwatch.org/na58292/2025/01/23/oral-agents-or-nasal-sprays-allergic-rhinitis</a></span></div></li><li id="https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1287320/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1287320/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1287320/full</a></span></div></li><li id="https://www.e-cep.org/journal/view.php?doi=10.3345/cep.2019.00325" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.e-cep.org/journal/view.php?doi=10.3345/cep.2019.00325" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.e-cep.org/journal/view.php?doi=10.3345/cep.2019.00325</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC5142440/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5142440/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC5142440/</a></span></div></li><li id="https://japi.org/article/japi-73-5-70" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://japi.org/article/japi-73-5-70" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://japi.org/article/japi-73-5-70</a></span></div></li><li id="https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.01094/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.01094/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.01094/full</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC6425064/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6425064/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC6425064/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10543051/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10543051/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10543051/</a></span></div></li><li id="https://www.all-imm.com/index.php/aei/article/view/1183/1771" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.all-imm.com/index.php/aei/article/view/1183/1771" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.all-imm.com/index.php/aei/article/view/1183/1771</a></span></div></li><li id="https://www.medcentral.com/drugs/monograph/6478-300014/montelukast-oral" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.medcentral.com/drugs/monograph/6478-300014/montelukast-oral" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.medcentral.com/drugs/monograph/6478-300014/montelukast-oral</a></span></div></li><li id="https://www.drugs.com/pro/montelukast-tablets.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugs.com/pro/montelukast-tablets.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.drugs.com/pro/montelukast-tablets.html</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC5625152/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5625152/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC5625152/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/25196099/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/25196099/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/25196099/</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK548264/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK548264/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK548264/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC6074176/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6074176/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC6074176/</a></span></div></li><li id="https://www.journal-of-hepatology.eu/article/S0168-8278%2803%2900085-0/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.journal-of-hepatology.eu/article/S0168-8278%2803%2900085-0/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.journal-of-hepatology.eu/article/S0168-8278%2803%2900085-0/fulltext</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/10712995/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/10712995/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/10712995/</a></span></div></li><li id="https://journal.chestnet.org/article/S0012-3692%2815%2932727-6/abstract" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journal.chestnet.org/article/S0012-3692%2815%2932727-6/abstract" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journal.chestnet.org/article/S0012-3692%2815%2932727-6/abstract</a></span></div></li><li id="https://academic.oup.com/qjmed/article-abstract/101/8/669/1539611" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/qjmed/article-abstract/101/8/669/1539611" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/qjmed/article-abstract/101/8/669/1539611</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC2935275/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2935275/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC2935275/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/10335014/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/10335014/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/10335014/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/33744471/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/33744471/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/33744471/</a></span></div></li><li id="https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.764279/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.764279/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.764279/full</a></span></div></li><li id="https://bmjpaedsopen.bmj.com/content/8/1/e002483" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmjpaedsopen.bmj.com/content/8/1/e002483" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmjpaedsopen.bmj.com/content/8/1/e002483</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/26620206/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/26620206/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/26620206/</a></span></div></li><li id="https://www.mdpi.com/1424-8247/18/3/379" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mdpi.com/1424-8247/18/3/379" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mdpi.com/1424-8247/18/3/379</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10523155/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10523155/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10523155/</a></span></div></li><li id="https://www.jacionline.org/article/S0091-6749%2809%2901247-0/pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.jacionline.org/article/S0091-6749%2809%2901247-0/pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.jacionline.org/article/S0091-6749%2809%2901247-0/pdf</a></span></div></li><li id="https://www.contemporarypediatrics.com/view/study-no-association-montelukast-neuropsychiatric-adverse-event-risk" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.contemporarypediatrics.com/view/study-no-association-montelukast-neuropsychiatric-adverse-event-risk" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.contemporarypediatrics.com/view/study-no-association-montelukast-neuropsychiatric-adverse-event-risk</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/34987393/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/34987393/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/34987393/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S1939455121000880" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S1939455121000880" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S1939455121000880</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10685197/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10685197/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10685197/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S2405844023090503" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S2405844023090503" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S2405844023090503</a></span></div></li><li id="https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1659852/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1659852/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1659852/full</a></span></div></li><li id="https://www.frontiersin.org/articles/10.3389/fphar.2025.1659852/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/articles/10.3389/fphar.2025.1659852/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/articles/10.3389/fphar.2025.1659852/full</a></span></div></li><li id="https://publications.ersnet.org/content/errev/32/169/230079" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://publications.ersnet.org/content/errev/32/169/230079" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://publications.ersnet.org/content/errev/32/169/230079</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/37758273/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/37758273/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/37758273/</a></span></div></li><li id="https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/s40360-025-00959-3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/s40360-025-00959-3" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/s40360-025-00959-3</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11733910/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11733910/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11733910/</a></span></div></li><li id="https://www.fda.gov/media/158486/download" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fda.gov/media/158486/download" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fda.gov/media/158486/download</a></span></div></li><li id="https://www.psychiatrist.com/pcc/montelukast-induced-behavioral-problems-child-bronchial-asthma/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.psychiatrist.com/pcc/montelukast-induced-behavioral-problems-child-bronchial-asthma/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.psychiatrist.com/pcc/montelukast-induced-behavioral-problems-child-bronchial-asthma/</a></span></div></li><li id="https://www.psychiatrist.com/pcc/montelukast-associated-psychosis-children/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.psychiatrist.com/pcc/montelukast-associated-psychosis-children/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.psychiatrist.com/pcc/montelukast-associated-psychosis-children/</a></span></div></li><li id="https://www.gov.uk/drug-safety-update/montelukast-reminder-of-the-risk-of-neuropsychiatric-reactions" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.gov.uk/drug-safety-update/montelukast-reminder-of-the-risk-of-neuropsychiatric-reactions" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.gov.uk/drug-safety-update/montelukast-reminder-of-the-risk-of-neuropsychiatric-reactions</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/34659626/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/34659626/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/34659626/</a></span></div></li><li id="https://newsroom.uw.edu/blog/concerned-about-asthma-drugs-side-effects-ask-a-doctor" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://newsroom.uw.edu/blog/concerned-about-asthma-drugs-side-effects-ask-a-doctor" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://newsroom.uw.edu/blog/concerned-about-asthma-drugs-side-effects-ask-a-doctor</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020829s033_020830s035_021409s012Approv.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020829s033_020830s035_021409s012Approv.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020829s033_020830s035_021409s012Approv.pdf</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20830s008_Singulair.cfm" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20830s008_Singulair.cfm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20830s008_Singulair.cfm</a></span></div></li><li id="https://www.fda.gov/drugs/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fda.gov/drugs/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fda.gov/drugs/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug</a></span></div></li><li id="https://www.ema.europa.eu/en/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_en.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ema.europa.eu/en/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_en.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ema.europa.eu/en/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_en.pdf</a></span></div></li><li id="https://www.gov.uk/drug-safety-update/montelukast-singulair-reminder-of-the-risk-of-neuropsychiatric-reactions" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.gov.uk/drug-safety-update/montelukast-singulair-reminder-of-the-risk-of-neuropsychiatric-reactions" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.gov.uk/drug-safety-update/montelukast-singulair-reminder-of-the-risk-of-neuropsychiatric-reactions</a></span></div></li><li id="https://www.gov.uk/government/news/outcome-of-mhra-review-of-neuropsychiatric-reactions-with-montelukast" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.gov.uk/government/news/outcome-of-mhra-review-of-neuropsychiatric-reactions-with-montelukast" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.gov.uk/government/news/outcome-of-mhra-review-of-neuropsychiatric-reactions-with-montelukast</a></span></div></li><li id="https://www.tga.gov.au/news/safety-alerts/montelukast" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.tga.gov.au/news/safety-alerts/montelukast" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.tga.gov.au/news/safety-alerts/montelukast</a></span></div></li><li id="https://www.tga.gov.au/news/safety-updates/more-prominent-safety-warnings-about-neuropsychiatric-effects-montelukast" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.tga.gov.au/news/safety-updates/more-prominent-safety-warnings-about-neuropsychiatric-effects-montelukast" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.tga.gov.au/news/safety-updates/more-prominent-safety-warnings-about-neuropsychiatric-effects-montelukast</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12220754/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12220754/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12220754/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/39099387/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/39099387/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/39099387/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9189082/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9189082/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9189082/</a></span></div></li><li id="https://www.acpjournals.org/doi/10.7326/0003-4819-132-11-200006060-00022" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.acpjournals.org/doi/10.7326/0003-4819-132-11-200006060-00022" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.acpjournals.org/doi/10.7326/0003-4819-132-11-200006060-00022</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3269585/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3269585/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3269585/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/21289076/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/21289076/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/21289076/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/27648490/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/27648490/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/27648490/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/20592724/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/20592724/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/20592724/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S0090955624031271" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S0090955624031271" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S0090955624031271</a></span></div></li><li id="https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.947" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.947" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.947</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC2000739/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2000739/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC2000739/</a></span></div></li><li id="https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=28881947-535f-e3de-e063-6394a90a0caf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=28881947-535f-e3de-e063-6394a90a0caf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=28881947-535f-e3de-e063-6394a90a0caf</a></span></div></li><li id="https://www.healthline.com/health/drugs/montelukast-oral-forms-interactions" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.healthline.com/health/drugs/montelukast-oral-forms-interactions" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.healthline.com/health/drugs/montelukast-oral-forms-interactions</a></span></div></li><li id="https://www.droracle.ai/articles/347688/does-montelukast-have-any-drug-interaction" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.droracle.ai/articles/347688/does-montelukast-have-any-drug-interaction" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.droracle.ai/articles/347688/does-montelukast-have-any-drug-interaction</a></span></div></li><li id="https://www.drugs.com/drug-interactions/montelukast.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugs.com/drug-interactions/montelukast.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.drugs.com/drug-interactions/montelukast.html</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/10234597/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/10234597/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/10234597/</a></span></div></li><li id="https://investor.endo.com/2012-08-06-Qualitest-Launches-Generic-Singulair-R" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://investor.endo.com/2012-08-06-Qualitest-Launches-Generic-Singulair-R" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://investor.endo.com/2012-08-06-Qualitest-Launches-Generic-Singulair-R</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20830_Singulair_admindocs.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20830_Singulair_admindocs.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20830_Singulair_admindocs.pdf</a></span></div></li><li id="https://www.singlecare.com/blog/singulair-generic/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.singlecare.com/blog/singulair-generic/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.singlecare.com/blog/singulair-generic/</a></span></div></li><li id="https://pharmatimes.com/news/fda_approves_first_generics_of_mercks_singulair_976848/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pharmatimes.com/news/fda_approves_first_generics_of_mercks_singulair_976848/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pharmatimes.com/news/fda_approves_first_generics_of_mercks_singulair_976848/</a></span></div></li><li id="https://www.linkedin.com/pulse/montelukast-drug-sales-market-applications-overview-ptbxc/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.linkedin.com/pulse/montelukast-drug-sales-market-applications-overview-ptbxc/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.linkedin.com/pulse/montelukast-drug-sales-market-applications-overview-ptbxc/</a></span></div></li><li id="https://www.grandviewresearch.com/industry-analysis/montelukast-sodium-market-report" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.grandviewresearch.com/industry-analysis/montelukast-sodium-market-report" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.grandviewresearch.com/industry-analysis/montelukast-sodium-market-report</a></span></div></li><li id="https://www.datainsightsmarket.com/reports/montelukast-1208984" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.datainsightsmarket.com/reports/montelukast-1208984" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.datainsightsmarket.com/reports/montelukast-1208984</a></span></div></li><li id="https://www.gabionline.net/generics/news/FDA-approves-generics-of-Merck-s-Singulair" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.gabionline.net/generics/news/FDA-approves-generics-of-Merck-s-Singulair" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.gabionline.net/generics/news/FDA-approves-generics-of-Merck-s-Singulair</a></span></div></li><li id="https://clincalc.com/DrugStats/Drugs/Montelukast" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://clincalc.com/DrugStats/Drugs/Montelukast" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://clincalc.com/DrugStats/Drugs/Montelukast</a></span></div></li><li id="https://www.fda.gov/media/131183/download" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fda.gov/media/131183/download" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fda.gov/media/131183/download</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S2667276624001069" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S2667276624001069" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S2667276624001069</a></span></div></li><li id="https://www.merck.com/news/merck-announces-full-year-and-fourth-quarter-2011-financial-results/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.merck.com/news/merck-announces-full-year-and-fourth-quarter-2011-financial-results/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.merck.com/news/merck-announces-full-year-and-fourth-quarter-2011-financial-results/</a></span></div></li><li id="https://www.fiercepharma.com/sales-and-marketing/merck-s-singulair-sales-free-fall-90-4-weeks" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fiercepharma.com/sales-and-marketing/merck-s-singulair-sales-free-fall-90-4-weeks" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fiercepharma.com/sales-and-marketing/merck-s-singulair-sales-free-fall-90-4-weeks</a></span></div></li><li id="https://www.goodrx.com/montelukast" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.goodrx.com/montelukast" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.goodrx.com/montelukast</a></span></div></li></ol></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw" id="_R_" async=""></script><script nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw\"}]\n"])</script><script nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Montelukast\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Montelukast\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Montelukast\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T13ac0,"])</script><script nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw">self.__next_f.push([1,"# Montelukast\n\n![Montelukast chemical structure](./_assets_/Montelukast.svg.png)  \nMontelukast is a selective, orally active antagonist of the cysteinyl leukotriene receptor 1 (CysLT1), which inhibits the physiologic actions of leukotriene D4, thereby reducing airway inflammation, bronchoconstriction, and related symptoms in respiratory conditions.[](https://www.ncbi.nlm.nih.gov/books/NBK459301/)[](https://go.drugbank.com/drugs/DB00471)  \nDeveloped by Merck \u0026 Co. and approved by the U.S. Food and Drug Administration (FDA) in 1998 as Singulair, it is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients as young as six months, prevention of exercise-induced bronchoconstriction in patients six years and older, and relief of symptoms associated with seasonal and perennial allergic rhinitis.[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug)[](https://www.ncbi.nlm.nih.gov/books/NBK459301/)[](https://www.fda.gov/safety/medical-product-safety-information/singulair-montelukast-and-all-montelukast-generics-strengthened-boxed-warning-due-restricting-use)  \nAvailable in tablet, chewable tablet, and granule formulations, montelukast offers once-daily dosing and has been widely prescribed as an add-on therapy to inhaled corticosteroids or as monotherapy for mild persistent asthma, contributing to improved asthma control in millions of patients globally without the need for inhaled delivery in some cases.[](https://www.ncbi.nlm.nih.gov/books/NBK459301/)[](https://go.drugbank.com/drugs/DB00471)  \nDespite its efficacy in leukotriene-mediated pathways, montelukast has faced scrutiny over potential neuropsychiatric adverse effects, prompting the FDA in 2020 to mandate a boxed warning highlighting risks of serious mood changes, depression, and suicidality based on post-marketing surveillance data involving thousands of reports, though causality remains debated in peer-reviewed analyses.[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug)[](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2792596)[](https://www.jwatch.org/na58696/2025/04/29/does-montelukast-cause-neuropsychiatric-side-effects)\n\n## History and Development\n\n### Discovery and Synthesis\n\n![Montelukast chemical structure](./_assets_/Montelukast.svg.png)\n\nMontelukast was discovered through a dedicated medicinal chemistry program at Merck Frosst Canada Ltd. in Montreal, Quebec, initiated in the early 1980s to develop selective antagonists for the leukotriene D4 (LTD4) receptor, recognized as a critical mediator in asthma pathophysiology following the 1979 identification of leukotrienes.[](https://www.merck.com/company-overview/history/)[](https://onlinelibrary.wiley.com/doi/10.1002/9781118219683.ch8) The effort, spanning nearly two decades, began with lead generation via screening of natural products and rational design based on LTD4 structure, progressing through iterative structure-activity relationship studies to optimize potency, selectivity for CysLT1 over other receptors, oral bioavailability, and duration of action.[](https://pubmed.ncbi.nlm.nih.gov/11774796/) Robert N. Young and team at Merck Frosst synthesized and evaluated hundreds of analogs, selecting montelukast (initially designated MK-0476) for its superior profile, including nanomolar affinity for human LTD4 receptors and once-daily dosing potential.[](https://onlinelibrary.wiley.com/doi/10.1002/9781118219683.ch8)\n\nThe initial synthesis of montelukast was detailed in European Patent EP 480717 B1, with priority filing on December 21, 1990, by Merck Frosst inventors including Young. This multi-step process commences with the preparation of a mercaptomethylcyclopropylacetic acid derivative, which undergoes alkylation with a dihalide to form a thioether linkage, followed by coupling to a 2-(2-chloroquinolin-3-yl)acetic acid moiety via amide bond formation using activating agents. Subsequent steps include reduction of a nitro group to an amine, acylation with a methoxyacetamide, and hydrolysis of an ester to the carboxylic acid, culminating in sodium salt formation. This route established the stereoselective assembly of montelukast's key structural elements, including the carboxymethylcyclopropyl and quinoline-piperazine motifs essential for receptor binding. Later improvements focused on yield, purity, and scalability, but the original method laid the foundation for clinical material production.[](https://pubs.acs.org/doi/10.1021/op900311z)\n\n### Clinical Trials Leading to Approval\n\nThe U.S. Food and Drug Administration approved montelukast sodium (branded as Singulair by Merck Research Laboratories) on February 20, 1998, for prophylaxis and chronic treatment of asthma in adults and adolescents aged 15 years and older.[](https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020829s000_SingulairTOC.cfm) This approval relied on efficacy and safety data from phase II dose-ranging studies and multiple phase III trials, which established montelukast as a once-daily oral leukotriene receptor antagonist superior to placebo in improving asthma control without the need for inhaled corticosteroids.[](https://www.tandfonline.com/doi/full/10.1586/eci.09.62)\n\nPivotal evidence came from three 12-week, multicenter, randomized, double-blind, placebo-controlled phase III studies enrolling a total of 2,471 patients aged 15 years or older with mild persistent asthma inadequately controlled by as-needed Î²-agonists alone.[](https://www.tandfonline.com/doi/full/10.1586/eci.09.62) In these trials, montelukast at 10 mg once daily in the evening significantly increased morning peak expiratory flow by 20â€“25 L/min, improved forced expiratory volume in one second (FEV\u003csub\u003e1\u003c/sub\u003e) by approximately 0.3â€“0.4 L or 8â€“13% from baseline, reduced daytime and nighttime asthma symptoms, and decreased Î²-agonist rescue use by 1â€“2 puffs per day compared to placebo, with all differences statistically significant (p \u003c 0.001).[](https://pubmed.ncbi.nlm.nih.gov/9625400/)[](https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/206943) One such study, involving 373 adults, reported montelukast-treated patients achieving a mean FEV\u003csub\u003e1\u003c/sub\u003e increase of 0.49 L versus 0.31 L for placebo, alongside fewer asthma exacerbations requiring corticosteroids.[](https://pubmed.ncbi.nlm.nih.gov/9625400/)\n\nSafety profiles across these trials showed montelukast was well tolerated, with adverse event rates comparable to placebo (around 80â€“90% incidence overall), primarily mild gastrointestinal or headache-related, and no significant differences in serious adverse events or discontinuations due to side effects.[](https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/206943)[](https://www.tandfonline.com/doi/full/10.1586/eci.09.62) Additional supportive data included a 12-week trial specifically for exercise-induced bronchoconstriction in 47 patients aged 15â€“55 years, where montelukast reduced the maximal percent fall in FEV\u003csub\u003e1\u003c/sub\u003e post-exercise from 40% to 20% versus placebo.[](https://www.nejm.org/doi/full/10.1056/NEJM199807163390302) These outcomes, derived from standardized endpoints like spirometry and symptom diaries, confirmed montelukast's role as an add-on or alternative controller without systemic steroid risks, informing the initial labeling excluding acute asthma relief.[](https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020829s000_SingulairTOC.cfm)\n\n### Patent Timeline and Expiry\n\nThe primary patent covering montelukast sodium, the active ingredient in Singulair, is U.S. Patent No. 5,565,473, which claims leukotriene antagonists including the compound.[](https://patents.google.com/patent/US5565473A/en) This patent traces its priority to an application filed on October 12, 1990, with the U.S. filing occurring on February 23, 1995, and issuance on October 15, 1996.[](https://patents.google.com/patent/US5565473A/en) Merck \u0026 Co., the developer, defended the patent against challenges, including a 2009 federal court ruling upholding its validity and enjoining generic entry by Teva Pharmaceuticals until the expiration date.[](https://www.fiercebiotech.com/biotech/merck-wins-singulair-patent-infringement-lawsuit)\n\nThe patent's original term was extended through regulatory adjustments and pediatric exclusivity, resulting in an effective expiry on August 3, 2012.[](https://www.fda.gov/media/166048/download) On that date, the U.S. Food and Drug Administration approved multiple abbreviated new drug applications for generic montelukast sodium, enabling market entry and substantial erosion of Singulair's U.S. sales, which exceeded $5 billion annually prior to expiry.[](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/090955Orig1s000ltr.pdf) Subsequent patents, such as U.S. Patent No. 8,007,830 for certain formulations, extended protection for specific products until October 24, 2022, but did not block generic versions of the core compound post-2012.[](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/090955Orig1s000ltr.pdf)\n\n## Pharmacology\n\n### Chemical Structure and Properties\n\n![Montelukast chemical structure](./_assets_/Montelukast.svg.png)\nMontelukast is chemically designated as 2-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid.[](https://www.chemspider.com/Chemical-Structure.4444507.html) The compound features a 7-chloroquinoline moiety linked via a trans-ethenyl bridge to a phenyl ring, which is connected to a chiral propyl chain bearing a 2-(1-hydroxy-1-methylethyl)phenyl substituent; this chain terminates in a sulfanylmethyl group attached to a cyclopropylacetic acid.[](https://pubchem.ncbi.nlm.nih.gov/compound/Montelukast) Its molecular formula is Câ‚ƒâ‚…Hâ‚ƒâ‚†ClNOâ‚ƒS, with a molecular weight of 586.19 g/mol.[](https://pubchem.ncbi.nlm.nih.gov/compound/Montelukast)\nThe pharmaceutical form is the monosodium salt, with the formula Câ‚ƒâ‚…Hâ‚ƒâ‚…ClNNaOâ‚ƒS and molecular weight of 608.18 g/mol.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020829s051_020830s052_021409s028lbl.pdf) Montelukast sodium appears as a hygroscopic, optically active, white to off-white, free-flowing powder.[](https://pdf.hres.ca/dpd_pm/00060653.PDF) It exhibits solubility in ethanol but limited aqueous solubility, consistent with its lipophilic profile indicated by a calculated logP of approximately 6.4.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020829s049%2C020830s051%2C021409s027lbl.pdf) The melting point of the free acid is reported as 145â€“148 Â°C in solvents such as toluene and methanol.[](https://www.chemicalbook.com/ChemicalProductProperty_US_CB7112818.aspx)\n\n### Mechanism of Action\n\nMontelukast is a selective and orally active antagonist of the cysteinyl leukotriene type 1 receptor (CysLT\u003csub\u003e1\u003c/sub\u003e), a G-protein-coupled receptor expressed on airway smooth muscle cells, macrophages, eosinophils, and other inflammatory cells.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020829s073%2C020830s075%2C021409s051lbl.pdf) Cysteinyl leukotrienes (LTC\u003csub\u003e4\u003c/sub\u003e, LTD\u003csub\u003e4\u003c/sub\u003e, and LTE\u003csub\u003e4\u003c/sub\u003e), derived from arachidonic acid metabolism via the 5-lipoxygenase pathway, are released from mast cells, eosinophils, and basophils in response to allergic or inflammatory stimuli.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020829s073%2C020830s075%2C021409s051lbl.pdf) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC4967539/) These mediators bind to CysLT\u003csub\u003e1\u003c/sub\u003e, triggering downstream signaling that promotes bronchoconstriction, enhanced mucus production, increased vascular permeability, eosinophil chemotaxis, and edema formation in the airways.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020829s073%2C020830s075%2C021409s051lbl.pdf) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC10953006/)\n\nBy competitively binding to CysLT\u003csub\u003e1\u003c/sub\u003e with high affinity (K\u003csub\u003ei\u003c/sub\u003e â‰ˆ 0.9 nM for LTD\u003csub\u003e4\u003c/sub\u003e inhibition) and without intrinsic agonist activity, montelukast prevents cysteinyl leukotrienes from eliciting these effects, thereby attenuating airway inflammation and hyperresponsiveness.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020829s073%2C020830s075%2C021409s051lbl.pdf) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC4967539/) Unlike 5-lipoxygenase inhibitors such as zileuton, montelukast does not block leukotriene biosynthesis but specifically antagonizes receptor-mediated actions, demonstrating selectivity for CysLT\u003csub\u003e1\u003c/sub\u003e over other leukotriene receptors (e.g., CysLT\u003csub\u003e2\u003c/sub\u003e) and unrelated receptors like histamine or prostaglandin types.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020829s073%2C020830s075%2C021409s051lbl.pdf) [](https://www.atsjournals.org/doi/10.1164/ajrccm.157.6.mar-2)\n\nIn pharmacodynamic studies, montelukast inhibits LTD\u003csub\u003e4\u003c/sub\u003e-induced bronchoconstriction in asthmatics, with near-complete blockade achieved at therapeutic doses (e.g., 5-10 mg), correlating with plasma concentrations above 5 nM.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020829s073%2C020830s075%2C021409s051lbl.pdf) This receptor antagonism reduces early- and late-phase asthmatic responses without altering histamine-mediated effects, underscoring its targeted role in leukotriene-driven pathology.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10953006/)\n\n### Pharmacokinetics and Metabolism\n\nMontelukast is rapidly absorbed after oral administration, achieving peak plasma concentrations typically within 3 to 4 hours in adults, with a mean absorption time of approximately 2.6 hours in females and 3.4 hours in males.[](https://onlinelibrary.wiley.com/doi/10.1046/j.1472-9725.2001.t01-1-00011.x) The oral bioavailability is estimated at around 64%, though systemic absorption of the administered dose is about 58%, with the remainder likely undergoing first-pass metabolism.[](https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/montelukast) Food does not significantly alter its absorption profile.[](https://www.ncbi.nlm.nih.gov/books/NBK459301/)\n\nThe drug exhibits high plasma protein binding, exceeding 99%, primarily to albumin, with a steady-state volume of distribution averaging 8 to 11 liters, indicating moderate tissue distribution.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020829s051_020830s052_021409s028lbl.pdf) [](https://labeling.pfizer.com/showlabeling.aspx?id=997)\n\nMontelukast undergoes extensive hepatic metabolism, with cytochrome P450 2C8 (CYP2C8) mediating approximately 80% of its biotransformation, contrary to earlier product information emphasizing CYP3A4 and CYP2C9; these isoforms play lesser roles.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6033076/) Multiple metabolites are formed, but the parent compound retains pharmacological activity.[](https://pubmed.ncbi.nlm.nih.gov/9351905/)\n\nElimination occurs primarily via biliary excretion into feces, with montelukast and its metabolites accounting for nearly exclusive fecal recovery and negligible urinary excretion, even in renal impairment.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020829s051_020830s052_021409s028lbl.pdf) The mean plasma elimination half-life ranges from 2.7 to 5.5 hours in healthy individuals, supporting once-daily dosing, and pharmacokinetics remain linear for oral doses up to 50 mg.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020829s051_020830s052_021409s028lbl.pdf) [](https://www.ncbi.nlm.nih.gov/books/NBK459301/)\n\n## Clinical Uses\n\n### Approved Indications\n\nMontelukast, marketed under the brand name Singulair, is approved by the U.S. Food and Drug Administration (FDA) for the prophylaxis and chronic treatment of asthma in adults and pediatric patients aged 12 months and older.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021409s036lbl.pdf) This indication encompasses maintenance therapy to reduce the frequency of asthma exacerbations and improve daytime and nighttime symptoms, but it is not intended for the relief of acute bronchospasm or status asthmaticus.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021409s036lbl.pdf) Approval for asthma was granted based on clinical trials demonstrating reductions in inhaled corticosteroid requirements and improvements in lung function metrics such as forced expiratory volume in one second (FEV1).[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021409s036lbl.pdf)\n\nThe drug is also indicated for the prevention of exercise-induced bronchoconstriction (EIB) in patients aged 6 years and older, with a single dose administered at least 2 hours prior to exercise shown to inhibit bronchoconstriction triggered by physical activity.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020829s073%2C020830s075%2C021409s051lbl.pdf) Efficacy in this context was established in trials where montelukast reduced the maximal percent fall in FEV1 following exercise challenge by approximately 50% compared to placebo.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021409s036lbl.pdf)\n\nFor allergic rhinitis, montelukast is approved to provide relief of symptoms associated with seasonal allergic rhinitis in adults and pediatric patients aged 2 years and older, and perennial allergic rhinitis in adults and pediatric patients aged 6 months and older.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021409s036lbl.pdf) These approvals stem from randomized controlled trials showing statistically significant improvements in total symptom scores, including nasal congestion, rhinorrhea, itching, and sneezing, versus placebo.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020829s046lbl.pdf) The FDA specifies that montelukast should not be used as monotherapy for allergic rhinitis but may be added to other treatments as appropriate.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021409s036lbl.pdf)\n\n### Dosage and Administration\n\nMontelukast is administered orally once daily, with or without food, for the prophylaxis and chronic treatment of asthma and for the management of allergic rhinitis. For asthma, dosing occurs in the evening regardless of time of day symptoms occur, while for allergic rhinitis alone, timing may be individualized; patients with both conditions receive only one dose daily in the evening. It is not indicated for acute asthma attacks or status asthmaticus, and patients must have appropriate rescue medication available. Doses should not exceed the recommended amount, and no more than one dose is permitted within 24 hours.[](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=23964723-2df8-4d0a-a53d-8538469672f1\u0026type=display)\n\nThe following table summarizes recommended dosages by age group, indication, and formulation:\n\n| Age Group          | Asthma                          | Allergic Rhinitis (Seasonal or Perennial) | Exercise-Induced Bronchoconstriction (EIB) |\n|--------------------|---------------------------------|------------------------------------------|--------------------------------------------|\n| â‰¥15 years         | 10 mg tablet, once daily evening | 10 mg tablet, once daily (timing flexible) | 10 mg tablet, single dose â‰¥2 hours before exercise (not if on daily therapy) |\n| 6â€“14 years        | 5 mg chewable tablet, once daily evening | 5 mg chewable tablet, once daily (timing flexible) | 5 mg chewable tablet, single dose â‰¥2 hours before exercise (not if on daily therapy) |\n| 2â€“5 years         | 4 mg chewable tablet or 4 mg oral granules, once daily evening | 4 mg chewable tablet or 4 mg oral granules, once daily (timing flexible) | Not established                            |\n| 12â€“23 months      | 4 mg oral granules, once daily evening | 4 mg oral granules, once daily (perennial only; timing flexible) | Not established                            |\n| 6â€“11 months       | Safety and efficacy not established | 4 mg oral granules, once daily (perennial only; timing flexible) | Not established                            |\n\nChewable tablets must be chewed before swallowing; film-coated tablets are swallowed whole. Oral granules may be administered directly into the mouth, dissolved in â‰¥1 teaspoon (5 mL) of cold or room-temperature baby formula or breast milk (for infants â‰¥12 months who are not breastfed), or mixed with a small amount of soft foods such as applesauce, mashed carrots, or ice cream, but only if the mixture is consumed within 15 minutes of preparation to avoid degradationâ€”do not mix with hot, acidic, or carbonated foods/drinks. Granules should not be chewed. No dose adjustments are required for mild-to-moderate hepatic insufficiency or renal impairment, but data are limited in severe cases.[](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=23964723-2df8-4d0a-a53d-8538469672f1\u0026type=display)\n\nFor EIB, montelukast provides protection for up to 24 hours but should not be used as a substitute for inhaled short-acting beta-agonists during acute episodes; routine administration before exercise is not recommended if the patient is already receiving daily montelukast for asthma or rhinitis. Missed doses should be skipped, with the next taken at the regular timeâ€”doubling is prohibited.[](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=23964723-2df8-4d0a-a53d-8538469672f1\u0026type=display)\n\n### Off-Label Applications\n\nMontelukast has been investigated for off-label use in chronic spontaneous urticaria (CSU), where it is often combined with antihistamines to achieve modest reductions in urticaria activity scores compared to antihistamines alone, based on a 2024 meta-analysis of randomized clinical trials.[](https://www.jacionline.org/article/S0091-6749%2824%2900571-2/fulltext) This adjunctive role is supported by evidence of leukotriene involvement in mast cell-mediated inflammation, though montelukast monotherapy shows limited standalone efficacy.[](https://onlinelibrary.wiley.com/doi/full/10.1111%252Fall.15850)\n\nIn atopic dermatitis (AD), particularly moderate-to-severe cases, montelukast has demonstrated inconsistent benefits as an adjunct therapy, with a 2018 systematic review concluding limited evidence for symptom improvement, primarily in adults.[](https://pubmed.ncbi.nlm.nih.gov/29777328/) A 2025 review similarly noted potential efficacy in adult AD patients but highlighted variability across studies, attributing this to heterogeneous leukotriene pathways in skin inflammation.[](https://medicaljournalssweden.se/actadv/article/view/43140/50291)\n\nFor COVID-19, montelukast has been explored in mild-to-moderate outpatients, where a 2024 randomized trial found it shortened time to sustained recovery by approximately one day versus placebo, potentially via anti-inflammatory effects on cytokine release and lung edema.[](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2825081) In hospitalized patients, observational data suggest reduced inflammation akin to preclinical models of viral respiratory distress, though large-scale confirmation remains pending.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7938648/)\n\nEmerging off-label applications include multiple sclerosis (MS), with 2024 real-world evidence indicating reduced relapse rates when added to standard therapies, possibly due to modulation of neuroinflammation via cysteinyl leukotriene receptors.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11073911/) Ongoing trials are assessing montelukast in Alzheimer's disease for mild cognitive impairment, hypothesizing benefits from its anti-inflammatory properties in amyloid-beta pathways, but results are preliminary.[](https://www.clinicaltrials.gov/study/NCT03991988) Off-label prescribing for chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea occurs, driven by interest in leukotriene-mediated airway remodeling, yet controlled evidence is sparse.[](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2792596) Overall, these uses underscore montelukast's repurposing potential in leukotriene-driven pathologies, tempered by the need for further randomized trials to establish causality and optimal dosing.\n\n## Efficacy Evidence\n\n### Clinical Trial Outcomes\n\nIn randomized, double-blind, placebo-controlled trials establishing montelukast's efficacy for asthma prophylaxis in adults, treatment with 10 mg daily for 12 weeks resulted in significant improvements in lung function and symptom control. Morning peak expiratory flow increased by an average of 20-25 L/min compared to placebo, while forced expiratory volume in 1 second (FEV1) improved by approximately 0.1-0.2 L.[](https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/206943)[](https://pubmed.ncbi.nlm.nih.gov/9625400/) Beta-agonist rescue use decreased by 27.7% in montelukast groups versus 1.6% with placebo, and asthma-specific quality-of-life scores rose by 0.3-0.5 points on standardized scales.[](https://www.acpjournals.org/doi/10.7326/ACPJC-2002-137-1-020)\n\nPediatric trials, such as a 12-month study in children aged 2-5 years, demonstrated a 31.9% reduction in exacerbation rates with montelukast 4 mg daily versus placebo, alongside fewer days with asthma symptoms and reduced healthcare utilization.[](https://www.atsjournals.org/doi/10.1164/rccm.200407-894OC) In adolescents and adults with exercise-induced bronchoconstriction, montelukast attenuated maximal fall in FEV1 by 50-60% post-exercise compared to 20-30% with placebo.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3513871/) However, a Cochrane meta-analysis of 19 pediatric RCTs found montelukast inferior to inhaled corticosteroids for overall symptom control and lung function gains, though it provided additive benefits in patients with comorbid allergic rhinitis.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7568952/)\n\nFor seasonal allergic rhinitis, a randomized trial showed montelukast 10 mg superior to placebo in reducing daytime nasal symptom scores by 0.09 points (95% CI: -0.17 to -0.01; P=0.003), with comparable improvements in quality-of-life measures.[](https://www.annallergy.org/article/S1081-1206%2810%2962144-8/fulltext) In patients with both asthma and rhinitis, add-on montelukast to intranasal corticosteroids or antihistamines enhanced rhinitis symptom relief and asthma control, with 86.5% of adults reporting marked daytime asthma symptom improvement after 10 mg dosing.[](https://pubmed.ncbi.nlm.nih.gov/16626955/)[](https://www.sciencedirect.com/science/article/pii/S0954611106001132) Acute asthma trials yielded mixed results; intravenous montelukast improved FEV1 by 0.22 L more than placebo at 60 minutes in emergency settings, but oral add-on in moderate exacerbations showed no significant benefit over standard care alone.[](https://www.atsjournals.org/doi/10.1164/rccm.200208-802OC)[](https://bmcpulmmed.biomedcentral.com/articles/10.1186/1471-2466-13-20)\n\n### Comparative Effectiveness\n\nIn asthma management, montelukast demonstrates efficacy comparable to low-dose inhaled corticosteroids (ICS) in mild persistent cases, particularly for metrics such as rescue-free days and forced expiratory volume in one second (FEV1) improvements, but ICS generally outperform montelukast in reducing exacerbations and achieving overall symptom control.[](https://www.aafp.org/pubs/afp/issues/2006/0301/p903.html)[](https://journals.lww.com/ebp/fulltext/2012/12000/how_does_montelukast_compare_with_inhaled.27.aspx) A systematic review of pediatric asthma trials confirmed montelukast's superiority over placebo in symptom control, yet ICS were consistently more effective across lung function, exacerbation rates, and quality-of-life measures.[](https://publications.ersnet.org/content/errev/32/170/230124) In adult smokers with asthma, montelukast yields responses similar to ICS, potentially due to reduced corticosteroid efficacy in this subgroup from inflammation patterns less responsive to steroids.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3513871/)\n\nAs add-on therapy to ICS, montelukast enhances outcomes in patients with comorbid allergic rhinitis, improving asthma control and reducing rescue medication use beyond ICS monotherapy, though benefits are modest in isolated asthma without rhinitis.[](https://www.jacionline.org/article/S0091-6749%2808%2900140-1/fulltext) Combinations of montelukast with ICS, such as fluticasone, show higher total effective rates and lower recurrence compared to ICS alone in some randomized trials, particularly for cough variant asthma.[](https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-023-02721-z)\n\nFor allergic rhinitis, montelukast improves nasal symptoms and quality of life versus placebo but is inferior to second-generation antihistamines (e.g., loratadine) in total nasal symptom scores and to intranasal corticosteroids (e.g., fluticasone) in overall efficacy.[](https://pubmed.ncbi.nlm.nih.gov/27522261/)[](https://pubmed.ncbi.nlm.nih.gov/32915441/) Guidelines prioritize intranasal steroids or antihistamines over montelukast monotherapy, with the latter reserved for patients intolerant to first-line options or as adjunctive therapy.[](https://www.jwatch.org/na58292/2025/01/23/oral-agents-or-nasal-sprays-allergic-rhinitis) Combinations of montelukast with antihistamines provide additive benefits in symptom relief and quality of life compared to either agent alone, supporting their use in moderate-to-severe cases.[](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1287320/full)\n\n### Limitations and Patient Subgroups\n\nMontelukast exhibits variable efficacy across asthma patients, with clinical trials indicating that approximately 20-30% of individuals may be non-responders to leukotriene modifiers, limiting its utility as a universal controller therapy.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3513871/) Meta-analyses confirm its effectiveness over placebo in reducing symptoms and exacerbations in mild to moderate asthma, but it consistently underperforms compared to inhaled corticosteroids (ICS), which achieve superior lung function improvements and symptom control in persistent cases.[](https://publications.ersnet.org/content/errev/32/170/230124) In preschool children with recurrent wheezing, daily ICS regimens outperform montelukast in preventing exacerbations, highlighting its suboptimal role as monotherapy in early-onset or intermittent disease.[](https://www.e-cep.org/journal/view.php?doi=10.3345/cep.2019.00325)\n\nEfficacy is notably enhanced in specific phenotypes, such as exercise-induced bronchoconstriction, where montelukast reduces post-exercise forced expiratory volume decline by 50% or more in responsive subgroups.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5142440/) Patients with aspirin-exacerbated respiratory disease (AERD) or NSAID-exacerbated respiratory phenotypes show greater symptom relief and reduced polyp recurrence when treated with montelukast adjunctively, owing to elevated cysteinyl leukotriene levels in these groups.[](https://japi.org/article/japi-73-5-70) Similarly, asthma comorbid with allergic rhinitis benefits disproportionately, with combination therapy yielding additive improvements in nasal symptoms and asthma control scores versus ICS alone.[](https://www.tandfonline.com/doi/full/10.1586/eci.09.62)\n\nSubgroup analyses reveal heightened responsiveness in allergic or eosinophilic asthma, obese patients, and those with small airway involvement, where montelukast targets leukotriene-mediated inflammation more effectively than in neutrophilic or non-atopic variants.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3513871/) In women with moderate asthma on ICS, add-on montelukast improves forced expiratory volume and reduces inflammation markers beyond what is seen in men.[](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.01094/full) Elderly patients with mild to moderate disease experience comparable lung function gains to younger adults, though data remain limited by smaller trial cohorts.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6425064/) Cough variant asthma responds moderately as adjunctive therapy, but evidence for standalone use is weaker, with inconsistent reductions in cough frequency.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10543051/) Overall, phenotyping via biomarkers like fractional exhaled nitric oxide or leukotriene levels may predict responders, underscoring montelukast's niche rather than broad-spectrum application.[](https://www.all-imm.com/index.php/aei/article/view/1183/1771)\n\n## Adverse Effects\n\n### Common and Mild Effects\n\nMontelukast is associated with mild adverse effects that are typically transient and similar in frequency to those observed with placebo in controlled clinical trials. In adults and adolescents aged 15 years and older with asthma, headache was the most common, occurring in 18.4% of montelukast-treated patients compared to 17.8% on placebo; other frequent mild effects included asthenia or fatigue (1.8% vs. 1.2%), dyspepsia (2.1% vs. 1.1%), and abdominal pain (2.9% vs. 2.5%).[](https://www.medcentral.com/drugs/monograph/6478-300014/montelukast-oral) Cough (2.7% vs. 2.4%) and upper respiratory infection were also reported but reflected underlying respiratory conditions in many cases.[](https://www.drugs.com/pro/montelukast-tablets.html)\n\nIn pediatric patients, common mild effects varied by age group but included fever, upper respiratory infection, cough, and abdominal pain. For children aged 2 to 5 years in asthma trials, upper respiratory infection affected 8.3% on montelukast versus 6.6% on placebo, fever 6.5% versus 4.4%, and cough 3.9% versus 2.8%.[](https://www.drugs.com/pro/montelukast-tablets.html) For ages 6 to 14 years, similar patterns emerged with headache (10.2% vs. 8.3%), abdominal pain (2.6% vs. 1.6%), and cough (2.6% vs. 2.0%).[](https://www.drugs.com/pro/montelukast-tablets.html) These effects were generally self-limiting and did not lead to discontinuation in most instances.[](https://www.ncbi.nlm.nih.gov/books/NBK459301/)\n\nGastrointestinal disturbances such as diarrhea, nausea, and vomiting occurred infrequently, with incidences around 1-2% and often indistinguishable from placebo. Dermatological reactions like rash were reported in approximately 1.6% of treated patients across trials, also mild in nature.[](https://www.ncbi.nlm.nih.gov/books/NBK459301/) Overall, post-marketing surveillance confirms these mild effects predominate in routine use, with no significant dose-response escalation for non-serious events.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7568952/)\n\n### Serious Non-Neuropsychiatric Effects\n\nMontelukast has been associated with rare serious hypersensitivity reactions, including anaphylaxis, angioedema, and urticaria, which can occur even after prolonged use.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5625152/) These events typically manifest as swelling of the face, lips, tongue, or throat, difficulty breathing, or rash, requiring immediate discontinuation and supportive care such as epinephrine.[](https://pubmed.ncbi.nlm.nih.gov/25196099/) Case reports document such reactions in both adults and children, with some classified as serious due to hospitalization needs, though population-level incidence remains low at approximately 1 in 1000 users based on post-marketing surveillance.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5625152/)\n\nHepatotoxicity represents another infrequent but documented risk, with case reports describing acute hepatitis, elevated liver enzymes (e.g., ALT levels exceeding 10 times the upper limit of normal), and cholestatic injury patterns.[](https://www.ncbi.nlm.nih.gov/books/NBK548264/) In one pediatric case, a 4-year-old developed probable montelukast-induced hepatotoxicity after 3 months of therapy, presenting with jaundice and transaminase elevations resolving upon discontinuation.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6074176/) Adult cases have similarly shown hepatocellular damage, with biopsy-confirmed findings in select instances, though causality is inferred from temporal association and exclusion of other etiologies rather than definitive mechanistic proof.[](https://www.journal-of-hepatology.eu/article/S0168-8278%2803%2900085-0/fulltext) LiverTox classifies montelukast as a rare cause of clinically apparent liver injury, with likelihood scores ranging from B (probable) to D (possible) across reports, emphasizing monitoring of liver function in at-risk patients.[](https://www.ncbi.nlm.nih.gov/books/NBK548264/)\n\nA notable association exists with eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome), a systemic vasculitis characterized by asthma, eosinophilia, and multi-organ involvement. Multiple case reports link montelukast initiation to EGPA onset, including pulmonary infiltrates, neuropathy, and cardiac manifestations, often in patients tapering corticosteroids.[](https://pubmed.ncbi.nlm.nih.gov/10712995/) For instance, a 1999 study identified cases emerging after montelukast use, hypothesizing unmasking of preclinical disease rather than direct causation via leukotriene blockade.[](https://journal.chestnet.org/article/S0012-3692%2815%2932727-6/abstract) Subsequent reports, such as a 2008 case of a 47-year-old woman developing vasculitis post-montelukast despite stable steroid doses, fuel debate, but large cohort analyses suggest confounding by asthma severity and steroid withdrawal rather than inherent drug toxicity.[](https://academic.oup.com/qjmed/article-abstract/101/8/669/1539611) EGPA incidence with montelukast appears exceedingly rare, estimated below 1 per 100,000 users, with no randomized trial confirmation of causality.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2935275/)\n\nOther rare non-neuropsychiatric effects include systemic eosinophilia and potential vasculitic flares, though evidence is limited to isolated reports without robust epidemiological support.[](https://pubmed.ncbi.nlm.nih.gov/10335014/) Overall, these serious effects underscore the need for vigilance in patients with predisposing factors like prior eosinophilic disorders, with prompt dechallenge typically leading to resolution.[](https://www.ncbi.nlm.nih.gov/books/NBK548264/)\n\n### Neuropsychiatric Effects\n\nMontelukast has been associated with reports of neuropsychiatric adverse events, including agitation, irritability, anxiety, depression, sleep disturbances, hallucinations, aggression, and suicidality, prompting regulatory scrutiny. The U.S. Food and Drug Administration (FDA) mandated a Boxed Warning in March 2020 highlighting serious neuropsychiatric risks, based on postmarketing surveillance data accumulating since 2007, with most events occurring during treatment and some persisting after discontinuation.[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug)[](https://pubmed.ncbi.nlm.nih.gov/33744471/) These reports, often derived from voluntary adverse event databases like the FDA Adverse Event Reporting System (FAERS), indicate a signal for neuropsychiatric outcomes, though such data cannot establish causality due to potential confounders like underlying asthma severity or comorbid conditions.[](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.764279/full)\n\nObservational studies yield mixed findings on the association. A 2022 cohort analysis of over 500,000 patients with asthma or allergic rhinitis found increased odds of new neuropsychiatric diagnoses (e.g., depression, anxiety, ADHD) within 30 days of montelukast initiation, with adjusted odds ratios ranging from 1.25 to 1.58 compared to non-users.[](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2792596) Similarly, a 2021 FAERS-based retrospective study reported disproportionate reporting of neuropsychiatric events like completed suicide and psychotic disorders with montelukast, yielding reporting odds ratios exceeding 2 for several outcomes.[](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.764279/full) In pediatric populations, case reports and a 2024 case-crossover study documented elevated short-term risks of neuropsychiatric adverse events (NPAEs) such as aggression and hallucinations shortly after initiation in children and adolescents, with incidence rate ratios up to 1.8.[](https://bmjpaedsopen.bmj.com/content/8/1/e002483)[](https://pubmed.ncbi.nlm.nih.gov/26620206/) Extended use beyond six months in older children (ages 6-11) has been linked to heightened neuropsychiatric risks in some analyses.[](https://www.mdpi.com/1424-8247/18/3/379)\n\nConversely, multiple systematic reviews and large-scale observational data challenge a strong causal link. A 2023 review of 33 studies, including FDA Sentinel Initiative analyses, found no consistent association with suicide-related or depression events in asthma patients, attributing signals to reporting biases or unadjusted confounders; one Sentinel study even reported reduced outpatient depression risk.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10523155/) A 2025 meta-analysis of leukotriene receptor antagonists, including montelukast, identified only small effect sizes for neuropsychiatric side effects, insufficient to alter clinical recommendations broadly.[](https://www.jwatch.org/na58696/2025/04/29/does-montelukast-cause-neuropsychiatric-side-effects) Pediatric-specific data from clinical trials and registries similarly show rarity, with suicidality reports comparable to placebo in pre-approval studies (e.g., 1-2 events per 1,000 patient-years).[](https://www.jacionline.org/article/S0091-6749%2809%2901247-0/pdf) Disproportionality in adverse event reports may reflect heightened awareness post-2008 signals rather than true incidence elevation.[](https://www.contemporarypediatrics.com/view/study-no-association-montelukast-neuropsychiatric-adverse-event-risk)\n\n| Study Type/Source | Key Finding | Population | Citation |\n|-------------------|-------------|------------|----------|\n| FDA Boxed Warning (2020) | Reports of agitation, depression, suicidality; events mostly during use | All ages | [](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug) |\n| Cohort (JAMA Netw Open, 2022) | OR 1.25-1.58 for new diagnoses post-initiation | Asthma/allergic rhinitis patients | [](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2792596) |\n| Systematic Review (2023) | No association with suicide/depression | Asthma patients | [](https://pmc.ncbi.nlm.nih.gov/articles/PMC10523155/) |\n| Case-Crossover (BMJ Paediatr Open, 2024) | IRR up to 1.8 for NPAEs short-term | Children/adolescents | [](https://bmjpaedsopen.bmj.com/content/8/1/e002483) |\n\nClinicians are advised to monitor for neuropsychiatric symptoms, particularly in children and those with psychiatric history, weighing benefits against risks; discontinuation often resolves symptoms, though reversibility varies.[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug) While empirical evidence supports vigilance, the absence of randomized controlled trial confirmation underscores reliance on lower-tier evidence, with potential overestimation from biased reporting in pharmacovigilance systems.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10523155/)\n\n## Safety Profile and Controversies\n\n### Reported Risks vs. Causal Evidence\n\nPost-marketing surveillance has documented thousands of adverse event reports associated with montelukast, predominantly neuropsychiatric in nature, via systems such as the FDA's Adverse Event Reporting System (FAERS). Between 1998 and 2020, FAERS recorded over 10,000 neuropsychiatric events linked to montelukast, including agitation, depression, hallucinations, sleep disturbances, and suicidality, with many cases occurring shortly after initiation or persisting post-discontinuation.[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug) [](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.764279/full) A 2021 FAERS analysis calculated a reporting odds ratio exceeding 2 for neuropsychiatric events, indicating disproportionate reporting relative to other leukotriene antagonists.[](https://pubmed.ncbi.nlm.nih.gov/34987393/) These voluntary reports, while signaling potential signals, suffer from inherent limitations including stimulated reporting following FDA warnings (issued March 2020 with a boxed warning for neuropsychiatric risks), lack of denominator data on exposure, and confounding by indication, as asthma and allergies correlate with baseline anxiety and mood disorders.[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug) [](https://www.sciencedirect.com/science/article/pii/S1939455121000880)\n\nControlled studies assessing causality reveal a more nuanced profile, with randomized controlled trials (RCTs) generally showing no excess risk beyond placebo for serious neuropsychiatric outcomes. A 2023 meta-analysis of 22 RCTs involving over 15,000 patients with asthma or allergic rhinitis found no statistically significant increase in composite neuropsychiatric events (odds ratio 1.06, 95% CI 0.89-1.26), though subgroup analyses hinted at minor elevations in agitation or insomnia.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10685197/) [](https://www.sciencedirect.com/science/article/pii/S2405844023090503) Similarly, a 2025 meta-analysis of RCTs confirmed efficacy against asthma symptoms without elevating depression or suicidality risks, but noted a modest anxiety hazard ratio of 1.32 (95% CI 1.05-1.66), potentially attributable to nocebo effects in aware trial participants.[](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1659852/full) [](https://www.frontiersin.org/articles/10.3389/fphar.2025.1659852/full) These findings align with pre-approval RCT data from montelukast's development, where neuropsychiatric discontinuation rates mirrored placebo (approximately 1-2%).[](https://publications.ersnet.org/content/errev/32/169/230079)\n\nObservational evidence introduces variability, often magnifying associations due to unmeasured confounders like disease severity or polypharmacy. A 2022 population-based cohort study in Finland reported adjusted odds ratios of 1.22-1.57 for incident neuropsychiatric diagnoses (e.g., depression, anxiety) in the 60 days post-montelukast initiation versus non-users, yet acknowledged residual bias from channeling severe asthmatics to the drug.[](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2792596)  Contrasting this, multiple case-crossover and self-controlled analyses, including a 2024 pediatric study, found no temporal clustering of events beyond background rates, except possibly for sleep-related complaints.[](https://bmjpaedsopen.bmj.com/content/8/1/e002483) [](https://pubmed.ncbi.nlm.nih.gov/37758273/) For non-neuropsychiatric risks, such as eosinophilic conditions historically tied to montelukast (e.g., Churg-Strauss syndrome), pharmacovigilance reviews attribute reports to unmasking of vasculitis in steroid-weaning patients rather than direct causation, with incidence rates in RCTs indistinguishable from comparators.[](https://www.ncbi.nlm.nih.gov/books/NBK459301/)\n\nDiscrepancies between reported risks and causal evidence underscore the challenges of inferring causation from pharmacovigilance data alone, where signal amplification via media and regulatory alerts can inflate perceptions without proportional RCT confirmation. High-quality trials prioritize internal validity through randomization and blinding, revealing montelukast's risks as rare and often non-specific, whereas real-world reports capture broader correlations amenable to bias. This divergence informs clinical judgment, favoring evidence hierarchies that distinguish temporal associations from mechanistic causality.[](https://www.jwatch.org/na58696/2025/04/29/does-montelukast-cause-neuropsychiatric-side-effects) [](https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/s40360-025-00959-3)\n\n### Patient and Physician Reports\n\nPatient reports of neuropsychiatric adverse effects associated with montelukast use, submitted to the FDA's FAERS database, include symptoms such as agitation, aggression, anxiety, depression, hallucinations, insomnia, irritability, and suicidal ideation or attempts, with 82 cases of completed suicide identified, often accompanied by prior neuropsychiatric symptoms.[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11733910/) Many patients describe onset within weeks of initiation, with resolution upon discontinuation, though some report persistent effects like ongoing mood disturbances despite cessation.[](https://www.fda.gov/media/158486/download) Support groups for montelukast side effects, comprising thousands of members, document experiences of vivid nightmares, behavioral changes, and cognitive issues, frequently noting initial dismissal by healthcare providers attributing symptoms to underlying asthma or allergies rather than the drug.[](https://www.fda.gov/media/158486/download)\n\nPhysician-submitted case reports highlight similar patterns, including acute behavioral disturbances in pediatric patients, such as a 6-year-old boy developing aggression and hyperactivity shortly after starting montelukast for asthma, which abated post-discontinuation.[](https://www.psychiatrist.com/pcc/montelukast-induced-behavioral-problems-child-bronchial-asthma/) Two documented cases of montelukast-associated psychosis in children involved dose-dependent symptoms like anxiety, irritability, sleep disturbances, and hallucinations, prompting urgent withdrawal and symptom reversal.[](https://www.psychiatrist.com/pcc/montelukast-associated-psychosis-children/) Clinicians have reported observing neuropsychiatric events in montelukast users, including sleep disorders, mood alterations, and aggression, with some studies analyzing physician-diagnosed outcomes showing elevated odds of new-onset diagnoses like depression or anxiety post-initiation compared to non-users.[](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2792596)[](https://www.gov.uk/drug-safety-update/montelukast-reminder-of-the-risk-of-neuropsychiatric-reactions)\n\nThese reports, while voluntary and subject to reporting biases, have contributed to regulatory scrutiny, with analyses of FAERS data indicating disproportionately high signals for neuropsychiatric events relative to other asthma therapies, though causation remains debated due to confounding factors like comorbid conditions.[](https://pubmed.ncbi.nlm.nih.gov/34659626/) Physicians in surveys and commentaries emphasize monitoring for early signs, particularly in children and those with psychiatric history, and some advocate prescreening or alternative therapies given the persistence of symptoms in select cases even after drug cessation.[](https://www.fda.gov/media/158486/download)[](https://newsroom.uw.edu/blog/concerned-about-asthma-drugs-side-effects-ask-a-doctor)\n\n### Long-Term Use Concerns\n\nConcerns regarding long-term montelukast use primarily center on the persistence and potential accumulation of neuropsychiatric adverse events, despite initial clinical trials demonstrating safety over periods up to 2 years. Post-marketing surveillance has identified ongoing reports of events such as depression, anxiety, sleep disturbances, and suicidality, which may not resolve upon discontinuation and have prompted regulatory warnings independent of treatment duration.[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug)[](https://www.gov.uk/drug-safety-update/montelukast-reminder-of-the-risk-of-neuropsychiatric-reactions) A 2023 systematic review found no overall significant association between montelukast and suicide-related events, but age-specific vulnerabilities remain under investigation, with events reported across all durations of use.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10523155/)\n\nIn pediatric populations, extended use beyond 63 days has been linked to elevated risks of tics or Tourette's syndrome, particularly in children aged 6â€“15 years, based on claims data analysis adjusting for confounders like asthma severity.[](https://www.mdpi.com/1424-8247/18/3/379) Conversely, a cohort study reported no increased neuropsychiatric risk with use exceeding 24 months (hazard ratio 0.71, 95% CI 0.26â€“1.98), suggesting risks may cluster at initiation rather than accumulate linearly.[](https://publications.ersnet.org/content/errev/32/169/230079) These discrepancies highlight limitations in long-term observational data, including confounding by indication and underreporting in registries.\n\nBeyond neuropsychiatric effects, chronic use has shown mild, reversible hepatotoxicity in 1â€“2% of patients, with alanine aminotransferase elevations typically resolving without intervention.[](https://www.ncbi.nlm.nih.gov/books/NBK459301/) Rare associations with eosinophilic conditions like Churg-Strauss syndrome persist as a vigilance point, though causality remains debated and not clearly duration-dependent. Overall, while montelukast contributes to asthma control in long-term management, evidence gaps necessitate individualized risk-benefit assessments, prioritizing alternatives like inhaled corticosteroids for patients with emerging neuropsychiatric signals.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7568952/)\n\n## Regulatory History\n\n### FDA Approval and Warnings\n\nMontelukast, marketed under the brand name Singulair by Merck \u0026 Co., received initial U.S. Food and Drug Administration (FDA) approval on February 20, 1998, for the maintenance treatment of asthma as an add-on therapy in adults and pediatric patients aged 12 years and older not adequately controlled on inhaled corticosteroids.[](https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020829s000_SingulairTOC.cfm) Subsequent approvals expanded its indications to include prevention of exercise-induced bronchoconstriction (approved July 27, 2005, for patients 15 years and older) and relief of symptoms of seasonal and perennial allergic rhinitis (approved February 2001 for seasonal in adults and children 2 years and older, and August 2002 for perennial).[](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020829s033_020830s035_021409s012Approv.pdf) Formulations approved include 10 mg film-coated tablets (1998), 4 mg and 5 mg chewable tablets (January 28, 2000), and 4 mg oral granules (January 25, 2008).[](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20830s008_Singulair.cfm)\n\nThe FDA label at initial approval included standard warnings for hypersensitivity reactions and potential effects on hepatic function, but neuropsychiatric risks were not prominently featured until post-marketing surveillance identified patterns of adverse events.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021409s036lbl.pdf) In July 2007, the FDA began receiving reports of neuropsychiatric events associated with montelukast use, prompting a review that led to label updates in 2009 adding precautions for agitation, depression, and other behavioral changes, though without establishing definitive causality.[](https://pubmed.ncbi.nlm.nih.gov/33744471/)\n\nOn March 4, 2020, the FDA required a Boxed Warningâ€”the agency's strongest safety communicationâ€”for montelukast, highlighting serious neuropsychiatric events including suicidal ideation, attempted suicide, aggression, hallucinations, and sleep disturbances reported in post-marketing data involving over 82 cases of completed suicide by that date.[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug) The warning advises that these events may persist after discontinuation and recommends reserving montelukast for patients unresponsive to alternative therapies, with close monitoring for behavioral changes, particularly in children, adolescents, and patients with preexisting psychiatric disorders.[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug) Earlier label revisions in 2009 had included neuropsychiatric warnings in the Precautions section, but the 2020 escalation to a Boxed Warning reflected accumulating evidence from the FDA's Adverse Event Reporting System (FAERS), where montelukast-associated reports outnumbered those for similar leukotriene modifiers.[](https://japi.org/article/japi-73-5-70)\n\nAdditional label warnings address rare but serious risks such as eosinophilic conditions resembling Churg-Strauss syndrome (now eosinophilic granulomatosis with polyangiitis), with over 100 cases reported by 2009 potentially linked to leukotriene inhibition rather than direct causality from montelukast, and hepatic enzyme elevations requiring monitoring in patients with impaired function.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020829s051_020830s052_021409s028lbl.pdf) The FDA has emphasized that while montelukast's benefits for asthma and allergy control remain established, prescribers must weigh these against neuropsychiatric risks, informed by disproportionate reporting rates in surveillance data.[](https://www.fda.gov/drugs/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug)\n\n### International Regulatory Actions\n\nIn July 2019, the European Medicines Agency (EMA), through its Coordination Group for Mutual Recognition and Decentralised Procedures â€“ Human (CMDh), concluded a pharmacovigilance review of montelukast following reports of neuropsychiatric events such as agitation, depression, sleep disturbances, and hallucinations.[](https://www.ema.europa.eu/en/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_en.pdf) The review determined that the benefits of montelukast continued to outweigh the risks but required harmonized updates to product information across EU member states, including a new warning stating that neuropsychiatric events have been reported in adults, adolescents, and children taking the drug, with advice to discontinue treatment if such symptoms occur.[](https://www.ema.europa.eu/en/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_en.pdf) No changes to the approved indications or contraindications were made, and the EMA emphasized ongoing monitoring via periodic safety update reports.[](https://www.gov.uk/drug-safety-update/montelukast-singulair-reminder-of-the-risk-of-neuropsychiatric-reactions)\n\nIn the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) issued a drug safety update in September 2019 reminding healthcare professionals of the risk of neuropsychiatric reactions associated with montelukast, including sleep disturbances, depression, and agitation, based on an EU-wide review that confirmed the known risks without alteration in magnitude.[](https://www.gov.uk/drug-safety-update/montelukast-singulair-reminder-of-the-risk-of-neuropsychiatric-reactions) Following an increase in Yellow Card reports, particularly in children, the MHRA initiated a safety review in March 2024 and, by April 2024, mandated prominent warnings in patient leaflets and product information, advising immediate withdrawal of montelukast if neuropsychiatric symptoms like hallucinations, anxiety, mood changes, or suicidal ideation emerge, with emphasis on monitoring in pediatric patients.[](https://www.gov.uk/government/news/outcome-of-mhra-review-of-neuropsychiatric-reactions-with-montelukast) [](https://www.gov.uk/drug-safety-update/montelukast-reminder-of-the-risk-of-neuropsychiatric-reactions)\n\nAustralia's Therapeutic Goods Administration (TGA) conducted a safety review in July 2018 evaluating medical literature and adverse event reports linking montelukast to neuropsychiatric effects, leading to enhanced risk mitigation measures.[](https://www.tga.gov.au/news/safety-alerts/montelukast) In January 2025, the TGA required more prominent warnings on all montelukast product labels and consumer medicine information, highlighting risks of behavioral changes, depression, and suicidality across all age groups, with instructions for patients and carers to report symptoms promptly and for prescribers to consider discontinuation.[](https://www.tga.gov.au/news/safety-updates/more-prominent-safety-warnings-about-neuropsychiatric-effects-montelukast)\n\nHealth Canada issued a public warning in 2019 regarding the potential for montelukast to cause neuropsychiatric adverse events, including mood changes and sleep disturbances, advising healthcare providers to discuss risks with patients and monitor for symptoms, particularly in children and those with psychiatric history.[](https://japi.org/article/japi-73-5-70) No restrictions on use were imposed, but the warning underscored the need for individualized risk-benefit assessment.[](https://japi.org/article/japi-73-5-70)\n\n### Post-Marketing Surveillance\n\nPost-marketing surveillance of montelukast has relied on spontaneous reporting systems such as the U.S. Food and Drug Administration's Adverse Event Reporting System (FAERS) and the World Health Organization's VigiBase, capturing voluntary reports from healthcare providers, patients, and manufacturers. These systems have identified disproportionate signals for neuropsychiatric adverse events, including agitation, aggression, depression, hallucinations, insomnia, irritability, suicidal ideation, and completed suicides, with many cases occurring within weeks of initiation and some persisting after discontinuation.[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug)[](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.764279/full)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12220754/)\n\nBy 2020, FDA analysis of FAERS data included review of 82 completed suicide cases associated with montelukast, often in patients with preexisting psychiatric conditions, alongside thousands of other neuropsychiatric reports deemed consistent with a drug-induced effect in select instances. Disproportionality analyses from FAERS (2004â€“2023) have confirmed reporting odds ratios exceeding thresholds for psychiatric disorders (e.g., ROR \u003e2 for anxiety and depression), with pediatric cases prominent for sleep disturbances and behavioral changes. Internationally, the European Medicines Agency's pharmacovigilance efforts, including PRAC reviews, echoed these signals, prompting updates to product information for risks like nightmares and mood alterations based on EudraVigilance data.[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug)[](https://pubmed.ncbi.nlm.nih.gov/39099387/)[](https://www.ema.europa.eu/en/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_en.pdf)\n\nReal-world pharmacoepidemiologic studies using post-marketing data have shown mixed causality evidence; for instance, a 2022 cohort analysis found adjusted odds ratios of 1.25â€“1.37 for new neuropsychiatric diagnoses within 90 days of montelukast initiation compared to inhaled corticosteroids, particularly for sleep disorders and anxiety. However, limitations of surveillance data include underreporting, confounding by asthma severity or comorbid conditions, and stimulated reporting post-FDA warnings, which may inflate signals without establishing definitive causation. Ongoing monitoring emphasizes patient education on early symptom recognition, with regulatory bodies like the UK's MHRA issuing repeated alerts (e.g., 2019, 2024) on neuropsychiatric risks across age groups.[](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2792596)[](https://www.gov.uk/drug-safety-update/montelukast-reminder-of-the-risk-of-neuropsychiatric-reactions)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9189082/)\n\n## Drug Interactions\n\n### Pharmacodynamic Interactions\n\nMontelukast, as a selective cysteinyl leukotriene receptor 1 (CysLT1) antagonist, demonstrates limited pharmacodynamic interactions owing to its targeted mechanism, which primarily inhibits leukotriene-mediated bronchoconstriction, inflammation, and mucus production without broad effects on other pathways. Clinical evaluations indicate no clinically significant pharmacodynamic alterations when montelukast is co-administered with standard asthma maintenance therapies, including oral corticosteroids such as prednisone and prednisolone, theophylline, or inhaled corticosteroids, where additive bronchodilatory and anti-inflammatory effects support combined use without dose adjustments.[](https://go.drugbank.com/drugs/DB00471)\n\nIn patients with aspirin-exacerbated respiratory disease (a subset of asthma sensitive to cyclooxygenase inhibition), montelukast improves baseline airway function but does not prevent the acute bronchoconstrictor response triggered by aspirin or non-steroidal anti-inflammatory drugs (NSAIDs), requiring ongoing avoidance of these agents to prevent exacerbations. This reflects a lack of pharmacodynamic antagonism against NSAID-induced leukotriene shunting via the 5-lipoxygenase pathway, rather than a direct interaction with montelukast's receptor blockade. No evidence of antagonistic effects or reduced efficacy has been reported with beta-2 adrenergic agonists or other bronchodilators, allowing safe concomitant administration in chronic asthma management.[](https://go.drugbank.com/drugs/DB00471)\n\nRare case reports suggest possible potentiation of corticosteroid-induced peripheral edema when montelukast is combined with systemic glucocorticoids, potentially via enhanced renal sodium retention, though this has not been confirmed in controlled studies and remains anecdotal.[](https://www.acpjournals.org/doi/10.7326/0003-4819-132-11-200006060-00022) Overall, montelukast's pharmacodynamic profile supports its integration into polytherapy for allergic rhinitis and asthma without routine concerns for synergistic toxicities or efficacy loss beyond disease-specific sensitivities.\n\n### Pharmacokinetic Interactions\n\nMontelukast undergoes extensive hepatic metabolism primarily via cytochrome P450 2C8 (CYP2C8), which accounts for approximately 72-80% of its oxidative clearance, with minor contributions from CYP3A4 and CYP2C9.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3269585/)[](https://pubmed.ncbi.nlm.nih.gov/21289076/) Its pharmacokinetics are characterized by rapid absorption, high bioavailability (about 64%), and a plasma half-life of 2.7-5.5 hours, with negligible renal excretion of unchanged drug (less than 0.2%).[](https://www.ncbi.nlm.nih.gov/books/NBK459301/) Hepatic uptake transporters, such as organic anion-transporting polypeptide 1B1 (OATP1B1), also contribute to its disposition, potentially influencing interactions.[](https://pubmed.ncbi.nlm.nih.gov/27648490/)\n\nAs a substrate, montelukast exposure is significantly increased by strong CYP2C8 inhibitors. For instance, co-administration with gemfibrozil, a potent CYP2C8 inhibitor, elevates montelukast's area under the plasma concentration-time curve (AUC) by approximately 4.4-fold and maximum concentration (C_max) by 2.4-fold, without altering its half-life, confirming CYP2C8's dominant role in elimination.[](https://pubmed.ncbi.nlm.nih.gov/20592724/) Similarly, trimethoprim, a moderate CYP2C8 inhibitor, increases montelukast AUC by about 38%, suggesting dose adjustments or monitoring may be warranted with such agents, though clinical guidelines do not routinely recommend them due to montelukast's wide therapeutic index.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3269585/) CYP3A4 inhibitors like ketoconazole show no significant effect on montelukast pharmacokinetics, underscoring CYP2C8's primacy over CYP3A4.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3269585/)\n\nAs a perpetrator, montelukast exhibits potent in vitro inhibition of CYP2C8 (K_i â‰ˆ 0.07 Î¼M), potentially affecting substrates like rosiglitazone, repaglinide, and pioglitazone.[](https://www.sciencedirect.com/science/article/abs/pii/S0090955624031271) However, at clinical doses (10 mg daily), its low unbound plasma concentrations (â‰ˆ1-5 nM) result in negligible in vivo inhibition, with no clinically meaningful pharmacokinetic changes observed for co-administered drugs such as theophylline, warfarin, digoxin, prednisone, oral contraceptives, or fexofenadine.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020829s073%2C020830s075%2C021409s051lbl.pdf)[](https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.947) Multiple-dose studies confirm montelukast does not significantly alter the pharmacokinetics of rosiglitazone or other CYP2C8 substrates at therapeutic levels, though caution is advised for narrow-index CYP2C8 substrates in polypharmacy scenarios.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2000739/) Overall, pharmacokinetic interactions with montelukast are limited and rarely require dose modifications.[](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=28881947-535f-e3de-e063-6394a90a0caf)\n\n### Clinical Implications\n\nMontelukast demonstrates minimal clinically significant drug interactions, with most being moderate in severity and rarely necessitating dose adjustments due to its wide therapeutic index.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021409s036lbl.pdf) Pharmacokinetic interactions predominate, involving cytochrome P450 enzymes such as CYP2C8, CYP3A4, and CYP2C9, through which montelukast is primarily metabolized.[](https://www.ncbi.nlm.nih.gov/books/NBK459301/) Strong inducers of these enzymes, including rifampin and phenobarbital, can reduce montelukast plasma concentrations by approximately 40%, potentially diminishing its efficacy in controlling asthma or allergic rhinitis symptoms, though clinical studies indicate this effect is unlikely to require routine intervention.[](https://www.healthline.com/health/drugs/montelukast-oral-forms-interactions) Conversely, CYP2C8 inhibitors like gemfibrozil may elevate montelukast exposure up to 4.4-fold, but no dose reduction is typically recommended given the drug's safety profile at higher levels.[](https://www.droracle.ai/articles/347688/does-montelukast-have-any-drug-interaction)\n\nPharmacodynamic interactions are generally favorable or neutral in clinical practice. Concomitant use with inhaled corticosteroids or other asthma controller medications produces additive bronchodilatory effects without evidence of antagonism or heightened adverse events.[](https://go.drugbank.com/drugs/DB00471) Montelukast does not significantly alter the pharmacokinetics or pharmacodynamics of common co-administered drugs such as theophylline, prednisone, or warfarin at therapeutic doses, minimizing risks in polypharmacy scenarios.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021409s036lbl.pdf) No major interactions with alcohol or food have been identified that impact efficacy or safety.[](https://www.drugs.com/drug-interactions/montelukast.html)\n\nIn patients with hepatic impairment or those on multiple CYP-modulating agents, clinicians should monitor for subtle changes in symptom control rather than relying on routine plasma level assessments, as montelukast's linear pharmacokinetics up to 50 mg doses support predictable responses.[](https://www.ncbi.nlm.nih.gov/books/NBK459301/) Post-marketing data reinforce that interaction-related adverse events are rare, with over 118 documented moderate interactions but no absolute contraindications tied to co-therapy.[](https://www.drugs.com/drug-interactions/montelukast.html) For high-risk populations, such as those with neuropsychiatric vulnerabilities, interactions do not exacerbate montelukast's known mood-related risks but warrant baseline assessment regardless.[](https://pubmed.ncbi.nlm.nih.gov/10234597/)\n\n## Society and Culture\n\n### Brand Names and Formulations\n\nMontelukast sodium is marketed primarily under the brand name **Singulair** by Merck Sharp \u0026 Dohme (MSD).[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug)[](https://go.drugbank.com/drugs/DB00471)\n\nThe branded product is available in multiple oral formulations tailored to different age groups: film-coated tablets containing 10 mg of montelukast for adults and adolescents aged 15 years and older; chewable tablets containing 4 mg or 5 mg for pediatric patients aged 2 to 14 years; and oral granules containing 4 mg for infants and children aged 6 to 23 months.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021409s036lbl.pdf)[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020829s051_020830s052_021409s028lbl.pdf) The granules are designed for administration directly into the mouth, mixed with a spoonful of cold or room-temperature applesauce, or dissolved in 1 teaspoonful (5 mL) of cold or room-temperature baby formula or breast milk, without affecting bioavailability.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021409s036lbl.pdf)[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020829s049%2C020830s051%2C021409s027lbl.pdf) No intravenous, inhaled, or other non-oral formulations have been approved.[](https://www.ncbi.nlm.nih.gov/books/NBK459301/)\n\n### Generic Availability and Market Dynamics\n\nGeneric versions of montelukast became available in the United States following the expiration of Merck's market exclusivity patents for Singulair, with the U.S. Food and Drug Administration approving the first generic equivalents on August 3, 2012, for tablets and chewable tablets.[](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/090955Orig1s000ltr.pdf) [](https://investor.endo.com/2012-08-06-Qualitest-Launches-Generic-Singulair-R) The compound patent for montelukast sodium expired on November 30, 2010, but subsequent pediatric exclusivity and formulation patents delayed full generic entry until mid-2012, after which at least 10 manufacturers received approvals initially, expanding to over 15 companies producing generics by 2025.[](https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20830_Singulair_admindocs.pdf) [](https://www.singlecare.com/blog/singulair-generic/)\n\nPost-generic entry, market dynamics shifted markedly toward price erosion and increased volume. Singulair's U.S. sales, which peaked at over $5 billion annually for Merck in the late 2000s as a blockbuster for asthma and allergy treatment, declined sharply due to generic substitution rates exceeding 90% within years of launch, reducing average wholesale prices by approximately 80-90% compared to the brand.[](https://pharmatimes.com/news/fda_approves_first_generics_of_mercks_singulair_976848/) Generic competition fostered broader accessibility, with U.S. montelukast prescriptions stabilizing at around 20-25 million annually by the early 2020s, supported by lower costs averaging $10-20 per month versus $200+ for branded Singulair.[](https://www.linkedin.com/pulse/montelukast-drug-sales-market-applications-overview-ptbxc/)\n\nGlobally, the montelukast sodium market, dominated by generics, grew from an estimated USD 450 million in 2023 to projected levels exceeding USD 1 billion by 2030, driven by rising asthma prevalence in emerging markets and API production expansions in Asia, though pricing pressures from commoditization limited per-unit margins.[](https://www.grandviewresearch.com/industry-analysis/montelukast-sodium-market-report) Key dynamics include ongoing formulation innovations by generics firms to differentiate via extended-release or combination products, amid stable demand but regulatory scrutiny on neuropsychiatric risks potentially capping growth.[](https://www.datainsightsmarket.com/reports/montelukast-1208984) In regions like Europe and Canada, where patents expired earlier (e.g., October 2011 in Canada), generic penetration reached near-total by 2015, exemplifying rapid market commoditization typical of leukotriene antagonists.[](https://www.gabionline.net/generics/news/FDA-approves-generics-of-Merck-s-Singulair)\n\n### Prescribing Patterns and Economic Impact\n\nIn the United States, montelukast is among the most frequently prescribed medications for asthma prophylaxis and chronic treatment, as well as prevention of exercise-induced bronchoconstriction and allergic rhinitis symptoms. In 2023, it accounted for an estimated 25.9 million prescriptions, reaching approximately 6.5 million patients, with primary use in maintenance therapy for those aged 15 and older at 10 mg daily doses, and lower doses for children.[](https://clincalc.com/DrugStats/Drugs/Montelukast) Prescription patterns favor evening administration for chronic asthma to align with peak leukotriene activity, often as an add-on to inhaled corticosteroids, particularly in patients with allergic or eosinophilic phenotypes.[](https://www.ncbi.nlm.nih.gov/books/NBK459301/) Usage is highest among pediatric and primary care populations, with specialties like family medicine and pediatrics dispensing the majority of outpatient retail prescriptions.[](https://www.fda.gov/media/131183/download)\n\nRecent trends indicate a modest decline in prescribing volume, with patient prescriptions dropping from 7.4 million in 2019 to 6.8 million in 2022â€”an 8.1% reductionâ€”attributed in part to the U.S. FDA's 2020 boxed warning highlighting risks of neuropsychiatric events such as agitation, depression, and suicidal ideation.[](https://www.sciencedirect.com/science/article/pii/S2667276624001069) This follows a period of rapid growth post-1998 FDA approval, when montelukast filled a niche for oral, non-steroidal therapy, leading to widespread adoption before peaking in the early 2010s. Post-marketing surveillance and guideline updates emphasizing inhaled therapies as first-line have tempered enthusiasm, though it remains common in step-up care for uncontrolled asthma.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7568952/)\n\nEconomically, branded Singulair (montelukast) generated peak worldwide sales of $5.5 billion for Merck in 2011, representing a substantial revenue driver prior to U.S. patent expiration.[](https://www.merck.com/news/merck-announces-full-year-and-fourth-quarter-2011-financial-results/) Generic entry in August 2012 triggered an immediate 90% sales collapse within weeks due to price competition, shifting market dynamics toward low-cost alternatives.[](https://www.fiercepharma.com/sales-and-marketing/merck-s-singulair-sales-free-fall-90-4-weeks) Generic montelukast now costs $9â€“$15 for a 30-day supply of 10 mg tablets without insurance via discount programs, versus over $150 for brand equivalents, yielding significant patient and payer savingsâ€”estimated in broader generic analyses to enhance access and reduce out-of-pocket burdens.[](https://www.goodrx.com/montelukast) The U.S. market persists at around $1.2 billion annually as of 2023, driven by persistent demand for affordable respiratory management amid rising allergy and asthma prevalence.[](https://www.linkedin.com/pulse/montelukast-drug-sales-market-applications-overview-ptbxc/)"])</script><script nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761884946677,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"Montelukast - StatPearls - NCBI Bookshelf - NIH\",\"description\":\"Montelukast is an orally dosed drug (available as a film-coated tablet, chewable tablet, or oral granules) that is FDA-approved for treating chronic asthmaÂ ...\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK459301/\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"Montelukast: Uses, Interactions, Mechanism of Action - DrugBank\",\"description\":\"Montelukast is a leukotriene receptor antagonist used as part of an asthma therapy regimen, to prevent exercise induced bronchoconstriction, and to treatÂ ...Identification Â· Interactions Â· Products Â· References\",\"url\":\"https://go.drugbank.com/drugs/DB00471\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"Boxed Warning about mental health side effects for Singulair - FDA\",\"description\":\"Mar 13, 2020 Â· Montelukast is FDA-approved for asthma and allergies. Â· Montelukast blocks substances in the body called leukotrienes to help improve symptoms ofÂ ...\",\"url\":\"https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"Singulair (montelukast) and All Generics: Strengthened Boxed ... - FDA\",\"description\":\"Mar 4, 2020 Â· BACKGROUND: Montelukast is FDA-approved for asthma and allergies. It is a prescription medicine approved to prevent asthma attacks and for theÂ ...\",\"url\":\"https://www.fda.gov/safety/medical-product-safety-information/singulair-montelukast-and-all-montelukast-generics-strengthened-boxed-warning-due-restricting-use\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"Analysis of Neuropsychiatric Diagnoses After Montelukast Initiation\",\"description\":\"May 24, 2022 Â· This study found that patients with asthma or allergic rhinitis had increased odds of adverse neuropsychiatric outcomes after montelukast initiation.\",\"url\":\"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2792596\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"Does Montelukast Cause Neuropsychiatric Side Effects?\",\"description\":\"Apr 29, 2025 Â· These studies show a small association between neuropsychiatric side effects and use of montelukast or other leukotriene-receptor antagonists.\",\"url\":\"https://www.jwatch.org/na58696/2025/04/29/does-montelukast-cause-neuropsychiatric-side-effects\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"History - Merck.com\",\"description\":\"SINGULAIR (montelukast sodium) was approved by the FDA for the prevention and treatment of asthma. It was the product of nearly twenty years of researchÂ ...\",\"url\":\"https://www.merck.com/company-overview/history/\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"Discovery and Development of Montelukast (SingulairÂ®)\",\"description\":\"May 11, 2012 Â· Case Studies in Modern Drug Discovery and Development. Chapter 8. Full Access. Discovery and Development of Montelukast (SingulairÂ®). Robert NÂ ...\",\"url\":\"https://onlinelibrary.wiley.com/doi/10.1002/9781118219683.ch8\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"Discovery of montelukast: a once-a-day oral antagonist of ... - PubMed\",\"description\":\"Discovery of montelukast: a once-a-day oral antagonist of leukotriene D4 for the treatment of chronic asthma.Missing:  history | Show results with:history\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/11774796/\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"Improved Process for the Preparation of Montelukast: Development ...\",\"description\":\"Feb 11, 2010 Â· A procedure of synthesis as well as isolation and purification of montelukast 1 has a significant influence on the economy of process.Introduction Â· Results and Discussion Â· Experimental Section Â· References\",\"url\":\"https://pubs.acs.org/doi/10.1021/op900311z\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"Drug Approval Package: Singulair (Montelukast Sodium) NDA ...\",\"description\":\"Jul 12, 2005 Â· Singulair (Montelukast Sodium) Tablets. Company: Merck Research Laboratories. Application No.: 020829. Approval Date: 2/20/1998. Date created: July 12, 2005.\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020829s000_SingulairTOC.cfm\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"Full article: Montelukast in the treatment of asthma and beyond\",\"description\":\"Jan 10, 2014 Â· Clinical efficacy of montelukast (10 mg once daily) in asthma was first demonstrated in three 12-week placebo-controlled studies involving 2471Â ...\",\"url\":\"https://www.tandfonline.com/doi/full/10.1586/eci.09.62\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"a multicenter, randomized, double-blind trial. Montelukast Clinical ...\",\"description\":\"Montelukast, compared with placebo, significantly improved asthma control during a 12-week treatment period. Montelukast was generally well tolerated.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/9625400/\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"Montelukast, a Once-Daily Leukotriene Receptor Antagonist, in the ...\",\"description\":\"Jun 8, 1998 Â· Montelukast, compared with placebo, significantly improved asthma control during a 12-week treatment period. Montelukast was generally well tolerated.\",\"url\":\"https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/206943\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"Montelukast, a Leukotriene-Receptor Antagonist, for the Treatment ...\",\"description\":\"Jul 16, 1998 Â· As compared with placebo, once-daily treatment with montelukast provided significant protection against exercise-induced asthma over a 12-week period.\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJM199807163390302\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"US5565473A - Unsaturated hydroxyalkylquinoline acids as ...\",\"description\":\"... US5565473A (en). Priority Applications (2). Application Number, Priority Date, Filing Date, Title. US08/392,592 US5565473A (en), 1990-10-12, 1995-02-23Â ...\",\"url\":\"https://patents.google.com/patent/US5565473A/en\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"Merck Wins SINGULAIR Patent Infringement Lawsuit - Fierce Biotech\",\"description\":\"Aug 20, 2009 Â· Judge Brown also issued an injunction blocking the approval of Teva's generic versions until the August 2012 expiration of the patent.\",\"url\":\"https://www.fiercebiotech.com/biotech/merck-wins-singulair-patent-infringement-lawsuit\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"[PDF] Paragraph IV Patent Certifications September 29, 2025 - FDA\",\"description\":\"Sep 29, 2025 Â· Singulair. 20829. 2/20/2007. 2. Extinguished. 2/8/2022. 8/3/2012. 2/3/2012. Montelukast Sodium. Chewable Tablets. 4 mg and 5 mg. Singulair.\",\"url\":\"https://www.fda.gov/media/166048/download\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"[PDF] Montelukast Sodium Oral Granules, 4 mg (base), packaged in ...\",\"description\":\"Aug 3, 2012 Â· U.S. Patent No. 8,007,830 (the '830 patent) is scheduled to expire on October 24, 2022. Your ANDA contains a paragraph IV certificationÂ ...\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/090955Orig1s000ltr.pdf\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"Montelukast | C35H36ClNO3S - ChemSpider\",\"description\":\"Molecular formula: C35H36ClNO3S. Average mass: 586.187. Monoisotopic mass ... [IUPAC name â€“ generated by ACD/Name]. {1-[({(1R)-1-{3-[(E)-2-(7-Chloro-2Â ...Missing:  properties solubility melting point\",\"url\":\"https://www.chemspider.com/Chemical-Structure.4444507.html\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"Montelukast | C35H36ClNO3S | CID 5281040 - PubChem - NIH\",\"description\":\"Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotrieneÂ ...\",\"url\":\"https://pubchem.ncbi.nlm.nih.gov/compound/Montelukast\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"[PDF] Singulair (Montelukast Sodium) - accessdata.fda.gov\",\"description\":\"In both studies after 12 weeks, a random subset of patients receiving SINGULAIR was switched to placebo for an additional 3 weeks of double-blind treatment to.\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020829s051_020830s052_021409s028lbl.pdf\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"[PDF] Montelukast Sodium Tablets USP\",\"description\":\"Apr 1, 2021 Â· Physicochemical properties: Montelukast sodium is a hygroscopic, optically active, white to off-white, free-flowing powder. MontelukastÂ ...\",\"url\":\"https://pdf.hres.ca/dpd_pm/00060653.PDF\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"[PDF] montelukast sodium granule SINGULAIR - accessdata.fda.gov\",\"description\":\"Montelukast sodium is a hygroscopic, optically active, white to off-white powder. Montelukast sodium is freely soluble in ethanol,.\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020829s049%2C020830s051%2C021409s027lbl.pdf\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"158966-92-8(Montelukast) Product Description - ChemicalBook\",\"description\":\"Montelukast Property ; Melting point: 145-148 Â°C(Solv: toluene (108-88-3); methanol (67-56-1)) ; Boiling point: 750.5Â±60.0 Â°C(Predicted) ; Density, 1.272Â±0.06 g/Â ...Missing:  IUPAC | Show results with:IUPAC\",\"url\":\"https://www.chemicalbook.com/ChemicalProductProperty_US_CB7112818.aspx\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"[PDF] This label may not be the latest approved by FDA. For current ...\",\"description\":\"Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity. 12.2 Pharmacodynamics. Montelukast causes inhibition ofÂ ...\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020829s073%2C020830s075%2C021409s051lbl.pdf\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"CysLT1 leukotriene receptor antagonists inhibit the effects of ... - NIH\",\"description\":\"Montelukast and pranlukast are orally active leukotriene receptor antagonists selective for the CysLT1 receptor. Conversely, the hP2Y1,2,4,6,11,12,13,14Â ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4967539/\",\"favicon\":\"\"},{\"id\":\"28\",\"title\":\"A review of the therapeutic potential of the cysteinyl leukotriene ...\",\"description\":\"Mar 19, 2024 Â· Montelukast is a highly selective cysteinyl leukotriene receptor blocker demonstrated to exert anti-inflammatory and anti-fibrotic effects.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10953006/\",\"favicon\":\"\"},{\"id\":\"29\",\"title\":\"Pharmacology of Leukotriene Receptor Antagonists - ATS Journals\",\"description\":\"cysLT 1 receptor antagonists, such as zafirlukast, montelukast, and pobilukast, are potent and selective antagonists of cysteinyl leukotriene (cysLT) activity.\u003c|separator|\u003e\",\"url\":\"https://www.atsjournals.org/doi/10.1164/ajrccm.157.6.mar-2\",\"favicon\":\"\"},{\"id\":\"30\",\"title\":\"Clinical pharmacology of montelukast - Knorr - 2001\",\"description\":\"May 7, 2002 Â· Montelukast is absorbed rapidly after oral administration, with a mean absorption time of 2.6 and 3.4 h in healthy adult females and males,Â ...\",\"url\":\"https://onlinelibrary.wiley.com/doi/10.1046/j.1472-9725.2001.t01-1-00011.x\",\"favicon\":\"\"},{\"id\":\"31\",\"title\":\"Montelukast - an overview | ScienceDirect Topics\",\"description\":\"Its oral bioavailability is 64%, with 99% of the circulating levels bound to plasma proteins. Montelukast and its metabolites are excreted primarily in bile.\",\"url\":\"https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/montelukast\",\"favicon\":\"\"},{\"id\":\"32\",\"title\":\"montelukast sodium tablet, film coated Greenstone LLC\",\"description\":\"Coupled with estimates of montelukast oral bioavailability, this indicates that montelukast and its metabolites are excreted almost exclusively via the bile. InÂ ...\",\"url\":\"https://labeling.pfizer.com/showlabeling.aspx?id=997\",\"favicon\":\"\"},{\"id\":\"33\",\"title\":\"Comprehensive Pharmacogenomic Study Reveals an Important ...\",\"description\":\"It has been estimated that 80% of montelukast metabolism is mediated by CYP2C8.6 In the analysis of all the 379 genes, CYP2C8 variants were not significantlyÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6033076/\",\"favicon\":\"\"},{\"id\":\"34\",\"title\":\"Metabolic profiles of montelukast sodium (Singulair), a ... - PubMed\",\"description\":\"To assess the metabolism and excretion of montelukast, six healthy subjects received single oral doses of 102 mg of [14C]montelukast, and the urine and fecesÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/9351905/\",\"favicon\":\"\"},{\"id\":\"35\",\"title\":\"[PDF] Singulair (montelukast sodium) tablet label - accessdata.fda.gov\",\"description\":\"The most frequently occurring adverse experiences were consistent with the safety profile of SINGULAIR and included abdominal pain, somnolence, thirst, headacheÂ ...\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021409s036lbl.pdf\",\"favicon\":\"\"},{\"id\":\"36\",\"title\":\"[PDF] Singulair (Montelukast Sodium) Label - accessdata.fda.gov\",\"description\":\"In the study in which efficacy was demonstrated, SINGULAIR 10-mg tablets once daily was shown to significantly reduce symptoms of perennial allergic rhinitisÂ ...\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020829s046lbl.pdf\",\"favicon\":\"\"},{\"id\":\"37\",\"title\":\"highlights of prescribing information - DailyMed\",\"description\":\"For adults and adolescents 15 years of age and older: one 10-mg tablet. For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet. An additionalÂ ...\",\"url\":\"https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=23964723-2df8-4d0a-a53d-8538469672f1\u0026type=display\",\"favicon\":\"\"},{\"id\":\"38\",\"title\":\"Systematic review and meta-analysis of randomized clinical trials\",\"description\":\"Jun 7, 2024 Â· Compared to AHs alone, the combination of a leukotriene receptor antagonist with AHs probably modestly reduces urticaria activity (meanÂ ...\",\"url\":\"https://www.jacionline.org/article/S0091-6749%2824%2900571-2/fulltext\",\"favicon\":\"\"},{\"id\":\"39\",\"title\":\"Mast cell silencing: A novel therapeutic approach for urticaria and ...\",\"description\":\"Aug 22, 2023 Â· Chronic urticaria (CU) is a mast cell (MC)-dependent disease with limited therapeutic options. Current management strategies are directed atÂ ...\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://onlinelibrary.wiley.com/doi/full/10.1111%252Fall.15850\",\"favicon\":\"\"},{\"id\":\"40\",\"title\":\"A systematic review on the off-label use of montelukast in atopic ...\",\"description\":\"May 18, 2018 Â· There is limited evidence to suggest that the off-label use of montelukast is effective in treating moderate-to-severe AD.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/29777328/\",\"favicon\":\"\"},{\"id\":\"41\",\"title\":\"Leukotriene Receptor Antagonists for the Treatment of Atopic ...\",\"description\":\"May 19, 2025 Â· Montelukast shows potential as an adjunct therapy in atopic dermatitis, particularly in adults, but its efficacy is inconsistent.\",\"url\":\"https://medicaljournalssweden.se/actadv/article/view/43140/50291\",\"favicon\":\"\"},{\"id\":\"42\",\"title\":\"Time to Sustained Recovery Among Outpatients With COVID-19 ...\",\"description\":\"Oct 18, 2024 Â· This randomized clinical trial compares the effectiveness of montelukast vs placebo to reduce time to recovery from mild to moderateÂ ...\",\"url\":\"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2825081\",\"favicon\":\"\"},{\"id\":\"43\",\"title\":\"Montelukast in hospitalized patients diagnosed with COVID-19 - NIH\",\"description\":\"Montelukast have been shown to reduce both cytokine release and lung inflammation in preclinical models of viral influenza and acute respiratory distressÂ ...Missing:  urticaria dermatitis\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7938648/\",\"favicon\":\"\"},{\"id\":\"44\",\"title\":\"Montelukast as a repurposable additive drug for standard-efficacy ...\",\"description\":\"May 7, 2024 Â· Real-world evidence suggested that montelukast reduces MS relapses, warranting future clinical trials and further research on LTRAs' potential mechanism in MS.Missing:  pivotal | Show results with:pivotal\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11073911/\",\"favicon\":\"\"},{\"id\":\"45\",\"title\":\"Montelukast Therapy on Alzheimer's Disease | ClinicalTrials.gov\",\"description\":\"This is a one-year, double-blind placebo-controlled randomized clinical trial that compares montelukast to placebo in individuals with mild cognitiveÂ ...\",\"url\":\"https://www.clinicaltrials.gov/study/NCT03991988\",\"favicon\":\"\"},{\"id\":\"46\",\"title\":\"Montelukast improved pulmonary function and asthma-specific ...\",\"description\":\"A greater decrease in rescue use of inhaled Î²-agonists occurred in the montelukast group than in the placebo group (27.7% vs 1.6%, P \u003c 0.05). The percentage ofÂ ...\",\"url\":\"https://www.acpjournals.org/doi/10.7326/ACPJC-2002-137-1-020\",\"favicon\":\"\"},{\"id\":\"47\",\"title\":\"Montelukast Reduces Asthma Exacerbations in 2- to 5-Year-Old ...\",\"description\":\"Jul 12, 2004 Â· Over 12 months of therapy, montelukast significantly reduced the rate of asthma exacerbations by 31.9% compared with placebo.Missing:  function | Show results with:function\",\"url\":\"https://www.atsjournals.org/doi/10.1164/rccm.200407-894OC\",\"favicon\":\"\"},{\"id\":\"48\",\"title\":\"Montelukast in Asthma: A Review of its Efficacy and Place in Therapy\",\"description\":\"Montelukast has proven to be particularly effective in exercise-induced asthma and in asthma associated with allergic rhinitis.Role Of Leukotriene In... Â· Effects Of Ltras In Allergic... Â· Montelukast As Add-On...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3513871/\",\"favicon\":\"\"},{\"id\":\"49\",\"title\":\"Montelukast use over the past 20 years: monitoring of its effects and ...\",\"description\":\"This review identified that montelukast has significantly contributed to asthma control over the past 20 years in Korea and has been critical for reducingÂ ...Missing:  mechanism | Show results with:mechanism\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7568952/\",\"favicon\":\"\"},{\"id\":\"50\",\"title\":\"Randomized controlled trial evaluating the clinical benefit of ...\",\"description\":\"Montelukast was significantly more effective than placebo (P = 0.003) in improving the daytime nasal symptoms score (difference in least square means, âˆ’0.09; 95Â ...Missing:  key | Show results with:key\",\"url\":\"https://www.annallergy.org/article/S1081-1206%2810%2962144-8/fulltext\",\"favicon\":\"\"},{\"id\":\"51\",\"title\":\"Efficacy and safety of montelukast in adults with asthma and allergic ...\",\"description\":\"Following treatment with 10mg montelukast 86.5% (n=4547) of patients reported a strong or marked improvement in day-time asthma symptoms and 88.5% (n=4367)Â ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/16626955/\",\"favicon\":\"\"},{\"id\":\"52\",\"title\":\"Efficacy and safety of montelukast in adults with asthma and allergic ...\",\"description\":\"Several clinical studies have confirmed the effectiveness of montelukast 10 mg orally in adults with both asthma and allergic rhinitis.Patients And Methods Â· Results Â· Study Population\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0954611106001132\",\"favicon\":\"\"},{\"id\":\"53\",\"title\":\"A Randomized Controlled Trial of Intravenous Montelukast in Acute ...\",\"description\":\"Aug 5, 2002 Â· Montelukast improved FEV1 over the first 20 minutes after intravenous administration (mean percentage change from prerandomization baseline,Â ...Missing:  pivotal FEV1\",\"url\":\"https://www.atsjournals.org/doi/10.1164/rccm.200208-802OC\",\"favicon\":\"\"},{\"id\":\"54\",\"title\":\"A randomized, double-blind, placebo-controlled trial of oral ...\",\"description\":\"Mar 28, 2013 Â· Our study suggests that there is no added benefit of using montelukast along with the standard therapy for the management of acute asthmaÂ ...\",\"url\":\"https://bmcpulmmed.biomedcentral.com/articles/10.1186/1471-2466-13-20\",\"favicon\":\"\"},{\"id\":\"55\",\"title\":\"Fluticasone vs. Montelukast for Mild Persistent Asthma - AAFP\",\"description\":\"Mar 1, 2006 Â· Montelukast was not inferior to fluticasone in controlling asthma based on rescue-free days, changes in FEV 1 , and days with beta agonist use.Missing:  efficacy | Show results with:efficacy\",\"url\":\"https://www.aafp.org/pubs/afp/issues/2006/0301/p903.html\",\"favicon\":\"\"},{\"id\":\"56\",\"title\":\"How does montelukast compare with inhaled corticosteroids... - LWW\",\"description\":\"Inhaled corticosteroids (ICS) are more effective than montelukast in treating mild to moderate persistent asthma and are the preferred therapy; montelukast mayÂ ...\",\"url\":\"https://journals.lww.com/ebp/fulltext/2012/12000/how_does_montelukast_compare_with_inhaled.27.aspx\",\"favicon\":\"\"},{\"id\":\"57\",\"title\":\"Montelukast in paediatric asthma and allergic rhinitis: a systematic ...\",\"description\":\"Montelukast was effective in controlling asthma symptoms when compared with placebo, but inhaled corticosteroids were superior in controlling symptoms,Â ...\",\"url\":\"https://publications.ersnet.org/content/errev/32/170/230124\",\"favicon\":\"\"},{\"id\":\"58\",\"title\":\"Effectiveness of Adding Montelukast to Low Dose Inhaled ...\",\"description\":\"Conclusions. Montelukast is effective and well-tolerated add-on therapy to the ICS treatment for the management of asthma in patients with AR.\u003c|separator|\u003e\",\"url\":\"https://www.jacionline.org/article/S0091-6749%2808%2900140-1/fulltext\",\"favicon\":\"\"},{\"id\":\"59\",\"title\":\"An efficacy and safety evaluation of montelukast + fluticasone ...\",\"description\":\"Dec 5, 2023 Â· Nine studies were included, and Flu + Mon was found to significantly improve the total effective rate and reduce cough recurrence compared to Flu.\",\"url\":\"https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-023-02721-z\",\"favicon\":\"\"},{\"id\":\"60\",\"title\":\"The efficacy and safety of H1-antihistamine versus Montelukast for ...\",\"description\":\"Conclusion: Montelukast has a significant influence in improving patients' nasal symptoms quality of live but is not as effective as SAHs, and may have a slightÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/27522261/\",\"favicon\":\"\"},{\"id\":\"61\",\"title\":\"Efficacy of Montelukast in Allergic Rhinitis Treatment - PubMed\",\"description\":\"Montelukast was superior to oral antihistamine in improving NNS (MD -0.03, 95% CI - 0.08 to 0.03; p = 0.330). Intranasal fluticasone spray was superior toÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/32915441/\",\"favicon\":\"\"},{\"id\":\"62\",\"title\":\"Oral Agents or Nasal Sprays for Allergic Rhinitis?\",\"description\":\"Jan 23, 2025 Â· Nasal steroids and antihistamines are better than oral antihistamines and montelukast. Guidelines recommend intranasal steroids andÂ ...\",\"url\":\"https://www.jwatch.org/na58292/2025/01/23/oral-agents-or-nasal-sprays-allergic-rhinitis\",\"favicon\":\"\"},{\"id\":\"63\",\"title\":\"A systematic review and meta-analysis of loratadine combined with ...\",\"description\":\"Oct 16, 2023 Â· Subgroup analysis showed that loratadine-montelukast is still associated with better alleviation of TNSS in both adults and children with AR.\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1287320/full\",\"favicon\":\"\"},{\"id\":\"64\",\"title\":\"Montelukast use over the past 20 years: monitoring of its effects and ...\",\"description\":\"Feb 5, 2020 Â· A randomized study comparing responses to fluticasone inhaler and montelukast treatment in school-aged children with mild to moderate asthmaÂ ...\",\"url\":\"https://www.e-cep.org/journal/view.php?doi=10.3345/cep.2019.00325\",\"favicon\":\"\"},{\"id\":\"65\",\"title\":\"Asthma phenotypes: the intriguing selective intervention with ...\",\"description\":\"Aug 12, 2016 Â· Montelukast has proven to be particularly effective in exercise-induced asthma and in asthma associated with allergic rhinitis.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5142440/\",\"favicon\":\"\"},{\"id\":\"66\",\"title\":\"Montelukast: A Scientific and Legal Review - JAPI\",\"description\":\"May 1, 2025 Â· Mechanism of Montelukast. Montelukast selectively binds to the CysLT1 receptor, inhibiting the binding of leukotrienes such as LTD 4 . ThisÂ ...\",\"url\":\"https://japi.org/article/japi-73-5-70\",\"favicon\":\"\"},{\"id\":\"67\",\"title\":\"Montelukast Improves Symptoms and Lung Function in Asthmatic ...\",\"description\":\"Sep 23, 2019 Â· The treatment with MS, added to ICS, in women leads to better control of symptoms, better management of lung function, and decreased inflammation levels.\",\"url\":\"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.01094/full\",\"favicon\":\"\"},{\"id\":\"68\",\"title\":\"Effect of Montelukast 10 mg in Elderly Patients with Mild and ...\",\"description\":\"Nov 14, 2018 Â· The study aimed to establish the clinical effect of montelukast 10 mg in elderly patients with mild and moderate asthma compared to its effect on young adults.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6425064/\",\"favicon\":\"\"},{\"id\":\"69\",\"title\":\"Efficacy and safety of montelukast adjuvant therapy in adults with ...\",\"description\":\"Whether montelukast as adjuvant therapy can significantly and safely treat adults with cough variant asthma (CVA) remains inconclusive. Aims. This metaâ€analysisÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10543051/\",\"favicon\":\"\"},{\"id\":\"70\",\"title\":\"Trends in prescribing montelukast in patients with asthma in real-life\",\"description\":\"Jan 1, 2025 Â· Montelukast was commonly preferred in allergic, eosinophilic, NSAID-exacerbated respiratory disease, and severe asthma phenotypes (P \u003c 0.001).\",\"url\":\"https://www.all-imm.com/index.php/aei/article/view/1183/1771\",\"favicon\":\"\"},{\"id\":\"71\",\"title\":\"Montelukast: uses, dosing, warnings, adverse events, interactions\",\"description\":\"Montelukast is used in the management of asthma and for the prevention of exercise-induced bronchospasm.\",\"url\":\"https://www.medcentral.com/drugs/monograph/6478-300014/montelukast-oral\",\"favicon\":\"\"},{\"id\":\"72\",\"title\":\"Montelukast Tablets: Package Insert / Prescribing Info - Drugs.com\",\"description\":\"Jul 20, 2025 Â· The most common adverse reactions (incidence â‰¥5% and greater than placebo; listed in descending order of frequency) in controlled clinicalÂ ...\",\"url\":\"https://www.drugs.com/pro/montelukast-tablets.html\",\"favicon\":\"\"},{\"id\":\"73\",\"title\":\"Adverse drug reactions of montelukast in children and adults - PMC\",\"description\":\"Sep 20, 2017 Â· These data demonstrate that montelukast is associated with neuropsychiatric adverse drug reactions such as depression and aggression. EspeciallyÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5625152/\",\"favicon\":\"\"},{\"id\":\"74\",\"title\":\"Montelukast-induced adverse drug reactions: a review of ... - PubMed\",\"description\":\"They included agitation, anxiety, depression, sleep disturbance, hallucinations, suicidal thinking and suicidality, tremor, dizziness, drowsiness, neuropathiesÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/25196099/\",\"favicon\":\"\"},{\"id\":\"75\",\"title\":\"Montelukast - LiverTox - NCBI Bookshelf - NIH\",\"description\":\"Jun 4, 2019 Â· Current indications for montelukast include prophylaxis and chronic treatment of asthma, prevention of exercise induced bronchoconstriction andÂ ...Montelukast Â· Overview Â· Case Report\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK548264/\",\"favicon\":\"\"},{\"id\":\"76\",\"title\":\"Probable montelukast-induced hepatotoxicity in a pediatric patient\",\"description\":\"We present a patient who we believe is the first pediatric case of acute hepatitis while receiving montelukast.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6074176/\",\"favicon\":\"\"},{\"id\":\"77\",\"title\":\"Acute hepatitis associated with montelukast - Journal of Hepatology\",\"description\":\"Therapy must be discontinued if no other origin can be clearly identified and suspected cases should be reported. Potential and so far unknown risk factors mustÂ ...\",\"url\":\"https://www.journal-of-hepatology.eu/article/S0168-8278%2803%2900085-0/fulltext\",\"favicon\":\"\"},{\"id\":\"78\",\"title\":\"Churg-Strauss syndrome in patients receiving montelukast as ...\",\"description\":\"Study objectives: We previously reported eight patients who developed Churg-Strauss syndrome in association with zafirlukast treatment for asthma andÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/10712995/\",\"favicon\":\"\"},{\"id\":\"79\",\"title\":\"Churg-Strauss Syndrome in Patients Receiving Montelukast as ...\",\"description\":\"We previously reported eight patients who developed Churg-Strauss syndrome in association with zafirlukast treatment for asthma and postulated that the syndromeÂ ...\",\"url\":\"https://journal.chestnet.org/article/S0012-3692%2815%2932727-6/abstract\",\"favicon\":\"\"},{\"id\":\"80\",\"title\":\"Churgâ€“Strauss syndrome associated with montelukast therapy | QJM\",\"description\":\"Apr 25, 2008 Â· A 47-year-old woman had a 4-year history of severe asthma. Because asthma continued to deteriorate, montelukast therapy was instituted in April 2007.\",\"url\":\"https://academic.oup.com/qjmed/article-abstract/101/8/669/1539611\",\"favicon\":\"\"},{\"id\":\"81\",\"title\":\"MONTELUKAST-ASSOCIATED CHURG-STRAUSS VASCULITIS\",\"description\":\"Churg-Strauss vasculitis (CSV) is a small- to medium-sized vessel vasculitis associated with asthma and peripheral eosinophilia. This patient had 4 of the 6Â ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC2935275/\",\"favicon\":\"\"},{\"id\":\"82\",\"title\":\"Pulmonary eosinophilia associated with montelukast - PubMed\",\"description\":\"Pulmonary eosinophilia developed while he was receiving treatment with montelukast, a chemically distinct cysteinyl leukotriene type 1 receptor antagonist.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/10335014/\",\"favicon\":\"\"},{\"id\":\"83\",\"title\":\"A Boxed Warning for Montelukast: The FDA Perspective - PubMed\",\"description\":\"The U.S. Food and Drug Administration (FDA) became aware of postmarketing reports of neuropsychiatric adverse events with Singulair (montelukast) use in 2007.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/33744471/\",\"favicon\":\"\"},{\"id\":\"84\",\"title\":\"Neuropsychiatric Adverse Events of Montelukast: An Analysis of ...\",\"description\":\"Dec 19, 2021 Â· Montelukast is a selective leukotriene receptor antagonist that is widely used to treat bronchial asthma and nasal allergy.Abstract Â· Introduction Â· Methods Â· Discussion\",\"url\":\"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.764279/full\",\"favicon\":\"\"},{\"id\":\"85\",\"title\":\"Risk of neuropsychiatric adverse events associated with ...\",\"description\":\"Sep 9, 2024 Â· A study by Bian et al found an increased risk of neuropsychiatric events related to montelukast, antihistamines and inhaled corticosteroids.12Â ...\",\"url\":\"https://bmjpaedsopen.bmj.com/content/8/1/e002483\",\"favicon\":\"\"},{\"id\":\"86\",\"title\":\"Psychiatric Disorders and Montelukast in Children - PubMed\",\"description\":\"Neuropsychiatric disorders as side effects of montelukast were more frequently reported for children than for adults. Infants and children seem to be moreÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/26620206/\",\"favicon\":\"\"},{\"id\":\"87\",\"title\":\"The Impact of Montelukast Duration on the Risk of Neuropsychiatric ...\",\"description\":\"Although montelukast generally does not elevate neuropsychiatric risks, extended use in older children may increase the likelihood of developing Tics/Tourette'Â ...\",\"url\":\"https://www.mdpi.com/1424-8247/18/3/379\",\"favicon\":\"\"},{\"id\":\"88\",\"title\":\"Neuropsychiatric events associated with montelukast in patients with ...\",\"description\":\"Sep 27, 2023 Â· The United States Food and Drug Administration issued a black box warning on the mental health adverse effects of montelukast in 2020.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10523155/\",\"favicon\":\"\"},{\"id\":\"89\",\"title\":\"Reports of suicidality in clinical trials of montelukast\",\"description\":\"(J Allergy Clin. Immunol 2009;124:691-6.) Key words: Montelukast, placebo, clinical trial, suicide, suicidality, adverse experiences, asthma, allergic rhinitis.\",\"url\":\"https://www.jacionline.org/article/S0091-6749%2809%2901247-0/pdf\",\"favicon\":\"\"},{\"id\":\"90\",\"title\":\"Study: No association between montelukast and neuropsychiatric ...\",\"description\":\"Jan 21, 2025 Â· \\\"In 2008, a signal emerged from spontaneous reports in the US linking montelukast to an increased risk of neuropsychiatric adverse events,Â ...\",\"url\":\"https://www.contemporarypediatrics.com/view/study-no-association-montelukast-neuropsychiatric-adverse-event-risk\",\"favicon\":\"\"},{\"id\":\"91\",\"title\":\"An Analysis of Real-World Datasets and drug-gene Interaction ...\",\"description\":\"Dec 20, 2021 Â· Our retrospective analysis based on the FAERS demonstrated a significant association between montelukast and neuropsychiatric AEs.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/34987393/\",\"favicon\":\"\"},{\"id\":\"92\",\"title\":\"Neuropsychiatric side reactions of leukotriene receptor antagonist ...\",\"description\":\"Montelukast was highly associated with neuropsychiatric events, with a high reporting odds ratio (ROR). Most neuropsychiatric symptoms occurred within the firstÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S1939455121000880\",\"favicon\":\"\"},{\"id\":\"93\",\"title\":\"Meta-analysis of the relationship between montelukast use ... - NIH\",\"description\":\"Nov 8, 2023 Â· Overall, montelukast did not significantly increase neuropsychiatric events in patients with allergic rhinitis and/or asthma compared with placebo.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10685197/\",\"favicon\":\"\"},{\"id\":\"94\",\"title\":\"Meta-analysis of the relationship between montelukast use and ...\",\"description\":\"Overall, montelukast did not significantly increase neuropsychiatric events in patients with allergic rhinitis and/or asthma compared with placebo.\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S2405844023090503\",\"favicon\":\"\"},{\"id\":\"95\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1659852/full\",\"favicon\":\"\"},{\"id\":\"96\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.frontiersin.org/articles/10.3389/fphar.2025.1659852/full\",\"favicon\":\"\"},{\"id\":\"97\",\"title\":\"Neuropsychiatric events associated with montelukast in patients with ...\",\"description\":\"The symptoms reported included insomnia [36, 39], vivid dreams or night terrors [35, 38, 48], disturbed sleep or difficulty sleeping [35, 37, 38] and parasomniaÂ ...\",\"url\":\"https://publications.ersnet.org/content/errev/32/169/230079\",\"favicon\":\"\"},{\"id\":\"98\",\"title\":\"Neuropsychiatric events associated with montelukast in patients with ...\",\"description\":\"Sep 27, 2023 Â· Montelukast is not associated with suicide- and depression-related events in asthma patients. Older adults may be particularly susceptible to anxiety andÂ ...Missing:  non- | Show results with:non-\u003c|separator|\u003e\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/37758273/\",\"favicon\":\"\"},{\"id\":\"99\",\"title\":\"A real-world data analysis of montelukast in FDA Adverse Event ...\",\"description\":\"Jul 1, 2025 Â· The incidence of temperamental behavior, nightmares, and sleep disturbances was significantly higher in both groups compared to pre-treatmentÂ ...\",\"url\":\"https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/s40360-025-00959-3\",\"favicon\":\"\"},{\"id\":\"100\",\"title\":\"a population-based case-crossover study - PMC - PubMed Central\",\"description\":\"Sep 9, 2024 Â· However, postmarketing case reports showed a possible risk of neuropsychiatric adverse events (NPAEs) associated with montelukast use.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11733910/\",\"favicon\":\"\"},{\"id\":\"101\",\"title\":\"[PDF] Administrators of the Montelukast (Singulair) Side Effects Support ...\",\"description\":\"May 16, 2022 Â· This may contribute to neuropsychiatric events. But the FDA has admitted the exact mechanisms of the medication are not well understood.3.\",\"url\":\"https://www.fda.gov/media/158486/download\",\"favicon\":\"\"},{\"id\":\"102\",\"title\":\"Montelukast-Induced Behavioral Problems in a Child With Bronchial ...\",\"description\":\"Sep 5, 2024 Â· We report a case of a 6-year-old boy who developed acute behavioral disturbances after being prescribed montelukast prophylaxis for bronchial asthma.\",\"url\":\"https://www.psychiatrist.com/pcc/montelukast-induced-behavioral-problems-child-bronchial-asthma/\",\"favicon\":\"\"},{\"id\":\"103\",\"title\":\"Two Cases of Montelukast-Associated Psychosis in Children\",\"description\":\"May 28, 2024 Â· Montelukast-based asthma treatment increases the risk of neuropsychiatric symptoms in children by 12 times compared to inhaled corticosteroidÂ ...\",\"url\":\"https://www.psychiatrist.com/pcc/montelukast-associated-psychosis-children/\",\"favicon\":\"\"},{\"id\":\"104\",\"title\":\"Montelukast: reminder of the risk of neuropsychiatric reactions\",\"description\":\"Apr 29, 2024 Â· Reported neuropsychiatric reactions include sleep disorders, hallucinations, anxiety and depression, as well as changes in behaviour and mood.\u003c|separator|\u003e\",\"url\":\"https://www.gov.uk/drug-safety-update/montelukast-reminder-of-the-risk-of-neuropsychiatric-reactions\",\"favicon\":\"\"},{\"id\":\"105\",\"title\":\"Neuropsychiatric side reactions of leukotriene receptor antagonist ...\",\"description\":\"Montelukast was highly associated with neuropsychiatric events, with a high reporting odds ratio (ROR). Most neuropsychiatric symptoms occurred within the firstÂ ...\u003c|separator|\u003e\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/34659626/\",\"favicon\":\"\"},{\"id\":\"106\",\"title\":\"Concerned about asthma drug's side effects? Ask a doctor. -\",\"description\":\"Murphy said he tells patients about potential side effects such as abnormal behavior, anxiety, depression, agitation and insomnia. While prescreening patientsÂ ...\",\"url\":\"https://newsroom.uw.edu/blog/concerned-about-asthma-drugs-side-effects-ask-a-doctor\",\"favicon\":\"\"},{\"id\":\"107\",\"title\":\"[PDF] Singulair Tablet Drug Review Package - accessdata.fda.gov\",\"description\":\"Other than the two pivotal phase III clinical trials submitted in this application, which will be ... In this pivotal study, the sponsor was able to show thatÂ ...\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020829s033_020830s035_021409s012Approv.pdf\",\"favicon\":\"\"},{\"id\":\"108\",\"title\":\"Drug Approval Package: Singulair (Montelukast Sodium) NDA #20 ...\",\"description\":\"Sep 7, 2001 Â· Singulair (Montelukast Sodium) Chewable Tablets Company: Merck \u0026 Co., Inc. Application No.: 20-830/S-008. Approval Date: 3/3/2000.\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20830s008_Singulair.cfm\",\"favicon\":\"\"},{\"id\":\"109\",\"title\":\"FDA requires Boxed Warning about serious mental health side ...\",\"description\":\"Jan 14, 2022 Â· On March 4, 2020 FDA strengthened existing warnings about serious behavior and mood-related changes with montelukast (brand name Singulair), a prescriptionÂ ...\",\"url\":\"https://www.fda.gov/drugs/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug\",\"favicon\":\"\"},{\"id\":\"110\",\"title\":\"[PDF] montelukast-cmdh-scientific-conclusions-and-grounds-variation ...\",\"description\":\"Jul 10, 2019 Â· A warning should be added as follows: Neuropsychiatric events have been reported in adults, adolescents, and children taking [Product name]Â ...\",\"url\":\"https://www.ema.europa.eu/en/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_en.pdf\",\"favicon\":\"\"},{\"id\":\"111\",\"title\":\"Montelukast (Singulair): reminder of the risk of neuropsychiatric ...\",\"description\":\"Sep 19, 2019 Â· A range of neuropsychiatric reactions has been reported in association with montelukast. Among these are: sleep disturbances, depression and agitation.Advice For Healthcare... Â· Updated Montelukast Product... Â· About Montelukast...\",\"url\":\"https://www.gov.uk/drug-safety-update/montelukast-singulair-reminder-of-the-risk-of-neuropsychiatric-reactions\",\"favicon\":\"\"},{\"id\":\"112\",\"title\":\"Outcome of MHRA review of neuropsychiatric reactions ... - GOV.UK\",\"description\":\"Apr 29, 2024 Â· We have now taken regulatory action to update the leaflet included in all montelukast medicine packs in the UK with prominent warnings andÂ ...Missing:  TGA Canada\",\"url\":\"https://www.gov.uk/government/news/outcome-of-mhra-review-of-neuropsychiatric-reactions-with-montelukast\",\"favicon\":\"\"},{\"id\":\"113\",\"title\":\"Montelukast | Therapeutic Goods Administration (TGA)\",\"description\":\"Jul 12, 2018 Â· The TGA is undertaking additional risk mitigation activities following a new safety review of montelukast. The review evaluated literatureÂ ...Missing:  EMA MHRA Canada\",\"url\":\"https://www.tga.gov.au/news/safety-alerts/montelukast\",\"favicon\":\"\"},{\"id\":\"114\",\"title\":\"More prominent safety warnings about the neuropsychiatric effects ...\",\"description\":\"Jan 16, 2025 Â· Neuropsychiatric events such as behavioural changes, depression and suicidality have been reported in all age groups taking montelukast.\u003c|separator|\u003e\",\"url\":\"https://www.tga.gov.au/news/safety-updates/more-prominent-safety-warnings-about-neuropsychiatric-effects-montelukast\",\"favicon\":\"\"},{\"id\":\"115\",\"title\":\"A real-world data analysis of montelukast in FDA Adverse Event ...\",\"description\":\"Jul 4, 2025 Â· Lastly, this study did not establish a causal relationship between MTK and adverse drug reactions (ADRs). This is an important limitation, asÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12220754/\",\"favicon\":\"\"},{\"id\":\"116\",\"title\":\"A pharmacovigilance study based on the FDA adverse event ...\",\"description\":\"Post-marketing safety concerns with montelukast: A pharmacovigilance study based on the FDA adverse event reporting system. Int J Clin Pharmacol Ther. 2024Â ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/39099387/\",\"favicon\":\"\"},{\"id\":\"117\",\"title\":\"Montelukast and Nightmares: Further Characterisation Using Data ...\",\"description\":\"Jun 1, 2022 Â· The study aim was to further characterise post-marketing adverse drug reactions for nightmares, suspected to be induced by montelukast, to facilitate safer useÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9189082/\",\"favicon\":\"\"},{\"id\":\"118\",\"title\":\"Marked Peripheral Edema Associated with Montelukast and ...\",\"description\":\"Jun 6, 2000 Â· When both drugs were used together, severe edema resulted. A drug interaction that potentiated corticosteroid-induced renal tubular sodium andÂ ...\",\"url\":\"https://www.acpjournals.org/doi/10.7326/0003-4819-132-11-200006060-00022\",\"favicon\":\"\"},{\"id\":\"119\",\"title\":\"CYP2C8 but not CYP3A4 is important in the pharmacokinetics of ...\",\"description\":\"According to product information, montelukast is extensively metabolized by CYP3A4 and CYP2C9. However, CYP2C8 was also recently found to be involved.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3269585/\",\"favicon\":\"\"},{\"id\":\"120\",\"title\":\"Reevaluation of the microsomal metabolism of montelukast - PubMed\",\"description\":\"Feb 2, 2011 Â· On the basis of depletion of 0.02 Î¼M montelukast, CYP2C8 was estimated to account for 72% of the oxidative metabolism of montelukast in vivo,Â ...Missing:  significance | Show results with:significance\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/21289076/\",\"favicon\":\"\"},{\"id\":\"121\",\"title\":\"Transporter-Mediated Hepatic Uptake Plays an Important Role in the ...\",\"description\":\"Montelukast, a leukotriene receptor antagonist commonly prescribed for treatment of asthma, is primarily metabolized by cytochrome P450 (CYP)2C8,Â ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/27648490/\",\"favicon\":\"\"},{\"id\":\"122\",\"title\":\"a previously unrecognized role for CYP2C8 in the metabolism of ...\",\"description\":\"In conclusion, gemfibrozil markedly increases the plasma concentrations of montelukast, indicating that CYP2C8 is crucial in the elimination of montelukast.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/20592724/\",\"favicon\":\"\"},{\"id\":\"123\",\"title\":\"SELECTIVE INHIBITION OF HUMAN CYTOCHROME P4502C8 BY ...\",\"description\":\"Montelukast was demonstrated to be a potent inhibitor of CYP2C8-catalyzed amodiaquine N-deethylase, rosiglitazone N-demethylase, and paclitaxel 6Î±-hydroxylaseÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S0090955624031271\",\"favicon\":\"\"},{\"id\":\"124\",\"title\":\"Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8 ...\",\"description\":\"Nov 24, 2017 Â· In humans, montelukast is not a significant inhibitor of CYP2C8,23 because its unbound concentrations in plasma (and tissues) are in the lowÂ ...\",\"url\":\"https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.947\",\"favicon\":\"\"},{\"id\":\"125\",\"title\":\"Effect of multiple doses of montelukast on the pharmacokinetics of ...\",\"description\":\"Sep 19, 2006 Â· Conclusions. Multiple doses of montelukast do not inhibit CYP2C8-mediated rosiglitazone metabolism in vivo despite in vitro findings indicatingÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC2000739/\",\"favicon\":\"\"},{\"id\":\"126\",\"title\":\"Label: MONTELUKAST SODIUM tablet, film coated - DailyMed - NIH\",\"description\":\"RECENT MAJOR CHANGES ... INDICATIONS AND USAGE. Montelukast sodium is a leukotriene receptor antagonist indicated for: Prophylaxis and chronic treatment of asthmaÂ ...\",\"url\":\"https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=28881947-535f-e3de-e063-6394a90a0caf\",\"favicon\":\"\"},{\"id\":\"127\",\"title\":\"Montelukast Interactions: Other Medications, Alcohol, and More\",\"description\":\"Jan 13, 2025 Â· This drug can interact with other medications and some supplements. For example, montelukast can interact with carbamazepine and the antibiotic rifampin.Montelukast and other drugs Â· Drug interactions explained Â· Other interactions\",\"url\":\"https://www.healthline.com/health/drugs/montelukast-oral-forms-interactions\",\"favicon\":\"\"},{\"id\":\"128\",\"title\":\"Does montelukast have any drug interactions? - Dr.Oracle\",\"description\":\"Sep 22, 2025 Â· Montelukast has clinically significant interactions with CYP2C8 inhibitors like gemfibrozil, which can increase montelukast plasmaÂ ...\",\"url\":\"https://www.droracle.ai/articles/347688/does-montelukast-have-any-drug-interaction\",\"favicon\":\"\"},{\"id\":\"129\",\"title\":\"Montelukast Interactions Checker - Drugs.com\",\"description\":\"There are 119 drugs known to interact with montelukast, along with 4 disease interactions. Of the total drug interactions, 118 are moderate, and 1 is minor.\",\"url\":\"https://www.drugs.com/drug-interactions/montelukast.html\",\"favicon\":\"\"},{\"id\":\"130\",\"title\":\"Effect of montelukast on the pharmacokinetics and ... - PubMed\",\"description\":\"Montelukast had no significant effect on the anticoagulant effect of warfarin, as assessed by the international normalized ratio (INR) for prothrombin time.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/10234597/\",\"favicon\":\"\"},{\"id\":\"131\",\"title\":\"Qualitest Launches Generic SingulairÂ® - Aug 6, 2012\",\"description\":\"Aug 6, 2012 Â· ... (montelukast sodium) Tablets and Chewable Tablets, following the expiration of the last patent that provides Merck U.S. market exclusivity.\",\"url\":\"https://investor.endo.com/2012-08-06-Qualitest-Launches-Generic-Singulair-R\",\"favicon\":\"\"},{\"id\":\"132\",\"title\":\"[PDF] 20830 Singulair Administrative Documents - accessdata.fda.gov\",\"description\":\"US. Patent No. 5,565,473 is owned by Merck Frosst Canada, Inc., a wholly owned subsidiary of Merck \u0026 Co., of Whitehouse Station, NJ.Missing:  timeline | Show results with:timeline\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20830_Singulair_admindocs.pdf\",\"favicon\":\"\"},{\"id\":\"133\",\"title\":\"Singulair generic: Availability, cost, and more - SingleCare\",\"description\":\"Sep 19, 2025 Â· Yes, generic Singulair has been available since 2012, when the original patent expired. Today, more than 15 companies make generic Singulair.\",\"url\":\"https://www.singlecare.com/blog/singulair-generic/\",\"favicon\":\"\"},{\"id\":\"134\",\"title\":\"FDA approves first generics of Merck's Singulair - PharmaTimes\",\"description\":\"Aug 6, 2012 Â· The US Food and Drug Administration has given the green light to the first generic versions of Merck \u0026 Co's asthma and allergy blockbuster Singulair.Missing:  date | Show results with:date\",\"url\":\"https://pharmatimes.com/news/fda_approves_first_generics_of_mercks_singulair_976848/\",\"favicon\":\"\"},{\"id\":\"135\",\"title\":\"Montelukast Drug Sales Market by Applications - LinkedIn\",\"description\":\"Aug 20, 2025 Â· The U.S. Montelukast market is valued at approximately $1.2 billion in 2023, with a projected CAGR of 4.5% through 2030. Increasing asthma andÂ ...\",\"url\":\"https://www.linkedin.com/pulse/montelukast-drug-sales-market-applications-overview-ptbxc/\",\"favicon\":\"\"},{\"id\":\"136\",\"title\":\"Montelukast Sodium Market Size And Share Report, 2030\",\"description\":\"The global montelukast sodium market size was valued at USD 450.0 million in 2023 and is expected to grow at a CAGR of 15.6% from 2024 to 2030.Missing:  dynamics | Show results with:dynamics\",\"url\":\"https://www.grandviewresearch.com/industry-analysis/montelukast-sodium-market-report\",\"favicon\":\"\"},{\"id\":\"137\",\"title\":\"Strategic Insights for Montelukast Market Expansion\",\"description\":\"Generic Competition: The market is characterized by significant generic competition, impacting pricing strategies. Formulation Innovations: Companies areÂ ...\",\"url\":\"https://www.datainsightsmarket.com/reports/montelukast-1208984\",\"favicon\":\"\"},{\"id\":\"138\",\"title\":\"FDA approves generics of Merck's Singulair\",\"description\":\"In Australia, an extension on the molecule patent means that the patent will only expire in April 2013, while in Canada patents already expired in October 2011.\",\"url\":\"https://www.gabionline.net/generics/news/FDA-approves-generics-of-Merck-s-Singulair\",\"favicon\":\"\"},{\"id\":\"139\",\"title\":\"Montelukast - Drug Usage Statistics, ClinCalc DrugStats Database\",\"description\":\"Estimated number of prescriptions in the United States (2023), 25,893,501. Estimated number of patients in the United States (2023), 6,495,486. Average totalÂ ...Missing:  Statista | Show results with:Statista\",\"url\":\"https://clincalc.com/DrugStats/Drugs/Montelukast\",\"favicon\":\"\"},{\"id\":\"140\",\"title\":\"[PDF] Pediatric Utilization Patterns Montelukast, 2014-2018 - FDA\",\"description\":\"Sep 27, 2019 Â· Top prescribing specialties of montelukast (all ages) by number of prescriptions dispensed from U.S. outpatient retail pharmacies, 2018. 7.\",\"url\":\"https://www.fda.gov/media/131183/download\",\"favicon\":\"\"},{\"id\":\"141\",\"title\":\"Montelukast deprescribing in outpatient specialty clinics: A single ...\",\"description\":\"In 2019, montelukast was prescribed to 7,429,725 patients and decreased to 6,825,788 patients in 2022, indicating an 8.1 % decrease in montelukast prescriptionsÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S2667276624001069\",\"favicon\":\"\"},{\"id\":\"142\",\"title\":\"Merck Announces Full-Year and Fourth-Quarter 2011 Financial ...\",\"description\":\"Feb 2, 2012 Â· Full-year worldwide sales for SINGULAIR were $5.5 billion, a 10 percent increase compared with the prior year. The U.S. patent for SINGULAIRÂ ...Missing:  peak | Show results with:peak\",\"url\":\"https://www.merck.com/news/merck-announces-full-year-and-fourth-quarter-2011-financial-results/\",\"favicon\":\"\"},{\"id\":\"143\",\"title\":\"Merck's Singulair sales free-fall 90% in 4 weeks - Fierce Pharma\",\"description\":\"Sep 12, 2012 Â· Singulair has been the company's biggest seller and accounted for $3.3 billion of Merck's ($MRK) sales last year. For the most recent fullÂ ...Missing:  revenue | Show results with:revenue\",\"url\":\"https://www.fiercepharma.com/sales-and-marketing/merck-s-singulair-sales-free-fall-90-4-weeks\",\"favicon\":\"\"},{\"id\":\"144\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.goodrx.com/montelukast\",\"favicon\":\"\"}],\"images\":[{\"id\":\"64d88255b7d3\",\"caption\":\"Montelukast chemical structure\",\"url\":\"./_assets_/Montelukast.svg.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"64d88255b7d3\",\"caption\":\"Montelukast chemical structure\",\"url\":\"./_assets_/Montelukast.svg.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"64d88255b7d3\",\"caption\":\"Montelukast chemical structure\",\"url\":\"./_assets_/Montelukast.svg.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0}],\"fixedIssues\":[],\"slug\":\"Montelukast\",\"title\":\"Montelukast\",\"content\":\"$1f\",\"description\":\"Montelukast\\n\\nMontelukast chemical structure \\nMontelukast is a selective, orally active antagonist of the cysteinyl leukotriene receptor 1 (CysLT1), which inhibits the physiologic actions of...\",\"metadata\":{\"categories\":[\"Singulair\"],\"lastModified\":\"1761584320\",\"contentLength\":\"80576\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"487727\",\"recentViews\":\"487727\",\"dailyAvgViews\":16257.56640625,\"qualityScore\":1,\"lastViewed\":\"1761884946\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761884946673,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Montelukast\"],\"queryHash\":\"[\\\"page\\\",\\\"Montelukast\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Montelukast\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Montelukast is a selective, orally active antagonist of the cysteinyl leukotriene receptor 1 (CysLT1), which inhibits the physiologic actions of leukotriene D4, thereby reducing airway inflammation, bronchoconstriction, and related symptoms in respiratory conditions. Developed by Merck \u0026 Co. and approved by the U.S. Food and Drug Administration (FDA) in 1998 as Singulair, it is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients as young as six months,...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"Singulair\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Montelukast\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Montelukast\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"Montelukast is a selective, orally active antagonist of the cysteinyl leukotriene receptor 1 (CysLT1), which inhibits the physiologic actions of leukotriene D4, thereby reducing airway inflammation, bronchoconstriction, and related symptoms in respiratory conditions. Developed by Merck \u0026 Co. and approved by the U.S. Food and Drug Administration (FDA) in 1998 as Singulair, it is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients as young as six months,...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Montelukast\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Montelukast\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:44.320Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Montelukast\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"Montelukast is a selective, orally active antagonist of the cysteinyl leukotriene receptor 1 (CysLT1), which inhibits the physiologic actions of leukotriene D4, thereby reducing airway inflammation, bronchoconstriction, and related symptoms in respiratory conditions. Developed by Merck \u0026 Co. and approved by the U.S. Food and Drug Administration (FDA) in 1998 as Singulair, it is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients as young as six months,...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="YTU5MmIzMzktMmU4Yy00OGY2LWExMGItZjc1NzUwZTlkYmEw">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Montelukast\"}]}]\n"])</script></body></html>